<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1110211119
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tyronib
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IMATINIB MESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        795.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01XE01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML)</strong></p><p>&nbsp;</p><p>Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.</p><p>Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy</p><p>Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.</p><p>&nbsp;</p><p>Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL)</p><p><strong>&nbsp;</strong></p><p>Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).</p><p>Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)</p><p><strong>&nbsp;</strong></p><p>Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet- derived growth factor receptor) gene re-arrangements as determined.</p><p>Aggressive Systemic Mastocytosis (ASM)</p><p><strong>&nbsp;</strong></p><p>Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as determined.</p><p>Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL)</p><p><strong>&nbsp;</strong></p><p>Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR&alpha; fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR&alpha; fusion kinase negative or unknown.</p><p>Dermatofibrosarcoma Protuberans (DFSP)</p><p><strong>&nbsp;</strong></p><p>Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp; Warnings and precautions for use</p><p><strong>Fluid Retention and Edema</strong></p><p><strong>&nbsp;</strong></p><p>Imatinib mesylate is often associated with edema and occasionally serious fluid retention<em>. </em>Weigh and monitor patients regularly for signs and symptoms of fluid retention. Investigate unexpected rapid weight gain carefully and provide appropriate treatment. The probability of edema was increased with higher imatinib mesylate dose and age greater than 65 years in the CML studies.</p><p>&nbsp;</p><p>Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate, and in 2% to 6% of other adult CML patients taking imatinib mesylate. In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate, and in 2% to 6% of other adult CML patients taking imatinib mesylate<em>. </em>In a randomized trial in patients with newly diagnosed Ph+CML in chronic phase comparing imatinib mesylate and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib mesylate and in 3.9% of patients receiving nilotinib 300 mg twice daily. Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib mesylate arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm.</p><p>Hematologic Toxicity</p><p><strong>&nbsp;</strong></p><p>Treatment with imatinib mesylate is associated with anemia, neutropenia, and thrombocytopenia. Perform complete blood counts weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2 to 3 months). In CML, the occurrence of these cytopenias is dependent on the stage of disease and is more frequent in patients with accelerated phase CML or blast crisis than in patients with chronic phase CML. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias including neutropenia, thrombocytopenia and anemia. These generally occur within the first several months of therapy.</p><p>Congestive Heart Failure and Left Ventricular Dysfunction</p><p><strong>&nbsp;</strong></p><p>Congestive heart failure and left ventricular dysfunction have been reported in patients taking imatinib mesylate. Cardiac adverse reactions were more frequent in patients with advanced age or</p><p>&nbsp;</p><p>co-morbidities including previous medical history of cardiac disease. In an international randomized Phase 3 study in 1,106 patients with newly diagnosed Ph+ CML in chronic phase, severe cardiac failure and left ventricular dysfunction were observed in 0.7% of patients taking imatinib mesylate compared to 0.9% of patients taking IFN + Ara-C. In another randomized trial with newly diagnosed Ph+ CML patients in chronic phase that compared imatinib mesylate and nilotinib, cardiac failure was observed in 1.1% of patient in the imatinib mesylate arm and 2.2% of patients in the nilotinib 300 mg twice daily arm and severe (Grade 3 or 4) cardiac failure occurred in 0.7% of patients in each group. Carefully monitor patients with cardiac disease or risk factors for cardiac or history of renal failure. Evaluate and treat any patient with signs or symptoms consistent with cardiac or renal failure.</p><p>Hepatotoxicity</p><p><strong>&nbsp;</strong></p><p>Hepatotoxicity, occasionally severe, may occur with imatinib mesylate. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of imatinib mesylate. Monitor liver function (transaminases, bilirubin, and alkaline phosphatase) before initiation of treatment and monthly, or as clinically indicated. Manage laboratory abnormalities with imatinib mesylate interruption and/or dose reduction<em>. </em>When imatinib mesylate is combined with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been reports of acute liver failure. Monitoring of hepatic function is recommended.</p><p>Hemorrhage</p><p><strong>&nbsp;</strong></p><p>In a trial of imatinib mesylate versus IFN+Ara-C in patients with the newly diagnosed CML, 1.8% of patients had Grade 3/4 hemorrhage. In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib, GI hemorrhage occurred in</p><p>&nbsp;</p><p>1.4% of patients in the imatinib mesylate arm, and in 2.9% of patients in the nilotinib 300 mg twice daily arm. None of these events were Grade 3 or 4 in the imatinib mesylate arm; 0.7% were Grade 3 or 4 in the nilotinib 300 mg twice daily arm. In addition, gastric antral vascular ectasia has been reported in postmarketing experience.</p><p>Gastrointestinal Disorders</p><p><strong>&nbsp;</strong></p><p>Imatinib mesylate is sometimes associated with GI irritation. Imatinib mesylate should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation.</p><p>Hypereosinophilic Cardiac Toxicity</p><p><strong>&nbsp;</strong></p><p>In patients with hypereosinophilic syndrome with occult infiltration of HES cells within the myocardium, cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of imatinib mesylate therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding imatinib mesylate.</p><p>Myelodysplastic/myeloproliferative disease and systemic mastocytosis may be associated with high eosinophil levels. Consider performing an echocardiogram and determining serum troponin in patients with HES/CEL, and in patients with MDS/MPD or ASM associated with high eosinophil levels. If either is abnormal, consider prophylactic use of systemic steroids (1 to 2 mg/kg) for one to two weeks concomitantly with imatinib mesylate at the initiation of therapy.</p><p>Dermatologic Toxicities</p><p><strong>&nbsp;</strong></p><p>Bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported with use of imatinib mesylate. In some cases of bullous dermatologic</p><p>&nbsp;</p><p>reactions, including erythema multiforme and Stevens-Johnson syndrome reported during postmarketing surveillance, a recurrent dermatologic reaction was observed upon rechallenge. Several foreign postmarketing reports have described cases in which patients tolerated the reintroduction of imatinib mesylate therapy after resolution or improvement of the bullous reaction. In these instances, imatinib mesylate was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines.</p><p>Hypothyroidism</p><p><strong>&nbsp;</strong></p><p>Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib mesylate. Monitor TSH levels in such patients.</p><p>Embryo-fetal Toxicity</p><p><strong>&nbsp;</strong></p><p>Imatinib mesylate can cause fetal harm when administered to a pregnant woman. Imatinib mesylate was teratogenic in rats when administered during organogenesis at doses approximately equal to the maximum human dose of 800 mg/day based on body surface area. Significant post- implantation loss was seen in female rats administered imatinib mesylate at doses approximately one-half the maximum human dose of 800 mg/day based on body surface area. Advise sexually active female patients of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) when using imatinib mesylate and for 14 days after stopping imatinib mesylate. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.</p><p>&nbsp;</p><p>Growth Retardation in Children and Adolescents</p><p><strong>&nbsp;</strong></p><p>Growth retardation has been reported in children and pre-adolescents receiving imatinib mesylate. The long term effects of prolonged treatment with imatinib mesylate on growth in children are unknown. Therefore, monitor growth in children under imatinib mesylate treatment.</p><p>Tumor Lysis Syndrome</p><p><strong>&nbsp;</strong></p><p>Cases of Tumor Lysis Syndrome (TLS), including fatal cases, have been reported in patients with CML, GIST, ALL and eosinophilic leukemia receiving imatinib mesylate. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. Monitor these patients closely and take appropriate precautions. Due to possible occurrence of TLS, correct clinically significant dehydration and treat high uric acid levels prior to initiation of imatinib mesylate.</p><p>Impairments Related to Driving and Using Machinery</p><p><strong>&nbsp;</strong></p><p>Motor vehicle accidents have been reported in patients receiving imatinib mesylate. Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with imatinib mesylate. Recommend caution when driving a car or operating machinery.</p><p>Renal Toxicity</p><p><strong>&nbsp;</strong></p><p>A decline in renal function may occur in patients receiving imatinib mesylate. Median estimated glomerular filtration rate (eGFR) values in patients on imatinib mesylate 400 mg daily for newly- diagnosed CML (four randomized trials) and another clinical trial declined from a baseline value of 85 ml/min/1.73m<sup>2</sup> (N=1,190) to 75 ml/min/1.73m<sup>2</sup> at 12 months (N=1,082) and 69 ml/min/1.73m<sup>2</sup> at 60 months (N=549). Evaluate renal function prior to initiating imatinib mesylate</p><p>&nbsp;</p><p>and monitor during therapy, with attention to risk factors for renal dysfunction such as pre- existing renal impairment, diabetes mellitus, hypertension, and congestive heart failure.</p><p>&nbsp;</p><p>&nbsp;</p><p>Children and Adolescents:</p><p><strong>&nbsp;</strong></p><p>Growth retardation has been reported in children and pre-adolescents receiving imatinib mesylate. The long term effects of prolonged treatment with imatinib mesylate on growth in children are unknown. Therefore, monitor growth in children under imatinib mesylate treatment.</p><p>Pediatric:</p><p><strong>&nbsp;</strong></p><p><u>Pediatric Use:</u></p><p>&nbsp;</p><p>As in adult patients, imatinib was rapidly absorbed after oral administration in pediatric patients, with a Cmax of 2 to 4 hours. Apparent oral clearance was similar to adult values (11.0 L/hr/m2 in children vs. 10.0 L/hr/m2 in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in adults). Dosing in children at both 260 mg/m2 and 340 mg/m2 achieved an AUC similar to the 400 mg dose in adults. The comparison of AUC on Day 8 vs. Day 1 at 260 mg/m2 and 340&nbsp; mg/m2 dose levels revealed a 1.5-and 2.2-fold drug accumulation, respectively, after repeated once-daily dosing. Mean imatinib AUC did not increase proportionally with increasing dose.</p><p>Based on pooled population pharmacokinetic analysis in pediatric patients with hematological disorders (CML, or other hematological disorders treated with imatinib), clearance of imatinib increases with increasing body surface area (BSA). After correcting for the BSA effect, other demographics such as age, body weight and body mass index did not have clinically significant effects on the exposure of imatinib. The analysis confirmed that exposure of imatinib in pediatric patients receiving 260 mg/m2 once-daily (not exceeding 400 mg once-daily) or 340 mg/m2 once-</p><p>&nbsp;</p><p>daily (not exceeding 600 mg once-daily) were similar to those in adult patients who received imatinib 400 mg or 600 mg once-daily.</p><p>Drug Interactions</p><p><strong>&nbsp;</strong></p><p><strong>Agents Inducing CYP3A Metabolism</strong></p><p><strong>&nbsp;</strong></p><p>Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of imatinib mesylate, increased imatinib mesylate oral-dose clearance by 3.8-fold, which significantly (p less than 0.05) decreased mean Cmax and AUC.</p><p>Similar findings were observed in patients receiving 400 to 1200 mg/day imatinib mesylate tablets concomitantly with enzyme-inducing anti-epileptic drugs (EIAED) (e.g., carbamazepine, oxcarbamazepine, phenytoin, fosphenytoin, phenobarbital, and primidone). The mean dose normalized AUC for imatinib in the patients receiving EIAED&rsquo;s decreased by 73% compared to patients not receiving EIAED.</p><p>Concomitant administration of imatinib mesylate and St. John&rsquo;s Wort led to a 30% reduction in the AUC of imatinib.</p><p>Consider alternative therapeutic agents with less enzyme induction potential in patients when rifampin or other CYP3A4 inducers are indicated. Imatinib mesylate tablets doses up to 1200 mg/day (600 mg twice daily) have been given to patients receiving concomitant strong CYP3A4 inducers.</p><p>Agents Inhibiting CYP3A Metabolism</p><p><strong>&nbsp;</strong></p><p>There was a significant increase in exposure to imatinib (mean Cmax and AUC increased by 26% and 40%, respectively) in healthy subjects when imatinib mesylate was coadministered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution is recommended when administering</p><p>&nbsp;</p><p>imatinib mesylate with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice may also increase plasma concentrations of imatinib and should be avoided.</p><p>Interactions with Drugs Metabolized by CYP3A4</p><p><strong>&nbsp;</strong></p><p>Imatinib mesylate increases the mean Cmax and AUC of simvastatin (CYP3A4 substrate) 2-and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by imatinib mesylate. Particular caution is recommended when administering imatinib mesylate with CYP3A4 substrates that have a narrow therapeutic window (e.g., alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus).</p><p>Imatinib mesylate will increase plasma concentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).</p><p>Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin instead of warfarin.</p><p>Interactions with Drugs Metabolized by CYP2D6</p><p><strong>&nbsp;</strong></p><p>Imatinib mesylate increased the mean Cmax and AUC of metoprolol by approximately 23% suggesting that imatinib mesylate has a weak inhibitory effect on CYP2D6-mediated metabolism. No dose adjustment is necessary, however, caution is recommended when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.</p><p>&nbsp;</p><p>Interactions with Acetaminophen</p><p><strong>&nbsp;</strong></p><p><em>In vitro</em>, imatinib mesylate inhibits the acetaminophen O-glucuronidate pathway (Ki 58.5 &mu;M). Coadministration of imatinib mesylate (400 mg/day for 8 days) with acetaminophen (1000 mg single dose on day 8) in patients with CML did not result in any changes in the pharmacokinetics of acetaminophen. Imatinib mesylate pharmacokinetics were not altered in the presence of single- dose acetaminophen. There is no pharmacokinetic or safety data on the concomitant use of imatinib mesylate at doses greater than 400 mg/day or the chronic use of concomitant acetaminophen and imatinib mesylate.</p><p>Pregnancy and Breast feeding:</p><p><strong>&nbsp;</strong></p><p>Advise patients to inform their doctor if they are or think they may be pregnant. Advise women of reproductive potential to avoid becoming pregnant while taking imatinib mesylate tablets. Female patients of reproductive potential taking imatinib mesylate tablets should use highly effective contraception during treatment and for fourteen days after stopping treatment with imatinib mesylate tablets. Avoid breastfeeding during treatment and for 1 month after the last dose.</p><p><u>Pregnancy Testing</u></p><p>&nbsp;</p><p>Human postmarketing reports and animal studies have shown imatinib mesylate to be harmful to the developing fetus. Test pregnancy status in females with reproductive potential prior to the initiation of treatment with imatinib mesylate.</p><p>Contraception <u>Females</u></p><p>Advise female patients of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using imatinib mesylate during treatment and for fourteen days after stopping treatment with imatinib mesylate.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Infertility</u></p><p>&nbsp;</p><p>The risk of infertility in females or males of reproductive potential has not been studied in humans. In a rat study, the fertility in males and females was not affected.</p><p>Lactation</p><p><strong>&nbsp;</strong></p><p>Risk Summary</p><p>&nbsp;</p><p>Imatinib and its active metabolite are excreted into human milk. Because of the potential for serious adverse reactions in breastfed infants from imatinib mesylate, advise a lactating woman not to breastfeed during treatment and for 1 month after the last dose.</p><p>Human Data</p><p>&nbsp;</p><p>Based on data from 3 breastfeeding women taking imatinib mesylate, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite. Considering the combined concentration of imatinib and active metabolite, a breastfed infant could receive up to 10% of the maternal therapeutic dose based on body weight.</p><p>Driving and Using Machines</p><p><strong>&nbsp;</strong></p><p>Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with Imatinib Mesylate tablets. Therefore, caution patients about driving a car or operating machinery see the following:</p><p>Impairments Related to Driving and Using Machinery</p><p><strong>&nbsp;</strong></p><p>Motor vehicle accidents have been reported in patients receiving Imatinib mesylate tablets . Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with Imatinib Mesylate tablets. Recommend caution when driving a car or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>DOSAGE AND ADMINISTRATION</strong></p><p><strong>Drug Administration</strong></p><p>The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day.</p><p>For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 mL for a 100 mg tablet, and 200 mL for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).</p><p>For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablet to reduce exposure to iron.</p><p>Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.</p><p>Adult Patients with Ph+ CML CP, AP, or BC</p><p><strong>&nbsp;</strong></p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis.</p><p>In CML, a dose increase from 400 mg to 600 mg in adult patients with chronic phase disease, or from 600 mg to 800 mg (given as 400 mg twice daily) in adult patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe non- leukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3</p><p>&nbsp;</p><p>months of treatment, failure to achieve a cytogenetic response after 6 to 12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response.</p><p>Pediatric Patients with Ph+ CML CP</p><p><strong>&nbsp;</strong></p><p>The recommended dose of imatinib mesylate tablets for children with newly diagnosed Ph+ CML is 340 mg/m<sup>2</sup>/day (not to exceed 600 mg). Imatinib mesylate tablets treatment can be given as a once daily dose or the daily dose may be split into two&ndash;one portion dosed in the morning and one portion in the evening. There is no experience with imatinib mesylate tablets treatment in children under 1 year of age.</p><p>Adult Patients with Ph+ ALL</p><p><strong>&nbsp;</strong></p><p>The recommended dose of imatinib mesylate tablets is 600 mg/day for adult patients with relapsed/refractory Ph+ ALL.</p><p>Adult Patients with MDS/MPD</p><p><strong>&nbsp;</strong></p><p>Determine PDGFRb gene rearrangements status prior to initiating treatment. Information on FDA-approved tests for the detection of PDGFRb rearrangements is available at http://www.fda.gov/companiondiagnostics.</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with MDS/MPD.</p><p>Adult Patients with ASM</p><p><strong>&nbsp;</strong></p><p>Determine D816V c-Kit mutation status prior to initiating treatment. Information on FDA- approved test for the detection of D816V c-Kit mutation is available at http://www.fda.gov/companiondiagnostics.</p><p>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with ASM without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with imatinib mesylate tablets 400 mg/day may be considered for patients with ASM not responding satisfactorily to other therapies. For patients with ASM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR&alpha;, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.</p><p>Adult Patients with HES/CEL</p><p><strong>&nbsp;</strong></p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with HES/CEL. For HES/CEL patients with demonstrated FIP1L1-PDGFR&alpha; fusion kinase, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.</p><p>2.9 Adult Patients with DFSP</p><p><strong>&nbsp;</strong></p><p>The recommended dose of imatinib mesylate tablets is 800 mg/day for adult patients with DFSP.</p><p>&nbsp;</p><p>2.12 Dose Modification Guidelines</p><p><strong>&nbsp;</strong></p><p><em>Concomitant Strong CYP3A4 inducers: </em>The use of concomitant strong CYP3A4 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin, phenobarbital). If patients must be coadministered a strong CYP3A4 inducer, based on pharmacokinetic studies, the dosage of imatinib mesylate tablets should be increased by at least 50%, and clinical response should be carefully monitored.</p><p>&nbsp;</p><p><em>Hepatic Impairment: </em>Patients with mild and moderate hepatic impairment do not require a dose adjustment and should be treated per the recommended dose. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment<em>.</em></p><p><em>Renal Impairment: </em>Patients with moderate renal impairment (CrCL=20 to 39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCL=40 to 59 mL/min). For patients with moderate renal impairment doses greater than 400 mg are not recommended.</p><p>Imatinib should be used with caution in patients with severe renal impairment. A dose of 100 mg/day was tolerated in two patients with severe renal impairment<em>.</em></p><p>Dose Adjustment for Hepatotoxicity and Non-Hematologic Adverse Reactions</p><p><strong>&nbsp;</strong></p><p>If elevations in bilirubin greater than 3 times the institutional upper limit of normal (IULN) or in liver transaminases greater than 5 times the IULN occur, imatinib mesylate tablets should be withheld until bilirubin levels have returned to a less than 1.5 times the IULN and transaminase levels to less than 2.5 times the IULN. In adults, treatment with imatinib mesylate tablets may then be continued at a reduced daily dose (i.e., 400 mg to 300 mg, 600 mg to 400 mg or 800 mg to 600 mg). In children, daily doses can be reduced under the same circumstances from 340 mg/m<sup>2</sup>/day to 260 mg/m<sup>2</sup>/day.</p><p>If a severe non-hematologic adverse reaction develops (such as severe hepatotoxicity or severe fluid retention), imatinib mesylate tablets should be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event.</p><p>&nbsp;</p><p>Dose Adjustment for Hematologic Adverse Reactions</p><p><strong>&nbsp;</strong></p><p>Dose reduction or treatment interruptions for severe neutropenia and thrombocytopenia are recommended as indicated in Table 1.</p><p>Table 1: Dose Adjustments for Neutropenia and Thrombocytopenia</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1034"
 style='width:442.8pt;height:.5pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="8856,10">
 <v:line id="_x0000_s1035" style='position:absolute' from="0,5" to="8856,5"
  strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:442.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>ASM associated with eosinophilia</p><p>(starting dose 100 mg)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="_x0000_s1036"
 style='position:absolute;left:0;text-align:left;z-index:251660288;
 mso-position-horizontal-relative:page' from="66.6pt,-.1pt" to="509.4pt,-.1pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />HES/CEL with FIP1L1-PDGFR&alpha;</p><p>fusion kinase (starting dose 100 mg)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="_x0000_s1037"
 style='position:absolute;left:0;text-align:left;z-index:251661312;
 mso-position-horizontal-relative:page' from="66.6pt,-.15pt" to="509.4pt,-.15pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Chronic Phase CML (starting dose 400 mg)</p><p>&nbsp;</p><p>&nbsp;</p><p>MDS/MPD, ASM and HES/CEL</p><p>(starting dose 400 mg)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="_x0000_s1038"
 style='position:absolute;left:0;text-align:left;z-index:251662336;
 mso-position-horizontal-relative:page' from="66.6pt,-.15pt" to="509.4pt,-.15pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />Ph+ CML : Accelerated Phase and</p><p>Blast Crisis (starting dose 600 mg)</p><p>Ph+ ALL</p><p>(starting dose 600 mg)</p><p>&nbsp;</p><p>ANC<sup>1</sup> less than 1.0 x 10<sup>9</sup>/L</p><p>and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>ANC less than 0.5 x 10<sup>9</sup>/L and/or</p><p>platelets less than 10 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop imatinib mesylate tablets</p><p>until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume treatment with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume treatment with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume treatment with imatinib mesylate tablets at the original&nbsp; starting&nbsp; dose&nbsp;&nbsp; of&nbsp;&nbsp; 400 mg</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If recurrence of ANC less than</p><p>1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, repeat step 1 and resume imatinib mesylate tablets at a reduced dose of 300 mg</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Check if cytopenia is related to leukemia (marrow aspirate or biopsy)</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cytopenia is unrelated to leukemia, reduce dose of imatinib mesylate tablets to 400 mg</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cytopenia persists 2 weeks, reduce further to 300 mg</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If cytopenia persists 4 weeks and is still unrelated to leukemia, stop imatinib</p><p>DFSP</p><p>(starting dose 800 mg)</p><p>Pediatric newly diagnosed chronic phase CML (starting dose 340 mg/m<sup>2</sup>)</p><p>&nbsp;</p><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p><p>mesylate tablets until ANC greater than or equal to1 x 10<sup>9</sup>/L and platelets greater than or equal to 20 x 10<sup>9</sup>/L and then resume treatment at 300 mg</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:line id="_x0000_s1039" style='position:absolute;
 left:0;text-align:left;z-index:251664384;mso-position-horizontal-relative:page'
 from="66.6pt,-57.55pt" to="509.4pt,-57.55pt" strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if gte vml 1]><v:line id="_x0000_s1040"
 style='position:absolute;left:0;text-align:left;z-index:251665408;
 mso-position-horizontal-relative:page' from="66.6pt,.45pt" to="509.4pt,.45pt"
 strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" />Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume treatment with imatinib mesylate tablets at 600 mg</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:line id="_x0000_s1041" style='position:absolute;
 left:0;text-align:left;z-index:251666432;mso-position-horizontal-relative:page'
 from="66.6pt,80.9pt" to="509.4pt,80.9pt" strokeweight=".48pt">
 <w:wrap anchorx="page"/>
</v:line><![endif]--><img width="592" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" />In the event of recurrence of ANC less than 1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, repeat step 1 and resume imatinib mesylate tablets at reduced&nbsp; dose&nbsp; of&nbsp; 400 mg</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Resume treatment with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event of recurrence of ANC less than 1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, repeat step 1 and resume imatinib mesylate tablets at reduced&nbsp; dose&nbsp; of&nbsp; 260 mg/m<sup>2</sup></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1026"
 style='width:443.55pt;height:.5pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="8871,10">
 <v:line id="_x0000_s1027" style='position:absolute' from="0,5" to="2972,5"
  strokeweight=".48pt"/>
 <v:line id="_x0000_s1028" style='position:absolute' from="2958,5" to="5792,5"
  strokeweight=".48pt"/>
 <v:line id="_x0000_s1029" style='position:absolute' from="5778,5" to="8870,5"
  strokeweight=".48pt"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="593" height="1" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1027"
 type="#_x0000_t75" style='width:443.55pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>1ANC = absolute neutrophil count</p><p>If You Take more Imatinib Mesylate</p><p>Experience with doses greater than 800 mg is limited. Isolated cases of Imatinib Mesylate tablets overdose have been reported. In the event of over dosage, observe the patient and give appropriate supportive treatment.</p><p>Overdosage</p><p>Experience with doses greater than 800 mg is limited. Isolated cases of imatinib mesylate overdose have been reported. In the event of overdosage, observe the patient and give appropriate supportive treatment.</p><p>Adult Overdose</p><p>&nbsp;</p><p>1<strong>,200 to 1,600 mg (duration varying between 1 to 10 days)</strong>: Nausea, vomiting, diarrhea, rash erythema, edema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.</p><p><strong>1,800 to 3,200 mg (as high as 3,200 mg daily for 6 days): </strong>Weakness, myalgia, increased CPK, increased bilirubin, gastrointestinal pain.</p><p>6,400 mg (single dose): One case in the literature reported one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, neutrophil count decreased, increase transaminases.</p><p><strong>8 to 10 g (single dose): </strong>Vomiting and gastrointestinal pain have been reported.</p><p>A patient with myeloid blast crisis experienced Grade 1 elevations of serum creatinine, Grade 2 ascites and elevated liver transaminase levels, and Grade 3 elevations of bilirubin after inadvertently taking 1,200 mg of imatinib mesylate tablets daily for 6 days. Therapy was temporarily interrupted and complete reversal of all abnormalities occurred within 1 week. Treatment was resumed at a dose of 400 mg daily without recurrence of adverse reactions. Another patient developed severe muscle cramps after taking 1,600 mg of imatinib mesylate tablets daily for 6 days. Complete resolution of muscle cramps occurred following interruption of therapy and treatment was subsequently resumed. Another patient that was prescribed 400 mg daily, took 800 mg of imatinib mesylate tablets on Day 1 and 1,200 mg on Day 2. Therapy was interrupted, no adverse reactions occurred and the patient resumed therapy.</p><p>&nbsp;</p><p>Pediatric Overdose</p><p>One 3-year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhea and anorexia and another 3-yearold male exposed to a single dose of 980 mg experienced decreased white blood cell count and diarrhea.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with imatinib mesylate. Recommend caution when driving a car or operating machinery.</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:88.2pt;margin-top:19.4pt;width:382.5pt;height:124.75pt;z-index:-251649024;
  mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".48pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText style='margin-top:0in;margin-right:66.95pt;
     margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:
     150%'>The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax:
     +966-11-205-7662<o:p></o:p></p>
     <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
     +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.8pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Toll free phone:<span
     style='letter-spacing:-.15pt'> </span>8002490000<o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
     mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>E-mail:<span
     style='letter-spacing:-.1pt'> </span><a href="mailto:npc.drug@sfda.gov.sa"><span
     style='color:blue;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
     <p class=MsoBodyText style='margin-top:6.9pt;margin-right:0in;margin-bottom:
     0in;margin-left:14.2pt;margin-bottom:.0001pt;text-indent:-9.1pt;
     mso-list:l0 level1 lfo1;tab-stops:14.25pt'><![if !supportLists]><span
     style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;
     </span></span><![endif]><span dir=LTR></span>Website:<span
     style='letter-spacing:-.15pt'> </span><a href="http://www.sfda.gov.sa/npc"><span
     style='color:blue;text-decoration:none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="514" height="171" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Razan/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>o Other GCC States:</em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Imatinib Mesylate Tablets contains </strong>The active substance is Imatinib Mesylate. <strong><u>Imatinib Mesylate Tablets 100mg:</u></strong></p><p>Each film coated tablet contains Imatinib Mesylate 119. 5 0 mg Equivalent to Imatinib 100 mg</p><p><strong><u>Imatinib Mesylate Tablets 400mg :</u></strong></p><p>Each film coated tablet contains Imatinib Mesylate 478.00 mg Equivalent to Imatinib 400 mg <strong>The other ingredients are</strong>: Hypromellose 2910 5cps (Methocel E5 LV Premium), Microcrystalline cellulose (Avicel PH 102), Crospovidone (Kollidon CL), Colloidal silicon dioxide (Aerosil 200), Magnesium stearate, Purified water.</p><p><strong>Coating Composition: </strong>HPMC 2910/ Hypromellose, Titanium Dioxide, Macrogol/PEG, Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Imatinib Mesylate Tablets 100mg:
White to off white colored, round, biconvex scored, bevel edged, film coated tablets debossed with H on one side and 7 on the other side with score line.
Imatinib Mesylate Tablets 400mg :
White to off white colored, oval, biconvex scored, bevel edged, film coated tablets debossed with H on one side and 4 on the other side with score line.
How supplied:
Imatinib Mesylate Tablets are supplied in Blister pack
Imatinib Mesylate Tablets 100 - Box of 30 blister tablets (3x10’s) Imatinib Mesylate Tablets 400 - Box of 30 blister tablets (3x10’s) Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Saudi Amarox Industrial Company</p><p>Aljameah Street, Malaz quarter, Riyadh 11441 Saudi Arabia</p><p>Tel: +966 11 477 2215</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>لعلاج سرطان الدم النخاعي النخاعي المزمن والذي تم تشخيصه حديثا(أبيضاض نقوي مزمن) مع وجود صبغي فيلادلفيا</strong><strong> </strong><strong>(</strong><strong>Ph + CML</strong><strong>)</strong></p><p dir="RTL">للمرضى البالغين والأطفال الذين تم تشخيصهم حديثًا بسرطان الدم النخاعي المزمن (أبيضاض نقوي مزمن) مع وجود كروموسوم فيلادلفيا (Ph + CML)</p><p dir="RTL"><strong>لعلاج حالات سرطان الدم النخاعي (</strong><strong>Ph + CML</strong><strong>) في مرحلة النوبة البالستية</strong><strong> </strong><strong>(BC)</strong><strong> ، أو الطور المتسارع </strong><strong>(AP)</strong><strong> ، أو الحالات المزمنة </strong><strong>(CP)</strong><strong> ، أو بعد العلاج بالإنترفيرون &ndash; ألفا </strong><strong>(IFN)</strong><strong> .</strong></p><p dir="RTL">علاج المرضى البالغين والأطفال الذين لديهم لوكيميا نخاعية مزمنة موجبة الكروموسوم فيلادلفيا (Ph + CML) في الطور المزمن، أو الطور المتسارع، أو في مرحلة النوبة البالستية، أو في المرحلة المزمنة بعد فشل العلاج بالإنترفيرون ألفا.</p><p dir="RTL"><strong>لعلاج المرضى البالغين الذين يعانون من سرطان الدم اللمفاوي الحاد موجبة الكروموسوم فيلادلفيا</strong><strong> </strong><strong>(</strong><strong>ALL</strong><strong>)</strong></p><p dir="RTL">المرضى البالغين الذين يعانون من سرطان الدم اللمفاوي الحاد مع وجود كروموسوم فيلادلفيا (Ph + ALL).</p><p dir="RTL"><strong>لعلاج مرض خلل التنسج النخاعي / </strong><strong>مرض</strong><strong>&nbsp; التكاثر النخاعي (</strong><strong>MDS / MPD</strong><strong>)</strong></p><p dir="RTL">المرضى البالغين المصابين بأمراض خلل التنسج النخاعي النقوي / مرض&nbsp; التكاثر النخاعي المتعلقة بتغيرات جينية في مستقبلات الجين PDGFR (مستقبلات عامل نمو مشتق من الصفائح الدموية) كما هو محدد.</p><p dir="RTL"><strong>لعلاج كثرة الخلايا البدينة الجهازي الهجومي </strong><strong>(ASM)</strong></p><p dir="RTL">المرضى البالغين الذين يعانون من كثرة الخلايا البدينة الجهازية العدوانية دون طفرة kit-c D816V.</p><p dir="RTL"><strong>لعلاج متلازمة فرط اليوزينيات (</strong><strong>HES</strong><strong>) و / أو إبيضاض اليوزينيات المزمن (</strong><strong>CEL</strong><strong>)</strong></p><p dir="RTL">المرضى البالغين المصابين بمتلازمة فرط اليوزينيات و / أو سرطان الدم المزمن الناجم عن فرط الحمض النووي (FIP1L1-PDGFR&alpha; kinase) (اختبار الطفرات أو فحص FISH الخاص ب CHIC2 allele deletion) وللمرضى الذين يعانون من HES و / أو CEL الذين يتصفون بأن لديهم FIP1L1-PDGFR&alpha; fusion kinase سلبي أو غير معروف.</p><p dir="RTL"><strong>لعلاج ساركوما الجلد الدهنية (</strong><strong>DFSP</strong><strong>)</strong></p><p dir="RTL">مخصص لعلاج الكبار الذين يعانون من ساركوما ليفية جلدية حدبية (DFSP) غير قابلة للجراحة .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>احتباس السوائل والوذمة</strong></p><p dir="RTL">غالبًا ما يرتبط تناول تايرونيب أقراص بالوذمة واحتباس السوائل في بعض الأحيان . فيجب مراقبة وزن المرضى بانتظام للتأكد من علامات وأعراض احتباس السوائل. ينبغي تشخيص الزيادة الغير متوقعة والسريعة في الوزن بعناية وتوفير العلاج المناسب. تزيد احتمالية حدوث الوذمة في حالة زيادة جرعة إيماتينيب ميسيلات أو إذا كان العمر أكبر من 65 عامًا في الدراسات على مرضى CML. تم الإبلاغ عن حدوث وذمة سطحية حادة في 1.5٪ من مرضى CML الذين تم تشخيصهم حديثًا والذين يتناولون تايرونيب أقراص ، وفي 2٪ إلى 6٪ من مرضى CML البالغين الآخرين الذين يتناولون تايرونيب أقراص بالإضافة إلى ذلك ، تم الإبلاغ عن تفاعلات أخرى للإحتباس الشديد بالسوائل (على سبيل المثال ، الانصباب الجنبي ، الانصباب التاموري ، الوذمة الرئوية ، والاستسقاء) في 1.3٪ من مرضى CML الذين تم تشخيصهم حديثًا والذين يتناولون تايرونيب أقراص ، وفي 2٪ إلى 6٪ من مرضى CML البالغين الآخرين اللذين يتناولون تايرونيب أقراص. في تجربة عشوائية على المرضى الذين تم تشخيصهم حديثًا Ph + CML في المرحلة المزمنة حيث يتم مقارنة إيماتينيب ميسيلات و نيلوتينيب ، حدثت أعراض لللإحتباس الشديد بالسوائل (درجة 3 أو 4) في 2.5٪ من المرضى الذين تناولوا إيماتينيب ميسيلات وفي 3.9٪ من المرضى الذين تناولوا نيلوتينيب 300 &nbsp;ملغم مرتين في اليوم. لوحظت حالات انصباب (بما في ذلك الانصباب الجنبي ، انصباب التامور ، الاستسقاء) أو الوذمة الرئوية في 2.1 ٪ (لم يكن أي منهم من الدرجة 3 أو 4) من المرضى اللذين يتناولون تايرونيب أقراص و 2.2 ٪ (0.7 ٪ من الدرجة 3 أو 4) من المرضى اللذين يتناولون نيلوتينيب 300 ملغم مرتين يوميا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تسمم الدم</strong></p><p dir="RTL">يرتبط العلاج بتناول تايرونيب أقراص بحدوث فقر الدم وانخفاض مستوى العدلات أو الخلايا المتعادلة في الدم ونقص الصفيحات. ينبغي إجراء فحص تعداد مكونات الدم الكاملة أسبوعيا خلال الشهر الأول ، كل أسبوعين خلال الشهر الثاني ، وبشكل دوري بعد ذلك كما هو مبين سريريا (على سبيل المثال ، كل 2-3 أشهر). في CML ، يعتمد حدوث هذا النقص في مكونات الدم على مرحلة المرض وهو أكثر شيوعًا في المرضى الذين يعانون من الطور المتسارع CML أو مرحلة النوبة البالستية مقارنة بالمرضى الذين يعانون من الطور المزمن CML. في مرضى CML عند الأطفال ، كانت حالات النقص في مكونات الدم الأكثر شيوعًا التي لوحظت هي من الدرجة 3 أو 4 من نقص الكريات البيض بما في ذلك انخفاض مستوى العدلات أو الخلايا المتعادلة في الدم ونقص الصفيحات وفقر الدم. هذه تحدث عادة خلال الأشهر القليلة الأولى من العلاج.</p><p dir="RTL"><strong>قصور القلب الاحتقاني وضعف البطين الأيسر</strong></p><p dir="RTL">تم الإبلاغ عن حالات قصور القلب الاحتقاني وضعف البطين الأيسر لدى المرضى الذين يتناولون تايرونيب أقراص. وكانت تلك التأثيرات السلبية في القلب &nbsp;بمعدلات أكثر في المرضى المسنين الذين يعانون من الأمراض الأخرى بما في ذلك التاريخ الطبي السابق لمرض بالقلب. في دراسة دولية عشوائية للمرحلة الثالثة شملت 1106 مريضاً من المصابين حديثاً Ph + CML في المرحلة المزمنة ، لوحظ &nbsp;حالات فشل قلبي حاد واختلال وظيفي في البطين الأيسر في 0.7٪ من المرضى الذين يتناولون تايرونيب أقراص مقارنة بـ 0.9٪ من المرضى الذين يتناولون IFN + Ara-C. في تجربة عشوائية أخرى مع مرضى Ph + CML الذين تم تشخيصهم حديثًا في المرحلة المزمنة حيث تمت مقارنة تأثير إيماتينيب ميسيلات ونيلوتينيب ، لوحظ حالات فشل قلبي في 1.1٪ من المرضى الذين يتناولون تايرونيب أقراص و 2.2٪ من المرضى الذين يتناولون نيلوتينييب 300 ملغم مرتين يوميًا لوحظ حدوث فشل قلبي شديد ( من الدرجة 3 أو 4) في 0.7 ٪ من المرضى في كل مجموعة. فيجب متابعة المرضى الذين يعانون من أمراض القلب أو عوامل الخطر بالقلب أو تاريخ الفشل الكلوي بعناية. ويجب تقييم وعلاج أي مريض لديه أعراض تشير إلى فشل القلب أو الكلى.</p><p dir="RTL"><strong>تسمم&nbsp;الكبد</strong></p><p dir="RTL">قد تحدث حالات تسمم&nbsp;الكبد وقد تكون شديدة في بعض الأحيان مع تناول تايرونيب أقراص. تم الإبلاغ عن حالات فشل الكبد القاتلة وإصابة الكبد التي تتطلب عمليات زرع كبد وذلك مع الاستخدام قصير الأجل وطويل الأجل لإيماتينيب ميسيلات. فيجب مراقبة وظائف الكبد (ناقلات الأمين (ترانس أميناز) ، البيليروبين ، والفوسفاتاز القلوي) قبل البدء في العلاج وشهريًا ، أو كما هو محدد سريريًا. ويجب العمل على تصحيح النتائج المخبرية المضطربة المرتبطة بانقطاع تناول تايرونيب أقراص و / أو تخفيض الجرعة. عندما يتم دمج إيماتينيب ميسيلات مع العلاج الكيميائي ، لوحظ تسمم الكبد على شكل ارتفاع مستويات ناقلات الأمين (ترانس أميناز) وفرط بيليروبين الدم. بالإضافة إلى ذلك ، كانت هناك تقارير عن فشل الكبد الحاد. فلذا يوصى بمراقبة وظائف الكبد.</p><p dir="RTL"><strong>النزف</strong></p><p dir="RTL">في تجربة للمقارنة بين إيماتينيب ميسيلات مقابل IFN + Ara-C في المرضى الذين يعانون من CML المشخص حديثًا ، كان هناك 1.8٪ من المرضى مصابون بنزيف من الدرجة 3/4. في تجربة عشوائية على المرضى الذين تم تشخيصهم حديثًا Ph + CML في المرحلة المزمنة للمقارنة بين إيماتينيب ميسيلات و نيلوتينييب ، حدث نزيف GI في 1.4٪ من المرضى الذين يتناولون إيماتينيب ميسيلات ، وفي 2.9٪ من مرضى نيلوتينييب 300 ملغم مرتين يوميا. لم يكن أي من هذه الحالات من الدرجة 3 أو 4 &nbsp;مع تناول تايرونيب أقراص. حيث كان 0.7 ٪ من الدرجة 3 أو 4 في نيلوتينييب 300 ملغم مرتين يوميا. بالإضافة إلى ذلك ، تم الإبلاغ عن توسع الأوعية الدموية الغريبة في المعدة في التجارب ما بعد التسويق.</p><p dir="RTL"><strong>اضطرابات الجهاز الهضمي</strong></p><p dir="RTL">أحيانا ما يرتبط تناول تايرونيب أقراص بحالات تهيج الجهاز الهضمي. ولذا ينبغي تناول تايرونيب أقراص مع الطعام وكأس كبير من الماء للحد من هذه المشكلة. كانت هناك تقارير نادرة ، بما في ذلك الوفيات ، من حالات ثقب الجهاز الهضمي.</p><p dir="RTL"><strong>سمية </strong><strong>القلب بفرط الحمضات او فَرْط اليوزينيَّات</strong><strong> </strong></p><p dir="RTL">في المرضى الذين يعانون من متلازمة فرط اليوزينيات مع ارتشاح غامض لخلايا HES داخل عضلة القلب ، ارتبطت بحالات الصدمة القلبية / خلل البطين الأيسر مع تحلل خلايا HES عند بدء العلاج بإيماتينيب ميسيلات. تم الإبلاغ عن أن الحالة يمكن عكسها عن طريق إعطاء المنشطات (السترويدات) داخليا ، وتدابير دعم الدورة الدموية والتوقف مؤقتا عن تناول تايرونيب أقراص. قد يترافق مرض خلل التنسج النخاعي / التكاثر النخاعي مع كثرة الخلايا البدينة الجهازية مع ارتفاع مستويات الحمضات. فيجب النظر في إجراء مخطط صدى القلب وتحديد سيرم التر وبونين في المرضى الذين يعانون من HES / CEL ، وفي المرضى الذين يعانون من MDS / MPD أو ASM المرتبطة بمستويات عالية من الحمضات. إذا كان أحدهما غير طبيعي ، ففكر في الاستخدام الوقائي للمنشطات (السترويدات) داخليا (من 1 إلى 2 مغم / كلغم) لمدة أسبوع إلى أسبوعين بالتزامن مع تناول تايرونيب أقراص في بداية العلاج.</p><p dir="RTL"><strong>السمية الجلدية</strong></p><p dir="RTL">تم الإبلاغ عن ردود الفعل الجلدية الفقاعية ، بما في ذلك حمامي متعددة الأشكال ومتلازمة ستيفنز جونسون ، مع استخدام إيماتينيب ميسيلات. في بعض حالات ردود الفعل الجلدية الفقاعية ، بما في ذلك حمامي متعددة الأشكال ومتلازمة ستيفنز جونسون المبلغ عنها خلال مراقبة ما بعد البيع ، لوحظ وجود تفاعل جلدي متكرر عند إعادة الإستخدام. وقد وصفت العديد من تقارير ما بعد البيع حالات كان فيها المرضى يتحملون إعادة استخدام علاج إيماتينيب ميسيلات بعد تحليل أو تحسين رد الفعل الفقاعي. في هذه الحالات ، استؤنف تناول إيماتينيب ميسيلات بجرعة أقل من تلك التي حدث فيها التفاعل ، وتلقى بعض المرضى أيضًا علاجًا مصاحبًا بالكورتيكوستيرويدات أو مضادات الهيستامين.</p><p dir="RTL"><strong>قصور الغدة الدرقية</strong></p><p dir="RTL">تم الإبلاغ عن حالات سريرية من قصور الغدة الدرقية لدى مرضى استئصال الغدة الدرقية الذين يخضعون لبدائل ليفوثيروكسين أثناء العلاج بتناول إيماتينيب ميسيلات. فيجب مراقبة مستويات TSH في هؤلاء المرضى.</p><p dir="RTL"><strong>تسمم الجنين</strong></p><p dir="RTL">يمكن أن يسبب إيماتينيب ميسيلات ضرر للجنين عند تناوله من قبل امرأة حامل. كان إيماتينيب ميسيلات سام للجنين في الفئران عند تناوله أثناء التولد العضوي بجرعات مساوية تقريبًا للجرعة البشرية القصوى البالغة 800 ملغم / يوم بناءً على مساحة سطح الجسم. شوهدت خسارة كبيرة بعد نقل الأجنة إلى داخل الرحم في الفئران التي يتم اعطائها إيماتينيب ميسيلات بجرعات تقارب نصف الجرعة البشرية القصوى البالغة 800 ملغم / يوم بناءً على مساحة سطح الجسم. يجب تقديم المشورة للمريضات في سن الإنجاب لاستخدام وسائل منع الحمل الفعالة (الطرق التي تؤدي إلى أقل من 1 ٪ معدلات الحمل) عند استخدام إيماتينيب ميسيلات ولمدة 14 يومًا بعد إيقاف إيماتينيب ميسيلات. إذا تم استخدام هذا الدواء أثناء الحمل أو إذا أصبحت المريضه حاملًا أثناء تناول هذا الدواء ، فأطلع المريض على الخطر المحتمل للجنين.</p><p dir="RTL"><strong>تأخر النمو في الأطفال والمراهقين</strong></p><p dir="RTL">تم الإبلاغ عن حالات تأخر النمو في الأطفال والمراهقين الذين يتناولون تايرونيب أقراص. الآثار الطويلة الأجل للعلاج المطول مع إيماتينيب ميسيلات على نمو الأطفال غير معروفة. لذلك ، يجب رصد النمو في الأطفال تحت العلاج إيماتينيب ميسيلات.</p><p dir="RTL"><strong>متلازمة تحلل الورم</strong></p><p dir="RTL">تم الإبلاغ عن حالات متلازمة تحلل الورم (TLS) ، بما في ذلك الحالات القاتلة ، في المرضى الذين يعانون من CML و GIST و ALL وسرطان الدم الحمضي الذي يتلقى إيماتينيب ميسيلات. المرضى المعرضون لخطر TLS هم أولئك الذين لديهم أورام ذات معدل تكاثري مرتفع أو يعانون من ورم مرتفع قبل العلاج. يجب مراقبة هؤلاء المرضى عن كثب واتخاذ الاحتياطات المناسبة. نظرًا لاحتمال حدوث TLS ، قم معالجة الجفاف بشكل كبير سريريًا وعلاج مستويات حمض اليوريك المرتفعة قبل بدء تناول تايرونيب أقراص.</p><p dir="RTL"><strong>الأضرار المتعلقة بالقيادة واستخدام الآلات</strong></p><p dir="RTL">تم الإبلاغ عن حوادث السيارات في المرضى الذين يتناولون تايرونيب أقراص. فيجب تقديم المشورة للمرضى بأنهم قد يتعرضون لآثار جانبية مثل الدوخة ، أو عدم وضوح الرؤية أو النعاس أثناء العلاج مع إيماتينيب ميسيلات. ولذا يوصي بالحذر عند قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>التسمم الكلوي</strong></p><p dir="RTL">قد يحدث انخفاض في وظيفة الكلى في المرضى الذين يتناولون تايرونيب أقراص. متوسط قيم معدل الترشيح الكبيبي (eGFR) في المرضى الذين يتناولون تايرونيب أقراص &nbsp;400 ملغم يوميًا للـ CML المشخص حديثًا (أربع تجارب عشوائية) وتراجعت تجربة سريرية أخرى من قيمة أساسية قدرها 85 مل / دقيقة / 1.73 م 2 (N = 1،190) إلى 75 مل / دقيقة / 1.73 م 2 في 12 شهرًا (N = 1،082) و 69 مل / دقيقة / 1.73 م 2 في 60 شهرًا (N = 549). ولذا يجب تقييم وظيفة الكلى قبل بدء العلاج بتناول تايرونيب أقراص ورصده أثناء العلاج ، مع الانتباه إلى عوامل الخطر لخلل وظائف الكلى مثل ضعف الكلى الموجود مسبقًا ، ومرض السكري ، وارتفاع ضغط الدم ، وفشل القلب الاحتقاني.</p><p dir="RTL"><strong>الأطفال والمراهقون:</strong></p><p dir="RTL">تم الإبلاغ عن حالات تأخر النمو في الأطفال والمراهقين الذين يتناولون تايرونيب أقراص. الآثار الطويلة الأجل للعلاج المطول مع تناول تايرونيب أقراص على نمو الأطفال غير معروفة. لذلك ، يجب رصد النمو في الأطفال تحت العلاج بتناول تايرونيب أقراص.</p><p dir="RTL"><strong>الأطفال:</strong></p><p dir="RTL"><u>الاستخدام في الأطفال:</u></p><p dir="RTL">كما هو الحال في المرضى البالغين ، تم امتصاص إيماتينيب بسرعة بعد تناوله عن طريق الفم في المرضى من الأطفال ، مع C<sub>max</sub> من 2 إلى 4 ساعات. حيث كانت قيم معدل التخلص من الجرعة الفموية مشابهًا لقيم البالغين (11.0 لتر / ساعة / متر مربع في الأطفال مقابل 10.0 لتر / ساعة / متر مربع في البالغين) ، كما كان نصف العمر (14.8 ساعة في الأطفال مقابل 17.1 ساعة في البالغين). حققت الجرعات عند الأطفال في كل من 260 ملغم / م 2 و 340 ملغم / م 2 AUC مماثلة لجرعة 400 ملغم في البالغين. كشفت مقارنة AUC في اليوم الثامن مقابل اليوم الأول عند مستويات جرعة 260 ملغم / م 2 و 340 ملغم / م 2 عن تراكم للأدوية 1.5 و 2.2 مرة ، على التوالي ، بعد الجرعات المتكررة مرة واحدة يوميًا. بما يعني أن AUC الخاصة بتناول إيماتينيب لم تزداد بشكل متناسب مع زيادة الجرعة. استنادًا إلى التحليل الدوائي السكاني المجمع في المرضى الأطفال الذين يعانون من اضطرابات الدم (CML ، أو غيرها من الاضطرابات الدموية التي تعالج باستخدام إيماتينيب) ، تزداد معدلات إزالة إيماتينيب بزيادة مساحة سطح الجسم (BSA). بعد التصحيح لتأثير مساحة سطح الجسم ، لم تؤثر الخصائص الأخرى مثل العمر ووزن الجسم ومؤشر كتلة الجسم بشكل هام سريريًا على التعرض للإيماتينيب. أكد التحليل أن التعرض للـ إيماتينيب في مرضى الأطفال الذين يتلقون 260 ملغم / م 2 مرة واحدة يوميًا (لا تتجاوز 400 ملغم مرة واحدة يوميًا) أو 340 ملغم / م 2 مرة يوميًا (لا يتجاوز 600 ملغم مرة واحدة يوميًا) كان مماثلًا لما يحدث عند البالغين المرضى الذين تناولوا إيماتينيب 400 ملغم أو 600 ملغم مرة واحدة يوميا.</p><p dir="RTL"><strong>التداخلات الدوائية</strong></p><p dir="RTL"><strong>العوامل التي تؤثر على أيض السيتوكروم</strong><strong> </strong><strong>CYP3A</strong><strong> </strong><strong>(المحفزات)</strong></p><p dir="RTL">المعالجة المسبقة للمتطوعين الأصحاء بجرعات متعددة من ريفامبين تليها جرعة واحدة من إيماتينيب ميسيلات ، وزيادة معدلات إزالة جرعة إيماتينيب ميسيلات عن طريق الفم بنسبة 3.8 أضعاف ، مما أدى إلى انخفاض ملحوظ (P أقل من 0.05) يعني C<sub>max</sub> و AUC.وقد لوحظت نتائج مماثلة في المرضى الذين يتناولون ما بين 400 إلى 1200 ملغم / يوم من تايرونيب أقراص بالتزامن مع الأدوية المضادة للصرع التي تحفز الإنزيم EIAED (مثل ، الكاربامازيبين ، أوكسكاربامازبين ، الفينيتوين ، فوسفينيتوين ، الفينوباربيتال ، وبريميدون). انخفض متوسط ​​الجرعة التي تم تطهيرها من AUC لـ إيماتينيب ميسيلات في المرضى الذين يتناولون EIAED بنسبة 73 ٪ مقارنة بالمرضى الذين لا يتناولون EIAED. لقد أدى تناول تايرونيب أقراص المصاحب لتناول نبتة سانت جون إلى انخفاض بنسبة 30 ٪ في AUC في إيماتينيب ميسيلات. ولذا يجب الأخذ في اعتبارك العوامل العلاجية البديلة ذات القدرة على تحفيز أقل للإنزيم عند المرضى اللذين يستخدمون ريفامبين أو محفزات CYP3A4 الأخرى. تم إعطاء جرعات من تايرونيب أقراص والتي تصل إلى 1200 ملغم / يوم (600 ملغم مرتين يوميًا) للمرضى الذين يتناولون محفزات CYP3A4 القوية المصاحبة.</p><p dir="RTL"><strong>العوامل التي تؤثر على أيض السيتوكروم</strong><strong> </strong><strong>CYP3A</strong><strong> </strong><strong>(المثبطات)</strong></p><p dir="RTL">كانت هناك زيادة كبيرة في التعرض لإيماتينيب (بما يعني أن C<sub>max</sub> و AUC بنسبة 26 ٪ و 40 ٪ ، على التوالي) في الأشخاص الأصحاء عندما تمت مشاركة تناول تايرونيب أقراص مع جرعة واحدة من الكيتوكونازول (مثبط CYP3A4). يُنصح بالحذر عند إعطاء إيماتينيب ميسيلات بالتزامن مع مثبطات CYP3A4 القوية (مثل الكيتوكونازول والإيتراكونازول والكلاريثروميسين والأتازانافير والإيندينافير والنافازودون والنيلفينافير والريتونافير والساكوينافير والتليثروميسين). عصير الجريب فروت قد يزيد من تركيزات إيماتينيب في البلازما ويجب تجنبه.</p><p dir="RTL"><strong>التداخلات مع الأدوية التي تتم عملية الأيض الخاصة بها بواسطة </strong><strong>CYP3A4</strong></p><p dir="RTL">إيماتينيب ميسيلات يزيد من متوسط C<sub>max</sub> و AUC من سيمفاستاتين (من ركائز CYP3A4) 2 و 3.5 أضعاف ، على التوالي ، مما يشير إلى تثبيط CYP3A4 بواسطة إيماتينيب ميسيلات. يوصى بالحذر خاصة عند استخدام إيماتينيب ميسيلات مع ركائز CYP3A4 ذات المدى العلاجي الضيق (على سبيل المثال ، الفينتانيل ، السيكلوسبورين ، الديرغوتامين ، الإرغوتامين ، الفنتانيل ، البيموزيد ، الكينيدين ، الكينيدين ، سيروليموس أو التاكروليموس).سيزيد إيماتينيب ميسيلات من تركيز البلازما للعقاقير الأخرى التي تتم عملية الأيض الخاصة بها بواسطة CYP3A4 (على سبيل المثال ، تريازولو- بنزوديازيبينات ، حاصرات قنوات الكالسيوم ديهيدروبيريدين ، بعض مثبطات إنزيم HMG-CoA ، وما إلى ذلك).نظرًا لأن عملية أيض الوارفارين تتم بواسطة CYP2C9 و CYP3A4 ، فإن المرضى الذين يحتاجون إلى منع تخثر الدم يجب أن يحصلوا على وزن جزيئي منخفض أو هيبارين قياسي بدلاً من الوارفارين.</p><p dir="RTL"><strong>التداخلات مع الأدوية التي تتم عملية الأيض الخاصة بها بواسطة </strong><strong>CYP2D6</strong></p><p dir="RTL">إيماتينيب ميسيلات يزيد من متوسط C<sub>max</sub> و AUC من الميتوبرولول بنحو 23 ٪ مما يشير إلى أن إيماتينيب ميسيلات له تأثير مثبط ضعيف على التمثيل الغذائي بوساطة CYP2D6. ليس من الضروري ضبط الجرعة ، ومع ذلك ، يوصى بالحذر عند إعطاء إيماتينيب ميسيلات مع ركائز CYP2D6 ذات المدى العلاجي الضيق.</p><p dir="RTL"><strong>التداخلات الدوائية مع الأسيتامينوفين</strong></p><p dir="RTL">&nbsp;يمنع إيماتينيب ميسيلات مسار أسيتامينوفين O- - جلوكورونيدات في نتائج المختبر (K<sub>i</sub> 58.5 &mu;M). لم يؤدِ التناول المتزامن لإيماتينيب ميسيلات (400 ملغم / يوم لمدة 8 أيام) مع أسيتامينوفين (1000 ملغم جرعة واحدة في اليوم الثامن) في المرضى الذين يعانون من CML إلى أي تغييرات في الحركية الدوائية للأسيتامينوفين. لم يتم تغيير دواء إيماتينيب ميسيلات في وجود أسيتامينوفين بجرعة وحيدة. لا توجد بيانات عن الحرائك الدوائية أو معلومات حول السلامة المصاحبة لإيماتينيب ميسيلات بجرعات أكبر من 400 ملغم / يوم أو الاستخدام المزمن لأسيتامينوفين و إيماتينيب ميسيلات معا.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">يجب تقديم المشورة للمرضى بوجوب إبلاغ الطبيب إذا كانوا أو يعتقدون أنها قد تكون حاملا. ويجب تقديم المشورة للنساء في سن الإنجاب لتجنب الحمل أثناء تناول تايرونيب أقراص. يجب على النساء ذوات القدرة الإنجابية الذين يتناولن تايرونيب أقراص أن يستخدمن موانع الحمل الفعالة للغاية أثناء العلاج ولمدة أربعة عشر يومًا بعد إيقاف العلاج بتايرونيب أقراص. يجب تجنب الرضاعة الطبيعية أثناء العلاج ولمدة شهر واحد بعد آخر جرعة.</p><p dir="RTL"><u>اختبار الحمل</u></p><p dir="RTL">لقد أظهرت تقارير ما بعد البيع في البشر والدراسات على الحيوانات أن إيماتينيب ميسيلات قد يكون ضار على الجنين النامي. فيجب اختبار حالة الحمل في الإناث ذوات القدرة الإنجابية قبل بدء العلاج بتناول تايرونيب أقراص.</p><p dir="RTL"><strong>وسائل منع الحمل</strong></p><p dir="RTL"><u>الإناث</u></p><p dir="RTL">يجب تقديم المشورة للمرضى الإناث ذوات القدرة الإنجابية لاستخدام وسائل منع الحمل الفعالة (الأساليب التي تؤدي إلى أقل من 1 ٪ معدلات الحمل) عند استخدام إيماتينيب ميسيلات أثناء العلاج ولمدة أربعة عشر يوما بعد التوقف عن العلاج بتناول تايرونيب أقراص.</p><p dir="RTL"><u>العقم</u></p><p dir="RTL">لم يتم دراسة خطر العقم عند الإناث أو الذكور من ذوي القدرة التناسلية في البشر. لكن في دراسة على الفئران ، لم تتأثر الخصوبة في الذكور والإناث.</p><p dir="RTL"><strong>الرضاعة</strong></p><p dir="RTL">ملخص المخاطر</p><p dir="RTL">يفرز إيماتينيب ومستقلبه النشط في حليب الأم . وبسبب احتمال حدوث ردود فعل سلبية خطيرة عند الرضع الذين يرضعون من أم تتناول تايرونيب أقراص ، فينصح المرأة المرضعة بعدم القيام بالرضاعة الطبيعية أثناء العلاج ولمدة شهر واحد بعد آخر جرعة.</p><p dir="RTL">البيانات البشرية</p><p dir="RTL">بناءً على بيانات من 3 نساء مرضعات يتناولن تايرونيب أقراص، فإنه تبلغ نسبة الحليب: البلازما حوالي 0.5 لإيماتينيب وحوالي 0.9 بالنسبة للمستقلب النشط. بالنظر إلى تركيز إيماتينيب المشترك والمستقلب النشط ، يمكن أن يحصل الرضيع الذي يرضع من الثدي على ما يصل إلى 10 ٪ من الجرعة العلاجية للأمهات بناءً على وزن الجسم.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب نصح المرضى بأنهم قد يتعرضون لآثار جانبية مثل الدوخة أو عدم وضوح الرؤية أو النعاس أثناء العلاج باستخدام تايرونيب أقراص. لذلك ، يجب توخي الحذر عند قيادة السيارة أو استخدام الآلات ويرجى النظر في ما يلي:</p><p dir="RTL"><strong>الآثار المتعلقة بالقيادة واستخدام الآلات</strong></p><p>تم الإبلاغ عن حوادث السيارات في المرضى الذين يتناولون تايرونيب أقراص. فيجب نصح المرضى بأنهم قد يتعرضون لآثار جانبية مثل الدوخة أو عدم وضوح الرؤية أو النعاس أثناء العلاج باستخدام</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة الموصى</strong><strong> </strong><strong>&nbsp;بها وطريقة التناول</strong></p><p dir="RTL"><strong>طريقة التناول </strong></p><p dir="RTL">يجب أن يتم تناول الجرعة الموصوفة عن طريق الفم ، مع وجبة وكوب كبير من الماء. يجب تناول الجرعات التي تبلغ 400 ملغم أو 600 ملغم مرة واحدة يوميًا ، في حين يجب تناول الجرعة التي قدرها 800 ملغم على أنها 400 ملغم مرتين يوميًا.</p><p dir="RTL">بالنسبة للمرضى غير القادرين على بلع الأقراص ، قد يتم وضع الأقراص في كوب من الماء أو عصير التفاح. يجب وضع العدد المطلوب من الأقراص في الحجم المناسب من المشروبات (حوالي 50 مل للقرص 100 ملغم ، و 200 مل للقرص 400 ملغم) ويقلب بملعقة. يجب أن يستخد المعلق مباشرة بعد الإنتشار الكامل للقرص .</p><p dir="RTL">بالنسبة للجرعات اليومية التي تبلغ 800 ملغم وأكثر ، يجب إجراء الجرعات باستخدام قرص 400 ملغم لتقليل التعرض للحديد.</p><p dir="RTL">قد يستمر العلاج طالما لا يوجد دليل على ظهور مرض كعرض جانبي أو سمية غير مقبولة.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من </strong><strong>Ph + CML CP</strong><strong> أو </strong><strong>AP</strong><strong> أو </strong><strong>BC</strong></p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 400 ملغم / يوم للمرضى البالغين في المرحلة المزمنة CML و 600 ملغم / يوم للمرضى البالغين في المرحلة المتسارعة أو في مرحلة النوبة البالستية.</p><p dir="RTL">في CML ، يمكن النظر في زيادة الجرعة من 400 ملغم إلى 600 ملغم في المرضى البالغين المصابين بأمراض المرحلة المزمنة ، أو من 600 ملغم إلى 800 ملغم (يعطى على 400 ملغم مرتين يوميًا) في المرضى البالغين في المرحلة المتسارعة أو في مرحلة النوبة البالستية وذلك في غياب التفاعلات الدوائية الضارة الشديدة و نقص&nbsp;الخلايا المتعادلة (قلة&nbsp;العدلات) أو نقص الصفيحات المرتبطة باللوكيميا في الحالات التالية: تطور المرض (في أي وقت) ، الفشل في تحقيق استجابة دموية مرضية بعد 3 أشهر على الأقل من العلاج ، الفشل في تحقيق استجابة خلوية إلى 12 شهرًا من العلاج ، أو فقدان استجابة دموية أو خلوية تم تحقيقها مسبقًا.</p><p dir="RTL"><strong>مرضى الأطفال الذين يعانون من </strong><strong>Ph + CML CP</strong></p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص للأطفال الذين تم تشخيصهم حديثًا Ph + CML هي 340 ملغم / م 2 / يوم (لا تتجاوز 600 ملغم). يمكن إعطاء علاج تايرونيب أقراص كجرعة مرة واحدة يوميًا أو يمكن تقسيم الجرعة اليومية إلى قسمين - جرعة واحدة في الصباح وجرعة واحدة في المساء. لا توجد تجربة عن استخدام تايرونيب أقراص في الأطفال دون سن 1 عام.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من </strong><strong>Ph +</strong><strong>&nbsp; </strong><strong>ALL</strong></p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 600 ملغم / يوم للمرضى البالغين الذين يعانون من انتكاسة / مقاومة المرض Ph + ALL.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من</strong><strong> </strong><strong>MDS / MPD</strong></p><p dir="RTL">يجب تشخيص أمراض خلل التنسج النخاعي النقوي / مرض&nbsp; التكاثر النخاعي المتعلقة بتغيرات جينية في مستقبلات الجين PDGFRb قبل بدء العلاج. تتوفر معلومات حول الاختبارات المعتمدة من إدارة الأغذية والعقاقير للكشف عن أمراض خلل التنسج النخاعي النقوي / مرض&nbsp; التكاثر النخاعي المتعلقة بتغيرات جينية في مستقبلات الجين PDGFRb على الموقع http://www.fda.gov/companiondiagnostics.</p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 400 ملغم / يوم للمرضى البالغين الذين يعانون من MDS / MPD.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من</strong><strong> </strong><strong>ASM</strong></p><p dir="RTL">يجب تحديد حالة كثرة الخلايا البدينة الجهازية العدوانية دون طفرة kit-c D816V قبل بدء العلاج. تتوفر معلومات حول الاختبار الذي وافقت عليه إدارة الأغذية والعقاقير (FDA) للكشف عن طفرة كثرة الخلايا البدينة الجهازية العدوانية دون طفرة kit-c D816V على الموقع http://www.fda.gov/companiondiagnostics.</p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 400 ملغم / يوم للمرضى البالغين الذين يعانون من ASM دون حدوث طفرة D816V c-Kit. إذا كانت حالة كثرة الخلايا البدينة الجهازية العدوانية دون طفرة kit-c D816V غير معروفة أو غير متوفرة ، يمكن اعتبار المعالجة بتايرونيب أقراص 400 ملغم / يوم للمرضى الذين لا يستجيبون ASM بشكل مرضٍ للعلاجات الأخرى. بالنسبة للمرضى الذين يعانون من ASM المرتبط بفرط الحمضات ، وهو مرض دموي نسيلي يتعلق بإنزيم fusion kinase FIP1L1-PDGFR&alpha; ، يوصى بجرعة تبدأ من 100 ملغم / يوم. يمكن اعتبار زيادة الجرعة من 100 ملغم إلى 400 ملغم لهؤلاء المرضى في حالة عدم وجود تفاعلات دوائية ضارة إذا أظهرت التقييمات عدم كفاية الاستجابة للعلاج.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من</strong><strong> </strong><strong>HES / CEL</strong></p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 400 ملغم / يوم للمرضى البالغين الذين يعانون من HES / CEL. بالنسبة إلى مرضى HES / CEL الذين لديهم (FIP1L1-PDGFR&alpha; kinase) ، يوصى بتناول جرعة تبدأ من 100 ملغم / يوم. يمكن اعتبار زيادة الجرعة من 100 ملغم إلى 400 ملغم لهؤلاء المرضى في حالة عدم وجود تفاعلات دوائية ضارة إذا أظهرت التقييمات عدم كفاية الاستجابة للعلاج.</p><p dir="RTL"><strong>المرضى البالغين الذين يعانون من</strong><strong> </strong><strong>DFSP</strong></p><p dir="RTL">الجرعة الموصى بها من تايرونيب أقراص هي 800 ملغم / يوم للمرضى البالغين الذين يعانون من DFSP.</p><p dir="RTL"><strong>مرجعية تعديل الجرعة</strong></p><p dir="RTL">محفزات CYP3A4 القوية المصاحبة: يجب تجنب استخدام محفزات CYP3A4 القوية المصاحبة (على سبيل المثال ، ديكساميثازون ، الفينيتوين ، كاربامازيبين ، ريفامبين ، ريفابوتين ، ريفامباكين ، الفيناباربيتال) إذا كان لابد من إعطاء المرضى محفزات CYP3A4 قوي ، استنادًا إلى دراسات الحرائك الدوائية ، فيجب زيادة جرعة تايرونيب أقراص بنسبة 50٪ على الأقل ، ويجب مراقبة الاستجابة السريرية بعناية.</p><p dir="RTL">القصور الكبدي: المرضى الذين يعانون من اختلال كبدي خفيف ومعتدل لا يحتاجون إلى تعديل الجرعة ويجب علاجهم في الجرعة الموصى بها. يجب خفض الجرعة بنسبة 25 ٪ من الجرعة الموصى بها للمرضى الذين يعانون من اختلال كبدي حاد.</p><p dir="RTL">القصور الكلوي: المرضى الذين يعانون من اختلال كلوي معتدل (CrCL = 20 إلى 39 مل / دقيقة) يجب أن يتم خفض جرعتهم بنسبة 50 ٪ في جرعة البداية الموصى بها ويمكن زيادة الجرعات المستقبلية على النحو المسموح به. لا ينصح بجرعات أكبر من 600 ملغم في المرضى الذين يعانون من اختلال كلوي خفيف (CrCL = 40 إلى 59 مل / دقيقة). لا ينصح للمرضى الذين يعانون من اختلال كلوي معتدل الجرعات أكبر من 400 ملغم.</p><p dir="RTL">يجب استخدام إيماتينيب ميسيلات بحذر عند مرضى القصور الكلوي الحاد. تم تحمل جرعة 100 ملغم / يوم في اثنين من المرضى الذين يعانون من ضعف كلوي حاد.</p><p dir="RTL"><strong>ضبط الجرعة لحالات تسمم الكبد وردود الفعل السلبية غير الدموية</strong></p><p dir="RTL">إذا كانت هناك ارتفاعات في البيليروبين أكبر من 3 أضعاف الحد الأعلى للقيم الطبيعية (IULN) أو في إنزيم ناقلات الأمين (ترانس أميناز) الكبدية التي تزيد عن 5 أضعاف IULN ، فيجب التوقف عن تناول تايرونيب أقراص حتى تعود مستويات البيليروبين إلى أقل من 1.5 أضعاف IULN و مستويات إنزيم ناقلة الأمين إلى أقل من 2.5 أضعاف IULN. عند البالغين ، قد يستمر العلاج بتايرونيب أقراص بجرعة يومية مخفضة (أي من 400 ملغم إلى 300 ملغم أو 600 ملغم إلى 400 ملغم أو 800 ملغم إلى 600 ملغم). عند الأطفال ، يمكن تخفيض الجرعات اليومية في نفس الظروف من 340 ملغم / م 2 / يوم إلى 260 ملغم / م 2 / يوم.إذا تطور رد الفعل السلبي غير الدموي الحاد (مثل التسمم الكبدي الوخيم أو احتباس السوائل الوخيم) ، فيجب التوقف عن تناول تايرونيب أقراص حتى يتم تصحيح الأمر. بعد ذلك ، يمكن استئناف العلاج حسب الحاجة اعتمادًا على الخطورة الأولية للحدث.</p><p dir="RTL">ضبط الجرعة لردود الفعل السلبية الدموية</p><p dir="RTL"><strong>يوصى بتخفيض الجرعة أو وقف العلاج في حالات نقص العدلات الشديد ونقص الصفيحات كما هو موضح في الجدول 1.</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">ASM المرتبطة بفرط الحمضات (جرعة البدء 100 ملغم)</p></td><td><p dir="RTL">ANC<sup>1</sup> أقل من 1.0 &times; 10<sup>9</sup> / لتر و / أوالصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. أوقف &nbsp;تناول تايرونيب أقراص حتى يصبح معدل ANC أكبر من أو يساوي 1.5 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 75 &times; 10<sup>9</sup> / L</p><p dir="RTL">2. استئناف العلاج باستخدام تايرونيب أقراص في الجرعة السابقة (أي الجرعة قبل التفاعل الضار الشديد)</p></td></tr><tr><td><p dir="RTL">متلازمة فرط اليوزينيات و / أو سرطان الدم المزمن الناجم عن فرط الحمض النووي الإنزيم (FIP1L1-PDGFR&alpha; kinase)</p></td><td><p dir="RTL">ANC أقل من 1.0 &times; 10<sup>9</sup> / لتر و / أوالصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. أوقف تايرونيب أقراص حتى يصبح معدل ANC أكبر من أو يساوي 1.5 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 75 &times; 10<sup>9</sup> / L</p><p dir="RTL">2. استئناف العلاج باستخدام تايرونيب أقراص في الجرعة السابقة (أي الجرعة قبل التفاعل الضار الشديد)</p></td></tr><tr><td><p dir="RTL">المرحلة المزمنة من CML (جرعة البدء 400 ملغم)</p><p dir="RTL">&nbsp;</p><p dir="RTL">MDS / MPD ، ASM و HES / CEL(جرعة البدء 400 ملغم)</p></td><td><p dir="RTL">ANC أقل من 1.0 &times; 10<sup>9</sup> / لتر و / أوالصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. أوقف تايرونيب أقراص حتى يصبح معدل ANC أكبر من أو يساوي 1.5 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 75 &times; 10<sup>9</sup> / L</p><p dir="RTL">2. استئناف العلاج مع أقراص إيماتينيب mesylate بجرعة البداية الأصلية من 400 ملغم</p><p dir="RTL">3. إذا كان تكرار ANC أقل من 1.0 &times; 10<sup>9</sup> / L و / أو الصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / L ، كرر الخطوة 1 واستئناف تايرونيب أقراص بجرعة مخفضة قدرها 300 ملغم</p></td></tr><tr><td><p dir="RTL">Ph + CML: الطور المتسارع حالة&nbsp; النوبة البالستية (جرعة بدءا 600 ملغم)Ph + ALL(جرعة البدء 600 ملغم)</p></td><td><p dir="RTL">ANC أقل من 0.5 &times; 10<sup>9</sup> / لتر و / أوالصفائح الدموية أقل من 10 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. تحقق مما إذا كان نقص الكريات البيض يرتبط بسرطان الدم (نضح النخاع أو الخزعة)</p><p dir="RTL">2. إذا لم يكن لحالة السيتوبينيا صلة بسرطان الدم ، قم بتخفيض جرعة تايرونيب أقراص إلى 400 ملغم.</p><p dir="RTL">3. إذا استمرت قلة الكريات الخضراء لمدة أسبوعين ، قلل إلى 300 ملغم</p><p dir="RTL">4. إذا استمرت قلة الخلايا لمدة 4 أسابيع ولا تزال غير مرتبطة بسرطان الدم ، توقف عن تناول تايرونيب أقراص إلى أن تزيد ANC أكبر من أو تساوي 1 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 20 &times; 10<sup>9</sup> / L ثم تستأنف العلاج عند 300 ملغم</p></td></tr><tr><td><p dir="RTL">DFSP(جرعة البدء 800 ملغم)</p></td><td><p dir="RTL">ANC أقل من 1.0 &times; 10<sup>9</sup> / L و / أوالصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. أوقف تايرونيب أقراص حتى يصبح معدل ANC أكبر من أو يساوي 1.5 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 75 &times; 10<sup>9</sup> / L2. استئناف العلاج مع تايرونيب أقراص في 600 ملغم</p><p dir="RTL">3. في حالة تكرار ANC أقل من 1.0 &times; 10<sup>9</sup> / L و / أو الصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / L ، كرر الخطوة 1 واستئناف تايرونيب أقراص بجرعة مخفضة قدرها 400 ملغم</p></td></tr><tr><td><p dir="RTL">الأطفال الذين تم تشخيصهم حديثًا المرحلة المزمنة CML(بدء جرعة 340 ملغ / م 2)</p></td><td><p dir="RTL">ANC أقل من 1.0 &times; 10<sup>9</sup> / L و / أوالصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / لتر</p></td><td><p dir="RTL">1. أوقف تايرونيب أقراص حتى يصبح معدل ANC أكبر من أو يساوي 1.5 &times; 10<sup>9</sup> / L والصفائح الدموية أكبر من أو تساوي 75 &times; 10<sup>9</sup> / L</p><p dir="RTL">2. استئناف العلاج باستخدام تايرونيب أقراص في الجرعة السابقة (أي الجرعة قبل التفاعل الضار الشديد)</p><p dir="RTL">3. في حالة تكرار ANC أقل من 1.0 &times; 10<sup>9</sup> / L و / أو الصفائح الدموية أقل من 50 &times; 10<sup>9</sup> / L ، كرر الخطوة 1 واستئناف تايرونيب أقراص بجرعة مخفضة قدرها 260 ملغم / م <sup>2</sup></p></td></tr></tbody></table><p dir="RTL"><sup>1</sup>ANC = مستوى العدلات أو الخلايا المتعادلة المطلق</p><p dir="RTL"><strong>الجرعة الزائدة من تايرونيب أقراص</strong></p><p dir="RTL">التجارب على جرعات أكبر من 800 ملغم محدودة. تم الإبلاغ عن حالات معزولة من تأثيرات الجرعة الزائدة من إيماتينيب ميسيلات. في حال الجرعة الزائدة ، يجب ملاحظة المريض واعطاء العلاج المناسب.</p><p dir="RTL"><strong>الجرعة الزائدة </strong><strong>للبالغين</strong></p><p dir="RTL"><strong>من 1200 إلى 1600 ملغم (تتراوح المدة بين 1 إلى 10 أيام): </strong>غثيان ، قيء ، إسهال ، حمامي طفح ، وذمة ، تورم ، تعب ، تشنجات عضلية ، نقص الصفيحات ، قلة الكريات الشاملة ، ألم بطني ، صداع ، انخفاض الشهية.</p><p dir="RTL"><strong>1800 حتي 3200 ملغم (</strong><strong>ما </strong><strong>يصل إلى 3200 ملغم يوميا لمدة 6 أيام):</strong> ضعف ، ألم عضلي ، زيادة نسبة CPK ، زيادة البيليروبين ، آلام في الجهاز الهضمي.</p><p dir="RTL">6400 ملغم (جرعة واحدة): ذكرت حالة واحدة في التقارير مريض واحد يعاني من الغثيان والقيء وآلام في البطن ، حمه ، وتورم في الوجه ، و انخفض عدد العدلات أو الخلايا المتعادلة ، وزيادة ناقلات الأمين (ترانس أميناز).</p><p dir="RTL"><strong>من 8 إلى 10 غرام (جرعة واحدة):</strong> تم الإبلاغ عن القيء وآلام الجهاز الهضمي.</p><p dir="RTL">تعرض مريض مصاب بأزمة انفجار النخاع المرتفع من الدرجة الأولى من الكرياتينين في الدم ، ومستويات من الدرجة الثانية ومستويات ترانس أميناز الكبدية المرتفعة ، والدرجة الثالثة من البيليروبين بعد تناول 1200 ملغم من تايرونيب أقراص يوميًا لمدة 6 أيام. تمت مقاطعة العلاج مؤقتًا وحدث انعكاس كامل لجميع الحالات غير الطبيعية خلال أسبوع واحد. تم استئناف العلاج بجرعة 400 ملغم يوميا دون تكرار ردود الفعل السلبية. أصيب مريض آخر بتشنجات عضلية شديدة بعد تناول 1600 ملغم من تايرونيب أقراص يوميًا لمدة 6 أيام. حدث القرار الكامل للتشنجات العضلية بعد توقف العلاج وتم استئناف العلاج لاحقًا. مريض آخر تم وصفه بـ 400 ملغم يوميًا ، تناول 800 ملغم من تايرونيب أقراص في اليوم الأول و 1200 ملغم في اليوم الثاني. توقف العلاج ، ولم تحدث ردود فعل سلبية واستأنف المريض العلاج.</p><p dir="RTL">الجرعة الزائدة في الأطفال</p><p dir="RTL">صبي يبلغ من العمر 3 سنوات تعرض لجرعة واحدة من 400 ملغم من القيء والإسهال وفقدان الشهية وصبي آخر عمره 3 سنوات يتعرض لجرعة واحدة من 980 ملغم عانى من انخفاض عدد خلايا الدم البيضاء والإسهال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تقديم المشورة للمرضى بأنهم قد يتعرضون لآثار جانبية مثل الدوخة ، أو عدم وضوح الرؤية أو النعاس أثناء العلاج بتناول تايرونيب أقراص. ويوصي بالحذر عند قيادة السيارة أو تشغيل الآلات.</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إذا زادت حدة أي من هذه الأعراض الجانبية ، أو لاحظت ظهور أعراض جانبية غير ما تم ذكره في هذه النشرة ، يرجى إبلاغ الطبيب المعالج أو الصيدلي . وهذا يشمل أي آثار جانبية محتملة غير مدرجة في هذه النشرة . يمكنك أيضا الإبلاغ عن الآثار الجانبية مباشرة (انظر التفاصيل أدناه) . بالإبلاغ عن الآثار الجانبية يمكنك المساعدة في توفير مزيد من المعلومات حول أمان هذا الدواء .</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:558px"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><!--[if mso & !supportInlineShapes & supportFields]><span
  style='mso-element:field-begin;mso-field-lock:yes'></span><span dir=LTR></span><span
  dir=LTR></span><span dir=LTR><span dir=LTR></span><span dir=LTR></span><span
  style='mso-spacerun:yes'> </span>SHAPE <span
  style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
  field-separator'></span></span><![endif]--></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; فاكس 7662-205-1-966+</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الاتصال على المركز الوطني للتيقظ والسلامة الدوائية +966-11-2038222 ، تحويلة: 2317-2356-2353-2354-2334-2340</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الهاتف المجاني: 8002490000</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني : npc .drug@sfda .gov .sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: www .sfda .gov .sa/npc</p></td></tr></tbody></table><!--[if mso & !supportInlineShapes & supportFields]><span
  dir=LTR><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;
   height:90.7pt'>
   <v:imagedata croptop="-65520f" cropbottom="65520f"/>
  </v:shape><span style='mso-element:field-end'></span></span><![endif]--><p>&nbsp;</p><p dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">&nbsp; &nbsp;يرجى الاتصال بالسلطة الصحية المختصة .</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء عند درجة حرارة أقل من 30 درجة مئوية..</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ هذا الدواء في العبوة الأصلية للحماية من الرطوبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول أيدي الأطفال أو على مرأى منهم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم تايرونيب أقراص بعد انتهاء تاريخ الصلاحية المذكور على العبوة الخارجية. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي أن يتم التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة . هذه التدابير تساعد في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما تحتويه تايرونيب أقراص </strong></p><p dir="RTL">المادة الفعالة هي إيماتينيب ميسيلات.</p><p dir="RTL">أقراص <strong>تايرونيب 100 ملغم</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 119.50 ملغم إيماتينيب ميسيلات مايكافئ إيماتينيب 100 ملغم .</p><p dir="RTL">أقراص <strong>تايرونيب 400 ملغم</strong></p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة على 478 ملغم إيماتينيب ميسيلات مايكافئ إيماتينيب 400 ملغم .</p><p dir="RTL"><strong>الصواغات الأخرى هي</strong>: هيبروميلوز 2910 &nbsp;5cps (ميثوسيل برميوم E5 LV ) <strong>، </strong>السليلوز دقيق التبلور ، أفيسيل PH 102 ، كروس بوفيدون(كوليدون CL ) ، ثاني أكسيد السيليكون الغروي (أيروسيل 200 ) ، ستيارات الماغنسيوم ، ماء نقي.</p><p dir="RTL"><strong>الصواغات الأخرى لطبقة الكسوة هي</strong>: هيبروميلوز 2910 HPMC ، ثاني أكسيد التيتانيوم ، بولي إيثيلين جليكول / ماكروجول ، تلك .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل تايرونيب أقراص ومحتويات العلبة ؟</strong></p><p dir="RTL"><strong>تايرونيب أقراص 100 ملغم</strong></p><p dir="RTL">أقراص دائرية الشكل محدبة الوجهين قابلة للتقسيم ذات لون أبيض إلى أبيض قاتم ، والأقراص مغلفة بطبقة رقيقة و مدموغة بحروف &quot;H&quot; من جانب و &quot;7&quot; على الجانب الآخر مع وجود خط للشطر.</p><p dir="RTL"><strong>تايرونيب أقراص 400 ملغم</strong></p><p dir="RTL">أقراص بيضاوية الشكل محدبة الوجهين قابلة للتقسيم ذات لون أبيض إلى أبيض قاتم ، &nbsp;والأقراص مشطوفة الحواف ومغلفة بطبقة رقيقة و مدموغة بحروف &quot;H&quot; من جانب و &quot;4&quot; على الجانب الآخر مع وجود خط للشطر.</p><p dir="RTL"><strong>توافر تايرونيب أقراص :</strong></p><p dir="RTL">يتوافر تايرونيب أقراص في عبوات حاوية .</p><p dir="RTL">تحتوي عبوة تايرونيب أقراص 100 ملغم على 30 قرص عبارة عن ثلاثة شرائط بكل منها 10 أقراص</p><p dir="RTL">تحتوي عبوة تايرونيب أقراص 400 ملغم على 30 قرص عبارة عن ثلاثة شرائط بكل منها 10 أقراص</p><p dir="RTL">قد لا تتوافر كافة العبوات في السوق</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب حق التسويق:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة &ndash; الملز &ndash; الرياض 11441</p><p dir="RTL">المملكة العربية السعودية .</p><p dir="RTL">تليفون: &nbsp;+ 966 114772215</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imatinib Mesylate Tablets 100mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imatinib Mesylate Tablets 100mg: 
Each film coated tablet contains Imatinib Mesylate 119. 5 0 mg Equivalent to Imatinib 100 mg 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Imatinib Mesylate Tablets 100mg: 
White to off white colored, round, biconvex scored, bevel edged, film coated tablets debossed with H on one side and 7 on the other side with score line. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Newly Diagnosed Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML) </strong>&nbsp;</p><p>Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.&nbsp;</p><p><strong>Ph+ CML in Blast Crisis (BC), Accelerated Phase (AP) or Chronic Phase (CP) After Interferon-alpha (IFN) Therapy </strong>&nbsp;</p><p>Patients with Philadelphia chromosome positive chronic myeloid leukemia in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.&nbsp;</p><p><strong>Adult patients with Ph+ Acute Lymphoblastic Leukemia (ALL) </strong>&nbsp;</p><p>Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL).</p><p><strong>Myelodysplastic/Myeloproliferative Diseases (MDS/MPD) </strong>&nbsp;</p><p>Adult patients with myelodysplastic/myeloproliferative diseases associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDAapproved test.&nbsp;</p><p><strong>Aggressive Systemic Mastocytosis (ASM) </strong>&nbsp;</p><p>Adult patients with aggressive systemic mastocytosis without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown.&nbsp;</p><p><strong>Hypereosinophilic Syndrome (HES) and/or Chronic Eosinophilic Leukemia (CEL) </strong>&nbsp;</p><p>Adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia who have the FIP1L1-PDGFR&alpha; fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFR&alpha; fusion kinase negative or unknown.&nbsp;</p><p><strong>Dermatofibrosarcoma Protuberans (DFSP) </strong>&nbsp;</p><p>Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Drug Administration </strong>&nbsp;</p><p>The prescribed dose should be administered orally, with a meal and a large glass of water. Doses of 400 mg or 600 mg should be administered once daily, whereas a dose of 800 mg should be administered as 400 mg twice a day.&nbsp;</p><p>For patients unable to swallow the film-coated tablets, the tablets may be dispersed in a glass of water or apple juice. The required number of tablets should be placed in the appropriate volume of beverage (approximately 50 mL for a 100 mg tablet, and 200 mL for a 400 mg tablet) and stirred with a spoon. The suspension should be administered immediately after complete disintegration of the tablet(s).&nbsp;</p><p>For daily dosing of 800 mg and above, dosing should be accomplished using the 400 mg tablet to reduce exposure to iron.&nbsp;</p><p>Treatment may be continued as long as there is no evidence of progressive disease or unacceptable toxicity.</p><p><strong>Adult Patients with Ph+ CML CP, AP, or BC </strong>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients in chronic phase CML and 600 mg/day for adult patients in accelerated phase or blast crisis.&nbsp;</p><p>In CML, a dose increase from 400 mg to 600 mg in adult patients with chronic phase disease, or from 600 mg to 800 mg (given as 400 mg twice daily) in adult patients in accelerated phase or blast crisis may be considered in the absence of severe adverse drug reaction and severe nonleukemia related neutropenia or thrombocytopenia in the following circumstances: disease progression (at any time), failure to achieve a satisfactory hematologic response after at least 3 months of treatment, failure to achieve a cytogenetic response after 6 to 12 months of treatment, or loss of a previously achieved hematologic or cytogenetic response.&nbsp;</p><p><strong>Pediatric Patients with Ph+ CML CP </strong>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets for children with newly diagnosed Ph+ CML is 340 mg/m<sup>2</sup>/day (not to exceed 600 mg). Imatinib mesylate tablets treatment can be given as a once daily dose or the daily dose may be split into two&ndash;one portion dosed in the morning and one portion in the evening. There is no experience with imatinib mesylate tablets treatment in children under 1 year of age.&nbsp;</p><p><strong>Adult Patients with Ph+ ALL </strong>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 600 mg/day for adult patients with relapsed/refractory Ph+ ALL.&nbsp;</p><p><strong>Adult Patients with MDS/MPD </strong>&nbsp;</p><p>Determine PDGFRb gene rearrangements status prior to initiating treatment. Information on FDA-approved tests for the detection of PDGFRb rearrangements is available at http://www.fda.gov/companiondiagnostics.&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with MDS/MPD.&nbsp;</p><p><strong>Adult Patients with ASM </strong>&nbsp;</p><p>Determine D816V c-Kit mutation status prior to initiating treatment. Information on FDAapproved test for the detection of D816V c-Kit mutation is available at http://www.fda.gov/companiondiagnostics.&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with ASM without the D816V c-Kit mutation. If c-Kit mutational status is not known or unavailable, treatment with imatinib mesylate tablets 400 mg/day may be considered for patients with ASM not responding satisfactorily to other therapies. For patients with ASM associated with eosinophilia, a clonal hematological disease related to the fusion kinase FIP1L1-PDGFR&alpha;, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.&nbsp;</p><p><strong>Adult Patients with HES/CEL </strong>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 400 mg/day for adult patients with HES/CEL. For HES/CEL patients with demonstrated FIP1L1-PDGFR&alpha; fusion kinase, a starting dose of 100 mg/day is recommended. Dose increase from 100 mg to 400 mg for these patients may be considered in the absence of adverse drug reactions if assessments demonstrate an insufficient response to therapy.&nbsp;</p><p><strong>Adult Patients with DFSP </strong>&nbsp;</p><p>The recommended dose of imatinib mesylate tablets is 800 mg/day for adult patients with DFSP.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Dose Modification Guidelines </strong>&nbsp;</p><p><em>Concomitant Strong CYP3A4 inducers: </em>The use of concomitant strong CYP3A4 inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin, phenobarbital). If patients must be coadministered a strong CYP3A4 inducer, based on pharmacokinetic studies, the dosage of imatinib mesylate tablets should be increased by at least 50%, and clinical response should be carefully monitored<em>]. </em>&nbsp;</p><p><em>Hepatic Impairment: </em>Patients with mild and moderate hepatic impairment do not require a dose</p><p>adjustment and should be treated per the recommended dose. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.</p><p><em>Renal Impairment: </em>Patients with moderate renal impairment (CrCL=20 to 39 mL/min) should receive a 50% decrease in the recommended starting dose and future doses can be increased as tolerated. Doses greater than 600 mg are not recommended in patients with mild renal impairment (CrCL=40 to 59 mL/min). For patients with moderate renal impairment doses greater than 400 mg are not recommended.&nbsp;</p><p>Imatinib should be used with caution in patients with severe renal impairment. A dose of 100 mg/day was tolerated in two patients with severe renal impairment.<em> </em></p><p><strong>Dose Adjustment for Hepatotoxicity and Non-Hematologic Adverse Reactions </strong>&nbsp;</p><p>If elevations in bilirubin greater than 3 times the institutional upper limit of normal (IULN) or in liver transaminases greater than 5 times the IULN occur, imatinib mesylate tablets should be withheld until bilirubin levels have returned to a less than 1.5 times the IULN and transaminase levels to less than 2.5 times the IULN. In adults, treatment with imatinib mesylate tablets may then be continued at a reduced daily dose (i.e., 400 mg to 300 mg, 600 mg to 400 mg or 800 mg to 600 mg). In children, daily doses can be reduced under the same circumstances from 340 mg/m<sup>2</sup>/day to 260 mg/m<sup>2</sup>/day.&nbsp;</p><p>If a severe non-hematologic adverse reaction develops (such as severe hepatotoxicity or severe fluid retention), imatinib mesylate tablets should be withheld until the event has resolved. Thereafter, treatment can be resumed as appropriate depending on the initial severity of the event.&nbsp;</p><p><strong>Dose Adjustment for Hematologic Adverse Reactions </strong>&nbsp;</p><p>Dose reduction or treatment interruptions for severe neutropenia and thrombocytopenia are recommended as indicated in Table 1.&nbsp;</p><p><strong>Table 1: Dose Adjustments for Neutropenia and Thrombocytopenia </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:591px"><tbody><tr><td style="vertical-align:top"><p>ASM associated with eosinophilia (starting dose 100 mg)&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ANC<sup>1</sup> less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>1.</p></td><td style="vertical-align:top"><p>Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Resume treatment with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase (starting dose 100 mg)&nbsp;</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.</p></td><td style="vertical-align:top"><p>Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Resume treatment with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Chronic Phase CML (starting</p><p>dose 400 mg)&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>MDS/MPD, ASM and HES/CEL&nbsp;</p><p>(starting dose 400 mg)&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.</p><p>2.</p></td><td style="vertical-align:top"><p>Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L&nbsp;</p><p>Resume treatment with imatinib mesylate tablets at the original starting dose of&nbsp;&nbsp;</p><p>400 mg</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.</p></td><td style="vertical-align:top"><p>If recurrence of ANC less than 1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, repeat step 1 and resume imatinib mesylate tablets at a reduced dose of 300 mg&nbsp;&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ph+ CML : Accelerated Phase and&nbsp;</p><p>Blast Crisis (starting dose 600 mg)&nbsp;</p><p>Ph+ ALL&nbsp;</p><p>(starting dose 600 mg)&nbsp;</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>ANC less than 0.5 x 10<sup>9</sup>/L and/or</p><p>platelets less than 10 x 10<sup>9</sup>/L</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.</p><p>2.</p></td><td style="vertical-align:top"><p>Check if cytopenia is related to leukemia (marrow aspirate or biopsy)&nbsp;</p><p>If cytopenia is unrelated to leukemia, reduce dose of imatinib mesylate tablets to</p><p>400 mg&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3.</p></td><td style="vertical-align:top"><p>If cytopenia persists 2 weeks, reduce further to 300 mg&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4.</p></td><td style="vertical-align:top"><p>If cytopenia persists 4 weeks and is still unrelated to leukemia, stop imatinib mesylate tablets until ANC greater than or equal to1 x 10<sup>9</sup>/L and platelets greater than or equal to 20 x 10<sup>9</sup>/L and then resume treatment at 300 mg&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>DFSP (starting dose 800 mg)&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p></td><td colspan="2" style="vertical-align:top"><p>1.</p></td><td style="vertical-align:top"><p>Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Resume treatment with imatinib mesylate tablets at 600 mg&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3.</p></td><td style="vertical-align:top"><p>In the event of recurrence of ANC less than 1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, repeat step 1 and resume imatinib mesylate tablets at reduced dose of&nbsp;&nbsp;</p><p>400 mg&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pediatric newly diagnosed chronic phase CML&nbsp;</p><p>(starting dose 340 mg/m<sup>2</sup>)&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>ANC less than 1.0 x 10<sup>9</sup>/L and/or</p><p>platelets less than 50 x 10<sup>9</sup>/L</p></td><td colspan="2" style="vertical-align:top"><p>1.</p></td><td style="vertical-align:top"><p>Stop imatinib mesylate tablets until ANC greater than or equal to 1.5 x 10<sup>9</sup>/L and platelets greater than or equal to 75 x 10<sup>9</sup>/L&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2.</p></td><td style="vertical-align:top"><p>Resume treatment &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with imatinib mesylate tablets at previous dose (i.e., dose before severe adverse reaction)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3.</p></td><td style="vertical-align:top"><p>In the event of recurrence of ANC less than 1.0 x 10<sup>9</sup>/L and/or platelets less than 50 x 10<sup>9</sup>/L, &nbsp;&nbsp;&nbsp; repeat &nbsp;&nbsp;&nbsp; step &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and resume &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; imatinib mesylate tablets at reduced dose of&nbsp;&nbsp;</p><p>260 mg/m<sup>2 </sup>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><sup>1</sup>ANC = absolute neutrophil count&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                None
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fluid Retention and Edema </strong>&nbsp;</p><p>Imatinib mesylate is often associated with edema and occasionally serious fluid retention<em>. </em>Weigh and monitor patients regularly for signs and symptoms of fluid retention. Investigate unexpected rapid weight gain carefully and provide appropriate treatment. The probability of edema was increased with higher imatinib mesylate dose and age greater than 65 years in the CML studies. Severe superficial edema was reported in 1.5% of newly diagnosed CML patients taking imatinib mesylate, and in 2% to 6% of other adult CML patients taking imatinib mesylate. In addition, other severe fluid retention (e.g., pleural effusion, pericardial effusion, pulmonary edema, and ascites) reactions were reported in 1.3% of newly diagnosed CML patients taking imatinib mesylate, and in 2% to 6% of other adult CML patients taking imatinib mesylate<em>. </em>In a randomized trial in patients with newly diagnosed Ph+CML in chronic phase comparing imatinib mesylate and nilotinib, severe (Grade 3 or 4) fluid retention occurred in 2.5% of patients receiving imatinib mesylate and in 3.9% of patients receiving nilotinib 300 mg twice daily. Effusions (including pleural effusion, pericardial effusion, ascites) or pulmonary edema were observed in 2.1% (none were Grade 3 or 4) of patients in the imatinib mesylate arm and 2.2% (0.7% Grade 3 or 4) of patients in the nilotinib 300 mg twice daily arm.&nbsp;</p><p><strong>Hematologic Toxicity </strong>&nbsp;</p><p>Treatment with imatinib mesylate is associated with anemia, neutropenia, and thrombocytopenia. Perform complete blood counts weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2 to 3 months). In CML, the occurrence of these cytopenias is dependent on the stage of disease and is more frequent in patients with accelerated phase CML or blast crisis than in patients with chronic phase CML. In pediatric CML patients the most frequent toxicities observed were Grade 3 or 4 cytopenias including neutropenia, thrombocytopenia and anemia. These generally occur within the first several months of therapy.</p><p>&nbsp;</p><p><strong>Congestive Heart Failure and Left Ventricular Dysfunction </strong>&nbsp;</p><p>Congestive heart failure and left ventricular dysfunction have been reported in patients taking imatinib mesylate. Cardiac adverse reactions were more frequent in patients with advanced age or co-morbidities including previous medical history of cardiac disease. In an international randomized Phase 3 study in 1,106 patients with newly diagnosed Ph+ CML in chronic phase, severe cardiac failure and left ventricular dysfunction were observed in 0.7% of patients taking imatinib mesylate compared to 0.9% of patients taking IFN + Ara-C. In another randomized trial with newly diagnosed Ph+ CML patients in chronic phase that compared imatinib mesylate and nilotinib, cardiac failure was observed in 1.1% of patient in the imatinib mesylate arm and 2.2% of patients in the nilotinib 300 mg twice daily arm and severe (Grade 3 or 4) cardiac failure occurred in 0.7% of patients in each group. Carefully monitor patients with cardiac disease or risk factors for cardiac or history of renal failure. Evaluate and treat any patient with signs or symptoms consistent with cardiac or renal failure.&nbsp;</p><p><strong>Hepatotoxicity </strong>&nbsp;</p><p>Hepatotoxicity, occasionally severe, may occur with imatinib mesylate. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of imatinib mesylate. Monitor liver function (transaminases, bilirubin, and alkaline phosphatase) before initiation of treatment and monthly, or as clinically indicated. Manage laboratory abnormalities with imatinib mesylate interruption and/or dose reduction. When imatinib mesylate is combined with chemotherapy, liver toxicity in the form of transaminase elevation and hyperbilirubinemia has been observed. Additionally, there have been reports of acute liver failure. Monitoring of hepatic function is recommended.&nbsp;</p><p><strong>Hemorrhage </strong>&nbsp;</p><p>In a trial of imatinib mesylate versus IFN+Ara-C in patients with the newly diagnosed CML, 1.8% of patients had Grade 3/4 hemorrhage. In a randomized trial in patients with newly diagnosed Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib, GI hemorrhage occurred in 1.4% of patients in the imatinib mesylate arm, and in 2.9% of patients in the nilotinib 300 mg twice daily arm. None of these events were Grade 3 or 4 in the imatinib mesylate arm; 0.7% were Grade 3 or 4 in the nilotinib 300 mg twice daily arm. In addition, gastric antral vascular ectasia has been reported in postmarketing experience.&nbsp;</p><p><strong>Gastrointestinal Disorders </strong>&nbsp;</p><p>Imatinib mesylate is sometimes associated with GI irritation. Imatinib mesylate should be taken with food and a large glass of water to minimize this problem. There have been rare reports, including fatalities, of gastrointestinal perforation.&nbsp;</p><p><strong>Hypereosinophilic Cardiac Toxicity </strong>&nbsp;</p><p>In patients with hypereosinophilic syndrome with occult infiltration of HES cells within the myocardium, cases of cardiogenic shock/left ventricular dysfunction have been associated with HES cell degranulation upon the initiation of imatinib mesylate therapy. The condition was reported to be reversible with the administration of systemic steroids, circulatory support measures and temporarily withholding imatinib mesylate.</p><p>Myelodysplastic/myeloproliferative disease and systemic mastocytosis may be associated with high eosinophil levels. Consider performing an echocardiogram and determining serum troponin in patients with HES/CEL, and in patients with MDS/MPD or ASM associated with high eosinophil levels. If either is abnormal, consider prophylactic use of systemic steroids (1 to 2 mg/kg) for one to two weeks concomitantly with imatinib mesylate at the initiation of therapy.&nbsp;</p><p><strong>Dermatologic Toxicities </strong>&nbsp;</p><p>Bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome, have been reported with use of imatinib mesylate. In some cases of bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome reported during postmarketing surveillance, a recurrent dermatologic reaction was observed upon rechallenge. Several foreign postmarketing reports have described cases in which patients tolerated the reintroduction of imatinib mesylate therapy after resolution or improvement of the bullous reaction. In these instances, imatinib mesylate was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines.&nbsp;</p><p><strong>Hypothyroidism </strong>&nbsp;</p><p>Clinical cases of hypothyroidism have been reported in thyroidectomy patients undergoing levothyroxine replacement during treatment with imatinib mesylate. Monitor TSH levels in such patients.&nbsp;</p><p><strong>Embryo-fetal Toxicity </strong>&nbsp;</p><p>Imatinib mesylate can cause fetal harm when administered to a pregnant woman. Imatinib mesylate was teratogenic in rats when administered during organogenesis at doses approximately equal to the maximum human dose of 800 mg/day based on body surface area. Significant postimplantation loss was seen in female rats administered imatinib mesylate at doses approximately one-half the maximum human dose of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 800 mg/day based on body surface area. Advise sexually active female patients of reproductive potential to use effective contraception (methods that result in less than 1% pregnancy rates) when using imatinib mesylate and for 14 days after stopping imatinib mesylate. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to a fetus.</p><p><strong>Growth Retardation in Children and Adolescents </strong>&nbsp;</p><p>Growth retardation has been reported in children and pre-adolescents receiving imatinib mesylate. The long term effects of prolonged treatment with imatinib mesylate on growth in children are unknown. Therefore, monitor growth in children under imatinib mesylate treatment.</p><p><strong>Tumor Lysis Syndrome </strong>&nbsp;</p><p>Cases of Tumor Lysis Syndrome (TLS), including fatal cases, have been reported in patients with CML, GIST, ALL and eosinophilic leukemia receiving imatinib mesylate. The patients at risk of TLS are those with tumors having a high proliferative rate or high tumor burden prior to treatment. Monitor these patients closely and take appropriate precautions. Due to possible occurrence of TLS, correct clinically significant dehydration and treat high uric acid levels prior to initiation of imatinib mesylate.&nbsp;</p><p><strong>Impairments Related to Driving and Using Machinery </strong>&nbsp;</p><p>Motor vehicle accidents have been reported in patients receiving imatinib mesylate. Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with imatinib mesylate. Recommend caution when driving a car or operating machinery.&nbsp;</p><p><strong>Renal Toxicity </strong>&nbsp;</p><p>A decline in renal function may occur in patients receiving imatinib mesylate. Median estimated glomerular filtration rate (eGFR) values in patients on imatinib mesylate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 400 mg daily for newly-diagnosed CML (four randomized trials) and another clinical trail declined from a</p><p>&nbsp;&nbsp;&nbsp; &nbsp;baseline value of 85 ml/min/1.73m<sup>2 </sup>(N=1,190) to 75 ml/min/1.73m<sup>2 </sup>at 12 months (N=1,082) and</p><p>&nbsp;</p><p>69 ml/min/1.73m<sup>2 </sup>at 60 months (N=549). Evaluate renal function prior to initiating imatinib mesylate and monitor during therapy, with attention to risk factors for renal dysfunction such as pre-existing renal impairment, diabetes mellitus, hypertension, and congestive heart failure</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Agents Inducing CYP3A Metabolism </strong>&nbsp;</p><p>Concomitant administration of imatinib mesylate and strong CYP3A4 inducers may reduce total exposure of imatinib; consider alternative agents.&nbsp;</p><p><strong>Agents Inhibiting CYP3A Metabolism </strong>&nbsp;</p><p>Concomitant administration of imatinib mesylate and strong CYP3A4 inhibitors may result in a significant imatinib exposure increase. Grapefruit juice may also increase plasma concentrations of imatinib; avoid grapefruit juice.&nbsp;&nbsp;</p><p><strong>Interactions with Drugs Metabolized by CYP3A4 </strong>&nbsp;</p><p>Imatinib mesylate will increase plasma concentration of CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.). Use caution when administering imatinib mesylate with CYP3A4 substrates that have a narrow therapeutic window.&nbsp;</p><p>Because warfarin is metabolized by CYP2C9 and CYP3A4, use low-molecular weight or standard heparin instead of warfarin in patients who require anticoagulation.</p><p><strong>Interactions with Drugs Metabolized by CYP2D6 </strong>&nbsp;</p><p>Use caution when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy&nbsp; </strong></p><p><em>Risk Summary </em>&nbsp;</p><p>Imatinib mesylate can cause fetal harm when administered to a pregnant woman based on human and animal data. There are no clinical studies regarding use of imatinib mesylate in pregnant women. There have been postmarket reports of spontaneous abortions and congenital anomalies from women who have been exposed to imatinib mesylate during pregnancy. Reproductive studies in rats have demonstrated that imatinib mesylate induced teratogenicity and increased incidence of congenital abnormalities following prenatal exposure to imatinib mesylate at doses equal to the highest recommended human dose of 800 mg/day based on body surface area. Advise women to avoid pregnancy when taking imatinib mesylate. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.&nbsp;</p><p>The background risk of major birth defects and miscarriage for the indicated population is not known; however, in the U.S. general population, the estimated background risk of major birth defects of clinically recognized pregnancies is 2 to 4% and of miscarriage is 15% to 20%.&nbsp; <em>Data </em>&nbsp;</p><p>Animal Data&nbsp;</p><p>In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of imatinib mesylate up to 100 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis.&nbsp;</p><p>In rats, imatinib mesylate was teratogenic at 100 mg/kg/day (approximately equal to the maximum human dose of 800 mg/day based on body surface area), the number of fetuses with encephalocoele and exencephaly was higher than historical control values and these findings were associated with missing or underdeveloped cranial bones. Lower mean fetal body weights were associated with retarded skeletal ossifications.&nbsp;</p><p>In rabbits, at doses 1.5 times higher than the maximum human dose of 800 mg/day based on body surface area, no effects on the reproductive parameters with respect to implantation sites, number of live fetuses, sex ratio or fetal weight were observed. The examinations of the fetuses did not reveal any drug related morphological changes.&nbsp;</p><p>In a pre-and postnatal development study in rats, pregnant rats received oral doses of imatinib mesylate during gestation (organogenesis) and lactation up to 45 mg/kg/day. Five animals developed a red vaginal discharge in the 45 mg/kg/day group on Days 14 or 15 of gestation, the significance of which is unknown since all females produced viable litters and none had increased post-implantation loss. Other maternal effects noted only at the dose of 45 mg/kg/day (approximately one-half the maximum human dose of 800 mg/day based on body surface area) included an increased numbers of stillborn pups and pups dying between postpartum Days 0 and 4. In the F<sup>1 </sup>offspring at this same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. There were no other significant effects in developmental parameters or behavioral testing. F<sup>1 </sup>fertility was not affected but reproductive effects were noted at 45 mg/kg/day including an increased number of resorptions and a decreased number of viable fetuses. The NOEL for both maternal animals and the F<sup>1</sup> generation was 15 mg/kg/day.&nbsp;</p><p><strong>Lactation&nbsp; </strong></p><p>&nbsp;</p><p>Risk Summary &nbsp;</p><p>Imatinib and its active metabolite are excreted into human milk. Because of the potential for serious adverse reactions in breastfed infants from imatinib mesylate, advise a lactating woman not to breastfeed during treatment and for 1 month after the last dose.&nbsp;</p><p>&nbsp;</p><p>Human Data &nbsp;</p><p>Based on data from 3 breastfeeding women taking imatinib mesylate, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite. Considering the combined concentration of imatinib and active metabolite, a breastfed infant could receive up to 10% of the maternal therapeutic dose based on body weight.&nbsp;</p><p><strong>Females and Males of Reproductive Potential&nbsp; </strong></p><p>&nbsp;</p><p>Pregnancy Testing &nbsp;</p><p>Human postmarketing reports and animal studies have shown imatinib mesylate to be harmful to the developing fetus. Test pregnancy status in females with reproductive potential prior to the initiation of treatment with imatinib mesylate.&nbsp;</p><p><em>Contraception </em>&nbsp;</p><p>Females&nbsp;</p><p>Advise female patients of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using imatinib mesylate during treatment and for fourteen days after stopping treatment with imatinib mesylate.&nbsp;</p><p>Infertility &nbsp;</p><p>The risk of infertility in females or males of reproductive potential has not been studied in humans. In a rat study, the fertility in males and females was not affected <em>.</em></p><p><strong>Pediatric Use </strong>&nbsp;</p><p>The safety and effectiveness of imatinib mesylate tablets have been demonstrated in pediatric patients with newly diagnosed Ph+ chronic phase CML<em>. </em>There are no data in children under 1 year of age.&nbsp;</p><p><strong>Geriatric Use </strong>&nbsp;</p><p>In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of patients with newly diagnosed CML, 6% of patients were older than 65 years. The frequency of edema was higher in patients older than 65 years as compared to younger patients; no other difference in the safety profile was observed. The efficacy of imatinib mesylate was similar in older and younger patients.&nbsp;</p><p><strong>Hepatic Impairment </strong>&nbsp;</p><p>The effect of hepatic impairment on the pharmacokinetics of both imatinib and its major metabolite, CGP74588, was assessed in 84 patients with cancer with varying degrees of hepatic impairment at imatinib doses ranging from 100 mg to 800 mg.</p><p>Mild and moderate hepatic impairment do not influence exposure to imatinib and CGP74588. In patients with severe hepatic impairment, the imatinib C<sub>max </sub>and area under curve (AUC) increased by 63% and 45% and the CGP74588 C<sub>max</sub> and AUC increased by 56% and 55%, relative to patients with normal hepatic function. Reduce the dose by 25% for patients with severe hepatic impairment.&nbsp;</p><p><strong>Table 2: Liver Function Classification </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p><strong>Liver Function </strong></p><p><strong>Test </strong></p></td><td style="vertical-align:top"><p><strong>Normal </strong></p><p><strong>(n=14) </strong></p></td><td style="vertical-align:top"><p><strong>Mild (n=30) </strong></p></td><td style="vertical-align:top"><p><strong>Moderate </strong></p><p><strong>(n=20) </strong></p></td><td style="vertical-align:top"><p><strong>Severe </strong></p><p><strong>(n=20) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Total Bilirubin</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>less than or equal to</p><p>ULN</p></td><td style="vertical-align:top"><p>greater than 1.0 to</p><p>1.5 times the ULN</p></td><td style="vertical-align:top"><p>greater than 1.5 to 3 times the ULN</p></td><td style="vertical-align:top"><p>greater than 3 to 10 times the ULN</p></td></tr><tr><td style="vertical-align:top"><p><strong>SGOT</strong></p><p>&nbsp;</p></td><td><p>less than or equal to</p><p>ULN</p></td><td style="vertical-align:top"><p>greater than ULN</p><p>(can be normal if Total Bilirubin is greater than ULN)</p></td><td><p>Any</p></td><td><p>Any</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ULN=upper limit of normal for the institution&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Renal Impairment&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p>The effect of renal impairment on the pharmacokinetics of imatinib was assessed in 59 patients with cancer and varying degrees of renal impairment at single and steady state imatinib doses ranging from 100 to 800 mg/day. The mean exposure to imatinib (dose normalized AUC) in patients with mild and moderate renal impairment increased 1.5-to 2-fold compared to patients with normal renal function. There are not sufficient data in patients with severe renal impairment. Dose reductions are necessary for patients with moderate and severe renal impairmen.&nbsp;</p><p><strong>Renal Function Classification </strong></p><p><strong>Renal Dysfunction </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal Function Tests </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p><strong>Mild</strong></p></td><td style="vertical-align:top"><p>CrCL = 40 to 59 mL/min</p></td></tr><tr><td style="vertical-align:top"><p><strong>Moderate </strong></p></td><td style="vertical-align:top"><p>CrCL = 20 to 39 mL/min</p></td></tr><tr><td style="vertical-align:top"><p><strong>Severe </strong></p></td><td style="vertical-align:top"><p>CrCL = less than 20 mL/min</p></td></tr><tr><td style="vertical-align:bottom"><p>CrCL = Creatinine Clearance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Advise patients that they may experience side effects such as dizziness, blurred vision or somnolence during treatment with Imatinib Mesylate tablets. Therefore, caution patients about driving a car or operating machinery [see Warnings and Precautions (Impairments Related to Driving and Using Machinery)].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluid Retention and Edema&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hematologic Toxicity&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Congestive Heart Failure and Left Ventricular Dysfunction&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatotoxicity&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemorrhage&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrointestinal Disorders&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypereosinophilic Cardiac Toxicity&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dermatologic Toxicities&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypothyroidism&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Embryo-fetal Toxicity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Growth Retardation in Children and Adolescents&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tumor Lysis Syndrome&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impairments Related to Driving and Using Machinery&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal Toxicity&nbsp;</p><p><strong>Clinical Trials Experience </strong>&nbsp;</p><p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.&nbsp;</p><p>Chronic Myeloid Leukemia&nbsp;</p><p>The majority of imatinib mesylate-treated patients experienced adverse reactions at some time. Imatinib mesylate was discontinued due to drug-related adverse reactions in 2.4% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing imatinib mesylate versus IFN+Ara-C, and in 12.5% of patients receiving imatinib mesylate in the randomized trial of newly diagnosed patients with Ph+ CML in chronic phase comparing imatinib mesylate and nilotinib. Imatinib mesylate was discontinued due to drug-related adverse reactions in 4% of patients in chronic phase after failure of interferon-alpha therapy, in 4% of patients in accelerated phase and in 5% of patients in blast crisis.&nbsp;</p><p>The most frequently reported drug-related adverse reactions were edema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhea and rash (Table 3 and Table 4 for newly diagnosed CML, Table 5 for other CML patients). Edema was most frequently periorbital or in lower limbs and was managed with diuretics, other supportive measures, or by reducing the dose of imatinib mesylate<em>. </em>The frequency of severe superficial edema was 1.5% to 6%.&nbsp;</p><p>A variety of adverse reactions represent local or general fluid retention including pleural effusion, ascites, pulmonary edema and rapid weight gain with or without superficial edema. These reactions appear to be dose related, were more common in the blast crisis and accelerated phase studies (where the dose was 600 mg/day), and are more common in the elderly. These reactions were usually managed by interrupting imatinib mesylate treatment and using diuretics or other appropriate supportive care measures. These reactions may be serious or life threatening.&nbsp;</p><p>Adverse reactions, regardless of relationship to study drug, that were reported in at least 10% of the imatinib mesylate treated patients are shown in Tables 3, 4, and 5.</p><p><strong>Table 3: Adverse Reactions Regardless of Relationship to Study Drug Reported in Newly Diagnosed CML Clinical Trial in the Imatinib Mesylate versus IFN+Ara-C Study (greater </strong><strong>&nbsp;than or equal to 10% of Imatinib Mesylate</strong> <strong>Treated Patients)<sup>(1)</sup></strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>All Grades&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTC Grades 3/4</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Imatinib&nbsp; Mesylate </strong></p></td><td style="vertical-align:top"><p><strong>IFN+Ara&minus;C </strong></p></td><td style="vertical-align:top"><p><strong>Imatinib Mesylate </strong></p></td><td style="vertical-align:top"><p><strong>IFN+Ara&minus;C </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Preferred Term </strong></p></td><td style="vertical-align:top"><p><strong>N=551 (%) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=533 (%) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=551 (%) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>N=533 (%) </strong>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fluid Retention&nbsp;</p></td><td style="vertical-align:top"><p>61.7&nbsp;</p></td><td style="vertical-align:top"><p>11.1&nbsp;</p></td><td style="vertical-align:top"><p>2.5&nbsp;</p></td><td style="vertical-align:top"><p>0.9&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&minus; Superficial Edema&nbsp;</p></td><td style="vertical-align:top"><p>59.9&nbsp;</p></td><td style="vertical-align:top"><p>9.6&nbsp;</p></td><td style="vertical-align:top"><p>1.5&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&minus; Other Fluid Retention</p><p>Reactions<sup>2</sup>&nbsp;</p></td><td><p>6.9&nbsp;</p></td><td><p>1.9&nbsp;</p></td><td><p>1.3&nbsp;</p></td><td><p>0.6&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea&nbsp;</p></td><td style="vertical-align:top"><p>49.5&nbsp;</p></td><td style="vertical-align:top"><p>61.5&nbsp;</p></td><td style="vertical-align:top"><p>1.3&nbsp;</p></td><td style="vertical-align:top"><p>5.1&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscle Cramps&nbsp;</p></td><td style="vertical-align:top"><p>49.2&nbsp;</p></td><td style="vertical-align:top"><p>11.8&nbsp;</p></td><td style="vertical-align:top"><p>2.2&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal Pain&nbsp;</p></td><td style="vertical-align:top"><p>47.0&nbsp;</p></td><td style="vertical-align:top"><p>44.8&nbsp;</p></td><td style="vertical-align:top"><p>5.4&nbsp;</p></td><td style="vertical-align:top"><p>8.6&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea&nbsp;</p></td><td style="vertical-align:top"><p>45.4&nbsp;</p></td><td style="vertical-align:top"><p>43.3&nbsp;</p></td><td style="vertical-align:top"><p>3.3&nbsp;</p></td><td style="vertical-align:top"><p>3.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rash and Related Terms&nbsp;</p></td><td style="vertical-align:top"><p>40.1&nbsp;</p></td><td style="vertical-align:top"><p>26.1&nbsp;</p></td><td style="vertical-align:top"><p>2.9&nbsp;</p></td><td style="vertical-align:top"><p>2.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue&nbsp;</p></td><td style="vertical-align:top"><p>38.8&nbsp;</p></td><td style="vertical-align:top"><p>67.0&nbsp;</p></td><td style="vertical-align:top"><p>1.8&nbsp;</p></td><td style="vertical-align:top"><p>25.1&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache&nbsp;</p></td><td style="vertical-align:top"><p>37.0&nbsp;</p></td><td style="vertical-align:top"><p>43.3&nbsp;</p></td><td style="vertical-align:top"><p>0.5&nbsp;</p></td><td style="vertical-align:top"><p>3.8&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Joint Pain&nbsp;</p></td><td style="vertical-align:top"><p>31.4&nbsp;</p></td><td style="vertical-align:top"><p>38.1&nbsp;</p></td><td style="vertical-align:top"><p>2.5&nbsp;</p></td><td style="vertical-align:top"><p>7.7&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal Pain&nbsp;</p></td><td style="vertical-align:top"><p>36.5&nbsp;</p></td><td style="vertical-align:top"><p>25.9&nbsp;</p></td><td style="vertical-align:top"><p>4.2&nbsp;</p></td><td style="vertical-align:top"><p>3.9&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nasopharyngitis&nbsp;</p></td><td style="vertical-align:top"><p>30.5&nbsp;</p></td><td style="vertical-align:top"><p>8.8&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage&nbsp;</p></td><td style="vertical-align:top"><p>28.9&nbsp;</p></td><td style="vertical-align:top"><p>21.2&nbsp;</p></td><td style="vertical-align:top"><p>1.8&nbsp;</p></td><td style="vertical-align:top"><p>1.7&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-GI Hemorrhage&nbsp;</p></td><td style="vertical-align:top"><p>1.6&nbsp;</p></td><td style="vertical-align:top"><p>1.1&nbsp;</p></td><td style="vertical-align:top"><p>0.5&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-CNS Hemorrhage&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia&nbsp;</p></td><td style="vertical-align:top"><p>24.1&nbsp;</p></td><td style="vertical-align:top"><p>38.8&nbsp;</p></td><td style="vertical-align:top"><p>1.5&nbsp;</p></td><td style="vertical-align:top"><p>8.3&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting&nbsp;</p></td><td style="vertical-align:top"><p>22.5&nbsp;</p></td><td style="vertical-align:top"><p>27.8&nbsp;</p></td><td style="vertical-align:top"><p>2.0&nbsp;</p></td><td style="vertical-align:top"><p>3.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia&nbsp;</p></td><td style="vertical-align:top"><p>18.9&nbsp;</p></td><td style="vertical-align:top"><p>8.3&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0.8&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cough&nbsp;</p></td><td style="vertical-align:top"><p>20.0&nbsp;</p></td><td style="vertical-align:top"><p>23.1&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td style="vertical-align:top"><p>0.6&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngolaryngeal Pain&nbsp;</p></td><td style="vertical-align:top"><p>18.1&nbsp;</p></td><td style="vertical-align:top"><p>11.4&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Upper Respiratory Tract Infection&nbsp;</p></td><td><p>21.2&nbsp;</p></td><td><p>8.4&nbsp;</p></td><td><p>0.2&nbsp;</p></td><td><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness&nbsp;</p></td><td style="vertical-align:top"><p>19.4&nbsp;</p></td><td style="vertical-align:top"><p>24.4&nbsp;</p></td><td style="vertical-align:top"><p>0.9&nbsp;</p></td><td style="vertical-align:top"><p>3.8&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia&nbsp;</p></td><td style="vertical-align:top"><p>17.8&nbsp;</p></td><td style="vertical-align:top"><p>42.6&nbsp;</p></td><td style="vertical-align:top"><p>0.9&nbsp;</p></td><td style="vertical-align:top"><p>3.0&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight Increased&nbsp;</p></td><td style="vertical-align:top"><p>15.6&nbsp;</p></td><td style="vertical-align:top"><p>2.6&nbsp;</p></td><td style="vertical-align:top"><p>2.0&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia&nbsp;</p></td><td style="vertical-align:top"><p>14.7&nbsp;</p></td><td style="vertical-align:top"><p>18.6&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>2.3&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Depression&nbsp;</p></td><td style="vertical-align:top"><p>14.9&nbsp;</p></td><td style="vertical-align:top"><p>35.8&nbsp;</p></td><td style="vertical-align:top"><p>0.5&nbsp;</p></td><td style="vertical-align:top"><p>13.1&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Influenza&nbsp;</p></td><td style="vertical-align:top"><p>13.8&nbsp;</p></td><td style="vertical-align:top"><p>6.2&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Bone Pain&nbsp;</p></td><td style="vertical-align:top"><p>11.3&nbsp;</p></td><td style="vertical-align:top"><p>15.6&nbsp;</p></td><td style="vertical-align:top"><p>1.6&nbsp;</p></td><td style="vertical-align:top"><p>3.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Constipation&nbsp;</p></td><td style="vertical-align:top"><p>11.4&nbsp;</p></td><td style="vertical-align:top"><p>14.4&nbsp;</p></td><td style="vertical-align:top"><p>0.7&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis&nbsp;</p></td><td style="vertical-align:top"><p>11.4&nbsp;</p></td><td style="vertical-align:top"><p>6.0&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td></tr></tbody></table><p><sup>(1)</sup> All adverse reactions occurring in greater than or equal to10% of imatinib mesylate treated patients are listed regardless of suspected relationship to treatment.&nbsp;</p><p>(2)</p><p>Other fluid retention reactions include pleural effusion, ascites, pulmonary edema, pericardial effusion, anasarca, edema aggravated, and fluid retention not otherwise specified.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_80469" o:spid="_x0000_s1055" style='width:443.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56327,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89287" o:spid="_x0000_s1056" style='position:absolute;
  width:56327;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5632704,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5632704,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5632704,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="591" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1037" type="#_x0000_t75" style='width:443.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Table 4: Most Frequently Reported Non-hematologic Adverse Reactions (Regardless of Relationship to Study Drug) in Patients with Newly Diagnosed Ph+ CML-CP in the Imatinib Mesylate</strong><strong> versus nilotinib Study (greater than or equal to 10% in Imatinib </strong></p><p><strong>Mesylate</strong><strong> 400 mg Once-Daily or nilotinib 300 mg Twice-Daily Groups) 60-Month Analysis<sup>a </sup></strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Patients with Newly Diagnosed Ph+ CML-CP</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Imatinib &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nilotinib</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Imatinib &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nilotinib</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mesylate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mesylate</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>400 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300 mg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 400 mg</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>300 mg</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>once daily</strong> &nbsp;&nbsp;&nbsp; <strong>twice daily</strong> &nbsp;&nbsp;&nbsp; <strong>once daily</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>twice </strong></p><p><strong>daily</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N=280&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=279&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=280</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N=279</strong></p><p><strong>b </strong></p><p><strong><u>Body System and Preferred Term</u></strong><u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>All Grades (%)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CTC Grades 3/4 (%)</strong></u></p><p>Skin and subcutaneous tissue&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>disorders&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 19&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alopecia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dry skin&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>Gastrointestinal disorders&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>upper&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal pain&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspepsia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>Nervous system disorders&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>General disorders and&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>administration site conditions&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthenia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Peripheral edema&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Face edema&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>Musculoskeletal and connective&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>tissue disorders&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myalgia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Arthralgia&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt; 1</p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasms&nbsp;</p></td><td style="vertical-align:top"><p>34&nbsp;</p></td><td style="vertical-align:top"><p>12&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pain in extremity&nbsp;</p></td><td style="vertical-align:top"><p>16&nbsp;</p></td><td style="vertical-align:top"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Back pain&nbsp;</p></td><td style="vertical-align:top"><p>17&nbsp;</p></td><td style="vertical-align:top"><p>19&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and&nbsp; mediastinal disorders&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Cough&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>13&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17&nbsp;</p></td><td style="vertical-align:bottom"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>0</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oropharyngeal pain&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>12&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnea&nbsp;</p></td><td style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>11&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations&nbsp;</p></td><td style="vertical-align:top"><p>Nasopharyngitis&nbsp;</p></td><td style="vertical-align:top"><p>21&nbsp;</p></td><td style="vertical-align:top"><p>27&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Upper respiratory&nbsp;</p><p>&nbsp;</p><p>tract infection&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>14&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>17&nbsp;</p></td><td style="vertical-align:bottom"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&lt; 1</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Influenza&nbsp;</p></td><td style="vertical-align:top"><p>9&nbsp;</p></td><td style="vertical-align:top"><p>13&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gastroenteritis&nbsp;</p></td><td style="vertical-align:top"><p>10&nbsp;</p></td><td style="vertical-align:top"><p>7&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders&nbsp;</p></td><td style="vertical-align:top"><p>Eyelid edema&nbsp;</p></td><td style="vertical-align:top"><p>19&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Periorbital edema&nbsp;</p></td><td style="vertical-align:top"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders&nbsp;</p></td><td style="vertical-align:top"><p>Insomnia&nbsp;</p></td><td style="vertical-align:top"><p>9&nbsp;</p></td><td style="vertical-align:top"><p>11&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorder&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension&nbsp;</p></td><td style="vertical-align:top"><p>4&nbsp;</p></td><td style="vertical-align:top"><p>10&nbsp;</p></td><td style="vertical-align:top"><p>&lt; 1&nbsp;</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>Excluding laboratory abnormalities&nbsp;</p><p><sup>b</sup>NCI Common Terminology Criteria for Adverse Events, Version 3.0&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>Table 5: Adverse Reactions Regardless of Relationship to Study Drug Reported in Other </strong></p><p><strong>CML Clinical Trials (greater than or equal to 10% of All Patients in any Trial)<sup>(1)</sup> </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong>Myeloid Blast Crisis</strong> <strong>(n=260) </strong>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p><strong>Accelerated Phase</strong> <strong>(n=235) </strong>&nbsp;</p></td><td colspan="5" rowspan="2" style="vertical-align:top"><p><strong>Chronic Phase, IFN</strong></p><p><strong>Failure</strong></p><p><strong>(n=532) </strong>&nbsp;</p><p><strong>% </strong>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>&nbsp;</p><p><strong>% </strong>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p><strong>% </strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Preferred Term</u></strong><u> </u></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>All </strong></p><p><strong><u>&nbsp;Grades&nbsp; </u></strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p><p><strong>Grade&nbsp; </strong></p><p><strong><u>3/4</u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All </strong>&nbsp;</p><p><strong><u>Grades </u></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Grade 3/4 </u></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>All </strong></p><p><strong><u>Grades </u></strong><u>&nbsp;</u></p></td><td colspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong><u>Grade 3/4 </u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Fluid Retention&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>72&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>11&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>76&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>69&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-Superficial Edema&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>66&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>74&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>67&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>- Other Fluid Retention&nbsp;&nbsp;&nbsp;&nbsp; Reactions <sup>(2)</sup>&nbsp;</p></td><td colspan="2"><p>22&nbsp;</p></td><td colspan="2"><p>6&nbsp;</p></td><td colspan="2"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2"><p>4&nbsp;</p></td><td colspan="2"><p>7&nbsp;</p></td><td colspan="3"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>71&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>73&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>63&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>3&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Muscle Cramps&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>28&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>1&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>47&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>62&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>54&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>58&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>36&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>43&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>57&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>48&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>3&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemorrhage&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>53&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>19&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>49&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>11&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>30&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-CNS Hemorrhage&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>3&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>1&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>-GI Hemorrhage&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>8&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>0.4&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal Pain&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>42&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>49&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>38&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>30&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>46&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>48&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>1&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin Rash&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>36&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>47&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>47&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>3&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>41&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>41&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>8&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>21&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>2&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Arthralgia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>25&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>34&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>40&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Headache&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>27&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>32&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>36&nbsp;</p></td><td style="vertical-align:top"><p>0.6&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Abdominal Pain&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>30&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>33&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>32&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Weight Increased&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>1&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>17&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>32&nbsp;</p></td><td style="vertical-align:top"><p>7&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Cough&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>14&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.8&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>27&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>20&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dyspepsia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>22&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>27&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Myalgia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>24&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>27&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Nasopharyngitis&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>17&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>22&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Asthenia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>18&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>21&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dyspnea&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>15&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>21&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>12&nbsp;</p></td><td style="vertical-align:top"><p>0.9&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Upper Respiratory Tract Infection&nbsp;</p></td><td colspan="2"><p>3&nbsp;</p></td><td colspan="2"><p>0&nbsp;</p></td><td colspan="3"><p>12&nbsp;</p></td><td colspan="2"><p>0.4&nbsp;</p></td><td colspan="2"><p>19&nbsp;</p></td><td><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anorexia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>14&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>17&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Night Sweats&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>13&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.8&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>17&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>1&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>14&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Constipation&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>16&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>16&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Dizziness&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>13&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>16&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pharyngitis&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Insomnia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>14&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>14&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pruritus&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>8&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>1&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>14&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>14&nbsp;</p></td><td style="vertical-align:top"><p>0.8&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypokalemia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>13&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>9&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>0.8&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Pneumonia&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>13&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Anxiety&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>8&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.8&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>8&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Liver Toxicity&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>5&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>6&nbsp;</p></td><td style="vertical-align:top"><p>3&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Rigors&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>12&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>10&nbsp;</p></td><td style="vertical-align:top"><p>0&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Chest Pain&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>7&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>10&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>11&nbsp;</p></td><td style="vertical-align:top"><p>0.8&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Influenza&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.8&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>6&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>11&nbsp;</p></td><td style="vertical-align:top"><p>0.2&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Sinusitis&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>11&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>0.4&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>9&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_59661" o:spid="_x0000_s1053" style='width:462.1pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="58689,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89289" o:spid="_x0000_s1054" style='position:absolute;
  width:58689;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5868924,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5868924,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5868924,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="616" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1036" type="#_x0000_t75" style='width:462.1pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><sup>(1)</sup>All adverse reactions occurring in greater than or equal to 10% of patients are listed regardless of suspected relationship to treatment.&nbsp;</p><p>(2)Other fluid retention reactions include pleural effusion, ascites, pulmonary edema, pericardial effusion, anasarca, edema aggravated, and fluid retention not otherwise specified.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_59662" o:spid="_x0000_s1051" style='width:462.85pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="58780,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89291" o:spid="_x0000_s1052" style='position:absolute;
  width:58780;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5878068,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5878068,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5878068,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="617" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1035" type="#_x0000_t75" style='width:462.85pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Hematologic and Biochemistry Laboratory Abnormalities&nbsp;</p><p>Cytopenias, and particularly neutropenia and thrombocytopenia, were a consistent finding in all studies, with a higher frequency at doses greater than or equal to 750 mg (Phase 1 study). The occurrence of cytopenias in CML patients was also dependent on the stage of the disease.&nbsp;</p><p>In patients with newly diagnosed CML, cytopenias were less frequent than in the other CML patients (see Tables 5, 6, and 7). The frequency of Grade 3 or 4 neutropenia and thrombocytopenia was between 2-and 3-fold higher in blast crisis and accelerated phase compared to chronic phase (see Tables 4 and 5). The median duration of the neutropenic and thrombocytopenic episodes varied from 2 to 3 weeks, and from 2 to 4 weeks, respectively.&nbsp;</p><p>These reactions can usually be managed with either a reduction of the dose or an interruption of treatment with imatinib mesylate, but may require permanent discontinuation of treatment.&nbsp;</p><p><strong>Table 6: Laboratory Abnormalities in Newly Diagnosed CML Clinical Trial (Imatinib Mesylate</strong><strong> versus IFN+Ara-C)&nbsp; </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:527px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Imatinib&nbsp; </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Mesylate </strong></p><p><strong>N=551 </strong></p></td><td style="vertical-align:top"><p><strong>IFN+Ara&minus;C </strong></p><p><strong>N=533 </strong></p><p><strong>% </strong></p></td></tr></tbody></table><p><strong>% </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:615px"><tbody><tr><td style="vertical-align:top"><p><strong>CTC Grades </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade 3 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade 4 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade 3 </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Grade 4 </strong></p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p><strong>Hematology Parameters*</strong></p><p>- Neutropenia*</p></td><td colspan="2" style="vertical-align:bottom"><p>13.1</p></td><td colspan="2" style="vertical-align:bottom"><p>3.6</p></td><td colspan="2" style="vertical-align:bottom"><p>20.8</p></td><td style="vertical-align:bottom"><p>4.5</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- Thrombocytopenia*</p></td><td colspan="2" style="vertical-align:top"><p>8.5</p></td><td colspan="2" style="vertical-align:top"><p>0.4</p></td><td colspan="2" style="vertical-align:top"><p>15.9</p></td><td style="vertical-align:top"><p>0.6</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- Anemia</p></td><td colspan="2" style="vertical-align:top"><p>3 3</p></td><td colspan="2" style="vertical-align:top"><p>1 1</p></td><td colspan="2" style="vertical-align:top"><p>4 1</p></td><td style="vertical-align:top"><p>0 2</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Biochemistry Parameters </strong></p><p>- Elevated Creatinine</p></td><td colspan="2" style="vertical-align:bottom"><p>0</p></td><td colspan="2" style="vertical-align:bottom"><p>0</p></td><td colspan="2" style="vertical-align:bottom"><p>0.4</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- Elevated Bilirubin</p></td><td colspan="2" style="vertical-align:top"><p>0.9</p></td><td colspan="2" style="vertical-align:top"><p>0.2</p></td><td colspan="2" style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alkaline</p><p>Phosphatase</p></td><td colspan="2" style="vertical-align:top"><p>0.2</p></td><td colspan="2" style="vertical-align:top"><p>0</p></td><td colspan="2" style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td colspan="2"><p>- Elevated SGOT /SGPT</p></td><td colspan="2"><p>4.7</p></td><td colspan="2"><p>0.5</p></td><td colspan="2"><p>7.1</p></td><td><p>0.4</p></td></tr><tr><td colspan="8" style="vertical-align:bottom"><p>*p less than 0.001 (difference in Grade 3 plus 4 abnormalities between the two treatment groups)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><strong>Table 7: Percent Incidence of Clinically Relevant Grade 3/4* Laboratory Abnormalities in the Newly Diagnosed CML Clinical Trial (Imatinib Mesylate versus nilotinib) </strong>&nbsp;</p><p><strong>&nbsp;</strong></p><p><sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup><strong>Imatinib Mesylate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>400 mg</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>nilotinib 300 mg</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>once-daily</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>twice-daily</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N=280</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N=279</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>(%)</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>(%)</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_63441" o:spid="_x0000_s1049" style='width:442.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56235,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89293" o:spid="_x0000_s1050" style='position:absolute;
  width:56235;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5623560,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5623560,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5623560,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="590" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1034" type="#_x0000_t75" style='width:442.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Hematologic Parameters</strong></p><p>Thrombocytopenia</p><p>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10</p><p>Neutropenia</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12</p><p>Anemia</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p><strong>Biochemistry Parameters </strong>&nbsp;</p><p>Elevated lipase</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9</p><p>Hyperglycemia&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 7</p><p>Hypophosphatemia&nbsp;</p><p>10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8</p><p>Elevated bilirubin (total)&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>Elevated SGPT (ALT)&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4</p><p>Hyperkalemia&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:502px"><tbody><tr><td style="vertical-align:top"><p>Hyponatremia&nbsp;</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td><td style="vertical-align:bottom"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalemia&nbsp;</p></td><td style="vertical-align:bottom"><p>2</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Elevated SGOT (AST)&nbsp;</p></td><td style="vertical-align:bottom"><p>1</p></td><td style="vertical-align:bottom"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>Decreased albumin&nbsp;</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcemia&nbsp;</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr><tr><td style="vertical-align:top"><p>Elevated alkaline phosphatase&nbsp;</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Elevated creatinine&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:bottom"><p>0</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&lt;1</p></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Group_x0020_65363"
 o:spid="_x0000_s1047" style='position:absolute;left:0;text-align:left;
 margin-left:-5.4pt;margin-top:-2.7pt;width:442.8pt;height:.5pt;z-index:251658240;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
 coordsize="56235,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89295" o:spid="_x0000_s1048" style='position:absolute;
  width:56235;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5623560,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5623560,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5623560,9144"/>
 </v:shape><w:wrap type="square"/>
</v:group><![endif]--><img width="590" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />*NCI Common Terminology Criteria for Adverse Events, version 3.0&nbsp;</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_65364" o:spid="_x0000_s1045" style='width:443.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56327,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89297" o:spid="_x0000_s1046" style='position:absolute;
  width:56327;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5632704,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5632704,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5632704,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="591" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1033" type="#_x0000_t75" style='width:443.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Table 8: Laboratory Abnormalities in Other CML Clinical Trials </strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:564px"><tbody><tr><td style="vertical-align:top"><p><strong>Myeloid Blast Crisis</strong></p><p>&nbsp;</p><p><strong>(n=260)</strong></p><p><strong>600 mg n=223</strong></p><p><strong>400 mg n=37</strong> <strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Accelerated Phase</strong></p><p><strong>(n=235)</strong></p><p><strong>600 mg n=158</strong></p><p><strong>400 mg n=77</strong> <strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Chronic Phase, IFN </strong></p><p><strong>Failure</strong></p><p><strong>(n=532)</strong></p><p><strong>400 mg</strong> <strong>% </strong></p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp; <strong>CTC Grades<sup>1</sup></strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 3</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 4</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 3</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 4</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 3</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Grade 4</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:590px"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Hematology Parameters </strong>&nbsp;</p><p>- Neutropenia&nbsp;</p><p>16</p></td><td style="vertical-align:bottom"><p>48</p></td><td style="vertical-align:bottom"><p>23</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>36</p></td><td style="vertical-align:bottom"><p>27</p></td><td style="vertical-align:bottom"><p>9</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- Thrombocytopenia&nbsp; 30</p></td><td style="vertical-align:bottom"><p>33</p></td><td style="vertical-align:bottom"><p>31</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>13</p></td><td style="vertical-align:bottom"><p>21</p></td><td style="vertical-align:bottom"><p>&lt;1</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>- Anemia&nbsp;</p><p>42</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p><strong>Biochemistry Parameters </strong>- Elevated Creatinine&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>1.5</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>1.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>0.2</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated Bilirubin&nbsp;</p></td><td style="vertical-align:bottom"><p>3.8</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>2.1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>0.6</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated Alkaline Phosphatase&nbsp;</p></td><td style="vertical-align:bottom"><p>4.6</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>5.5</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0.4</p></td><td style="vertical-align:bottom"><p>0.2</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated SGOT (AST)&nbsp;</p></td><td style="vertical-align:bottom"><p>1.9</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>3.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>2.3</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>- Elevated SGPT (ALT)&nbsp;</p></td><td style="vertical-align:bottom"><p>2.3</p></td><td style="vertical-align:bottom"><p>0.4</p></td><td style="vertical-align:bottom"><p>4.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0</p></td><td style="vertical-align:bottom"><p>2.1</p></td><td style="vertical-align:bottom"><p>0</p></td></tr></tbody></table><p>1</p><p>CTC Grades: neutropenia (Grade 3 greater than or equal to 0.5 to 1.0 x 10<sup>9</sup>/L, Grade 4 less than 0.5 x 10<sup>9</sup>/L), thrombocytopenia (Grade 3 greater than or equal to 10 to 50 x 10<sup>9</sup>/L, Grade 4 less than 10 x 10<sup>9</sup>/L), anemia (hemoglobin greater than or equal to 65 to 80 g/L, Grade 4 less than 65 g/L), elevated creatinine (Grade 3 greater than 3 to 6 x upper limit normal range [ULN], Grade 4 greater than 6 x ULN), elevated bilirubin (Grade 3 greater than 3 to 10 x ULN, Grade 4 greater than 10 x ULN), elevated alkaline phosphatase (Grade 3 greater than 5 to 20 x ULN, Grade 4 greater than 20 x ULN), elevated SGOT or SGPT (Grade 3 greater than 5 to 20 x ULN, Grade 4 greater than 20 x ULN)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_65365" o:spid="_x0000_s1043" style='width:443.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56327,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89299" o:spid="_x0000_s1044" style='position:absolute;
  width:56327;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5632704,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5632704,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5632704,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="591" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1032" type="#_x0000_t75" style='width:443.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Hepatotoxicity&nbsp;</p><p>Severe elevation of transaminases or bilirubin occurred in approximately 5% of CML patients (see Tables 7 and 8) and were usually managed with dose reduction or interruption (the median duration of these episodes was approximately 1 week). Treatment was discontinued permanently because of liver laboratory abnormalities in less than 1.0% of CML patients. One patient, who was taking acetaminophen regularly for fever, died of acute liver failure.&nbsp;</p><p>Adverse Reactions in Pediatric Population&nbsp;</p><p>Single agent therapy &nbsp;</p><p>The overall safety profile of pediatric patients treated with imatinib mesylate in 93 children studied was similar to that found in studies with adult patients, except that musculoskeletal pain was less frequent (20.5%) and peripheral edema was not reported. Nausea and vomiting were the most commonly reported individual adverse reactions with an incidence similar to that seen in adult patients. Most patients experienced adverse reactions at some time during the study. The incidence of Grade 3/4 events across all types of adverse reactions was 75%; the events with the highest Grade 3/4 incidence in CML pediatric patients were mainly related to myelosuppression.&nbsp;</p><p>Adverse Reactions in Other Subpopulations&nbsp;</p><p>In older patients (greater than or equal to 65 years old), with the exception of edema, where it was more frequent, there was no evidence of an increase in the incidence or severity of adverse reactions. In women there was an increase in the frequency of neutropenia, as well as Grade 1/2 superficial edema, headache, nausea, rigors, vomiting, rash, and fatigue. No differences were seen that were related to race but the subsets were too small for proper evaluation.&nbsp;</p><p>Acute Lymphoblastic Leukemia&nbsp;</p><p>The adverse reactions were similar for Ph+ ALL as for Ph+ CML. The most frequently reported drug-related adverse reactions reported in the Ph+ ALL studies were mild nausea and vomiting, diarrhea, myalgia, muscle cramps and rash. Superficial edema was a common finding in all studies and were described primarily as periorbital or lower limb edemas. These edemas were reported as Grade 3/4 events in 6.3% of the patients and may be managed with diuretics, other supportive measures, or in some patients by reducing the dose of imatinib mesylate.&nbsp;</p><p>Myelodysplastic/Myeloproliferative Diseases&nbsp;</p><p>Adverse reactions, regardless of relationship to study drug, that were reported in at least 10% of the patients treated with imatinib mesylate for MDS/MPD in the Phase 2 study, are shown in Table 9.</p><p>&nbsp;</p><p><strong>Table 9: Adverse Reactions Regardless of Relationship to Study Drug Reported (More than One Patient) in MPD Patients in the Phase 2 Study (greater than or equal to 10% All Patients) All Grades&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p><strong>N=7 </strong></p><p><strong>Preferred Term</strong></p><p><strong>n (%)</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_57028" o:spid="_x0000_s1041" style='width:450.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="57249,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89301" o:spid="_x0000_s1042" style='position:absolute;
  width:57249;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5724906,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5724906,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5724906,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="601" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1031" type="#_x0000_t75" style='width:450.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><table border="0" cellspacing="0" cellpadding="0" style="width:468px"><tbody><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>4 (57.1)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea</p></td><td style="vertical-align:top"><p>3 (42.9)</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>2 (28.6)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>2 (28.6)</p></td></tr><tr><td style="vertical-align:top"><p>Muscle Cramp</p></td><td style="vertical-align:top"><p>3 (42.9)</p></td></tr><tr><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>2 (28.6)</p></td></tr><tr><td style="vertical-align:top"><p>Periorbital Edema</p></td><td style="vertical-align:top"><p>2 (28.6)</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_57030" o:spid="_x0000_s1038" style='width:451.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="57340,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89303" o:spid="_x0000_s1039" style='position:absolute;
  width:28719;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2871978,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l2871978,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2871978,9144"/>
 </v:shape><v:shape id="Shape_x0020_89304" o:spid="_x0000_s1040" style='position:absolute;
  left:28628;width:28712;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2871216,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l2871216,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2871216,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="602" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1030" type="#_x0000_t75" style='width:451.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Aggressive Systemic Mastocytosis&nbsp;</p><p>All ASM patients experienced at least one adverse reaction at some time. The most frequently reported adverse reactions were diarrhea, nausea, ascites, muscle cramps, dyspnea, fatigue, peripheral edema, anemia, pruritus, rash and lower respiratory tract infection. None of the 5 patients in the Phase 2 study with ASM discontinued imatinib mesylate due to drug-related adverse reactions or abnormal laboratory values.&nbsp;</p><p>Hypereosinophilic Syndrome and Chronic Eosinophilic Leukemia&nbsp;</p><p>The safety profile in the HES/CEL patient population does not appear to be different from the safety profile of imatinib mesylate observed in other hematologic malignancy populations, such as Ph+ CML. All patients experienced at least one adverse reaction, the most common being gastrointestinal, cutaneous and musculoskeletal disorders. Hematological abnormalities were also frequent, with instances of CTC Grade 3 leukopenia, neutropenia, lymphopenia, and anemia.&nbsp;</p><p>Dermatofibrosarcoma Protuberans&nbsp;</p><p>Adverse reactions, regardless of relationship to study drug, that were reported in at least 10% of the 12 patients treated with imatinib mesylate for DFSP in the Phase 2 study are shown in Table 10.&nbsp;</p><p><strong>Table 10: Adverse Reactions Regardless of Relationship to Study Drug Reported in DFSP </strong></p><p><strong>Patients in the Phase 2 Study (greater than or equal to 10% All Patients) All Grades </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=12 </strong></p><p><strong>Preferred Term</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>n (%)</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_66617" o:spid="_x0000_s1036" style='width:450.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="57249,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89307" o:spid="_x0000_s1037" style='position:absolute;
  width:57249;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5724906,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5724906,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5724906,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="601" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1029" type="#_x0000_t75" style='width:450.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><table border="0" cellspacing="0" cellpadding="0" style="width:495px"><tbody><tr><td style="vertical-align:top"><p>Nausea&nbsp;</p></td><td style="vertical-align:top"><p>5 (41.7)</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhea&nbsp;</p></td><td style="vertical-align:top"><p>3 (25.0)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting&nbsp;</p></td><td style="vertical-align:top"><p>3 (25.0)</p></td></tr><tr><td style="vertical-align:top"><p>Periorbital Edema&nbsp;</p></td><td style="vertical-align:top"><p>4 (33.3)</p></td></tr><tr><td style="vertical-align:top"><p>Face Edema&nbsp;</p></td><td style="vertical-align:top"><p>2 (16.7)</p></td></tr><tr><td style="vertical-align:top"><p>Rash&nbsp;</p></td><td style="vertical-align:top"><p>3 (25.0)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue&nbsp;</p></td><td style="vertical-align:top"><p>5 (41.7)</p></td></tr><tr><td style="vertical-align:top"><p>Edema Peripheral&nbsp;</p></td><td style="vertical-align:top"><p>4 (33.3)</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia&nbsp;</p></td><td style="vertical-align:top"><p>2 (16.7)</p></td></tr><tr><td style="vertical-align:top"><p>Eye Edema&nbsp;</p></td><td style="vertical-align:top"><p>4 (33.3)</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation Increased&nbsp;</p></td><td style="vertical-align:top"><p>3 (25.0)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnea Exertional&nbsp;</p></td><td style="vertical-align:top"><p>2 (16.7)</p></td></tr><tr><td style="vertical-align:top"><p>Anemia</p></td><td style="vertical-align:top"><p>3 (25.0)</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top"><p>2 (16.7)</p></td></tr><tr><td style="vertical-align:top"><p>Anorexia&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 (16.7)</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_66618" o:spid="_x0000_s1033" style='width:451.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="57340,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89309" o:spid="_x0000_s1034" style='position:absolute;
  width:28719;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2871978,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l2871978,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2871978,9144"/>
 </v:shape><v:shape id="Shape_x0020_89310" o:spid="_x0000_s1035" style='position:absolute;
  left:28628;width:28712;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2871216,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2871216,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2871216,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="602" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:451.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Clinically relevant or severe laboratory abnormalities in the 12 patients treated with imatinib mesylate for DFSP in the Phase 2 study are presented in Table 11.</p><p><strong>Table 11: Laboratory Abnormalities Reported in DFSP Patients in the Phase 2 Study&nbsp; </strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=12 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong></p><p><strong>CTC Grades<sup>1</sup>&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Grade 4 </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % </strong></p><p><strong>% </strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_66619" o:spid="_x0000_s1030" style='width:442.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56235,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89313" o:spid="_x0000_s1031" style='position:absolute;
  width:42153;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="4215384,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l4215384,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,4215384,9144"/>
 </v:shape><v:shape id="Shape_x0020_89314" o:spid="_x0000_s1032" style='position:absolute;
  left:42153;width:14082;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1408176,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l1408176,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,1408176,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="590" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:442.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Hematology Parameters </strong>&nbsp;</p><p>-&nbsp;&nbsp; Anemia&nbsp;</p><p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>-&nbsp;&nbsp; Thrombocytopenia&nbsp;</p><p>17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>-&nbsp;&nbsp; Neutropenia&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8</p><p><strong>Biochemistry Parameters </strong>&nbsp;</p><p>-&nbsp;&nbsp; Elevated Creatinine&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_66839" o:spid="_x0000_s1028" style='width:442.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56235,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89317" o:spid="_x0000_s1029" style='position:absolute;
  width:56235;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5623560,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5623560,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5623560,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="590" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:442.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><sup>1</sup>CTC Grades: neutropenia (Grade 3 greater than or equal to 0.5 to 1.0 x 10<sup>9</sup>/L, Grade 4 less than 0.5 x 10<sup>9</sup>/L), thrombocytopenia (Grade 3 greater than or equal to 10 to 50 x 10<sup>9</sup>/L, Grade 4 less than 10 x 10<sup>9</sup>/L), anemia (Grade 3 greater than or equal to 65 to 80 g/L, Grade 4 less than 65 g/L), elevated creatinine (Grade</p><p>3 greater than 3 to 6 x upper limit normal range [ULN], Grade 4 greater than 6 x ULN)</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_66840" o:spid="_x0000_s1026" style='width:443.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56327,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89319" o:spid="_x0000_s1027" style='position:absolute;
  width:56327;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5632704,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5632704,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5632704,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="591" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:443.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Adverse Reactions from Multiple Clinical Trials&nbsp;</p><p><strong>Cardiac Disorders: </strong>&nbsp;</p><p>Estimated 1% to 10%: palpitations, pericardial effusion&nbsp;</p><p>Estimated 0.1% to 1%: congestive cardiac failure, tachycardia, pulmonary edema Estimated 0.01% to 0.1%: arrhythmia, atrial fibrillation, cardiac arrest, myocardial infarction, angina pectoris&nbsp;</p><p><strong>Vascular Disorders: </strong>&nbsp;</p><p>Estimated 1% to 10%: flushing, hemorrhage&nbsp;</p><p>Estimated 0.1% to 1%: hypertension, hypotension, peripheral coldness, Raynaud&rsquo;s phenomenon, hematoma, subdural hematoma&nbsp;</p><p><strong>Investigations</strong>:&nbsp;</p><p>Estimated 1% to 10%: blood CPK increased, blood amylase increased&nbsp;</p><p>Estimated 0.1% to 1%: blood LDH increased&nbsp;</p><p><strong>Skin and Subcutaneous Tissue Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: dry skin, alopecia, face edema, erythema, photosensitivity reaction, nail disorder, purpura&nbsp;</p><p>Estimated 0.1% to 1%: exfoliative dermatitis, bullous eruption, psoriasis, rash pustular, contusion, sweating increased, urticaria, ecchymosis, increased tendency to bruise, hypotrichosis, skin hypopigmentation, skin hyperpigmentation, onychoclasis, folliculitis, petechiae, erythema multiforme&nbsp;</p><p>Estimated 0.01% to 0.1%: vesicular rash, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, acute febrile neutrophilic dermatosis (Sweet&rsquo;s syndrome), nail discoloration, angioneurotic edema, leucocytoclastic vasculitis&nbsp;</p><p><strong>Gastrointestinal Disorders: </strong>&nbsp;</p><p>Estimated 1% to 10%: abdominal distention, gastroesophageal reflux, dry mouth, gastritis Estimated 0.1% to 1%: gastric ulcer, stomatitis, mouth ulceration, eructation, melena, esophagitis, ascites, hematemesis, chelitis, dysphagia, pancreatitis&nbsp; Estimated 0.01% to 0.1%: colitis, ileus, inflammatory bowel disease&nbsp;</p><p><strong>General Disorders and Administration Site Conditions</strong>:&nbsp;</p><p>Estimated 1% to 10%: weakness, anasarca, chills&nbsp;</p><p>Estimated 0.1% to 1%: malaise&nbsp;</p><p><strong>Blood and Lymphatic System Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: pancytopenia, febrile neutropenia, lymphopenia, eosinophilia Estimated</p><p>0.1% to 1%: thrombocythemia, bone marrow depression, lymphadenopathy Estimated 0.01% to</p><p>0.1%: hemolytic anemia, aplastic anemia&nbsp;</p><p><strong>Hepatobiliary Disorders</strong>:&nbsp;</p><p>Estimated 0.1% to 1%: hepatitis, jaundice&nbsp;</p><p>&nbsp;</p><p>Estimated 0.01% to 0.1%: hepatic failure and hepatic necrosis<sup>1</sup></p><p><strong>&nbsp;</strong></p><p><strong>Immune System Disorders: </strong>&nbsp;Estimated 0.01% to 0.1%: angioedema&nbsp;</p><p><strong>Infections and Infestations</strong>:&nbsp;</p><p>Estimated 0.1% to 1%: sepsis, herpes simplex, herpes zoster, cellulitis, urinary tract infection, gastroenteritis&nbsp;</p><p>Estimated 0.01% to 0.1%: fungal infection</p><p><strong>Metabolism and Nutrition Disorders:&nbsp; </strong></p><p>Estimated 1% to 10%: weight decreased, decreased appetite&nbsp;</p><p>Estimated 0.1% to 1%: dehydration, gout, increased appetite, hyperuricemia, hypercalcemia, hyperglycemia, hyponatremia, hyperkalemia, hypomagnesemia&nbsp;</p><p><strong>Musculoskeletal and Connective Tissue Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: joint swelling&nbsp;</p><p>Estimated 0.1% to 1%: joint and muscle stiffness, muscular weakness, arthritis&nbsp;</p><p><strong>Nervous System/Psychiatric Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: paresthesia, hypesthesia&nbsp;</p><p>Estimated 0.1% to 1%: syncope, peripheral neuropathy, somnolence, migraine, memory impairment, libido decreased, sciatica, restless leg syndrome, tremor&nbsp;</p><p>Estimated 0.01% to 0.1%: increased intracranial pressure<sup>1</sup>, confusional state, convulsions, optic neuritis&nbsp;</p><p><strong>Renal and Urinary Disorders: </strong>&nbsp;</p><p>Estimated 0.1% to 1%: renal failure acute, urinary frequency increased, hematuria, renal pain&nbsp;</p><p><strong>Reproductive System and Breast Disorders</strong>:&nbsp;</p><p>Estimated 0.1% to 1%: breast enlargement, menorrhagia, sexual dysfunction, gynecomastia, erectile dysfunction, menstruation irregular, nipple pain, scrotal edema&nbsp;</p><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: epistaxis&nbsp;</p><p>Estimated 0.1% to 1%: pleural effusion&nbsp;</p><p>Estimated 0.01% to 0.1%: interstitial pneumonitis, pulmonary fibrosis, pleuritic pain, pulmonary hypertension, pulmonary hemorrhage&nbsp;</p><p><strong>Eye, Ear and Labyrinth Disorders</strong>:&nbsp;</p><p>Estimated 1% to 10%: conjunctivitis, vision blurred, orbital edema, conjunctival hemorrhage, dry eye&nbsp;</p><p>Estimated 0.1% to 1%: vertigo, tinnitus, eye irritation, eye pain, scleral hemorrhage, retinal hemorrhage, blepharitis, macular edema, hearing loss, cataract&nbsp;</p><p>Estimated 0.01% to 0.1%: papilledema<sup>1</sup>, glaucoma&nbsp;</p><p>1</p><p>Including some fatalities&nbsp;</p><p><strong>Postmarketing Experience </strong>&nbsp;</p><p>The following additional adverse reactions have been identified during post approval use of imatinib mesylate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.&nbsp;</p><p>&nbsp;</p><p><strong>Infections: </strong>hepatitis B virus reactivation<sup>1</sup><strong> </strong></p><p>&nbsp;</p><p><strong>Nervous System Disorders</strong>: cerebral edema<sup>1</sup><strong> </strong></p><p><strong>Eye Disorders</strong>: vitreous hemorrhage&nbsp;</p><p>&nbsp;</p><p><strong>Cardiac Disorders</strong>: pericarditis, cardiac tamponade<sup>1</sup><strong> </strong></p><p><strong>Vascular Disorders</strong>: thrombosis/embolism, anaphylactic shock&nbsp;</p><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong>: acute respiratory failure<sup>1</sup>, interstitial lung disease&nbsp;</p><p><strong>Gastrointestinal Disorders</strong>: ileus/intestinal obstruction, tumor hemorrhage/tumor necrosis, gastrointestinal perforation<sup>1</sup>, diverticulitis, gastric antral vascular ectasia.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Skin and Subcutaneous Tissue Disorders</strong>: lichenoid keratosis, lichen planus, toxic epidermal necrolysis, palmar-plantar erythrodysesthesia syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), pseudoporphyria&nbsp;</p><p><strong>Musculoskeletal and Connective Tissue Disorders</strong>: avascular necrosis/hip osteonecrosis, rhabdomyolysis/myopathy, growth retardation in children, musculoskeletal pain upon treatment discontinuation (including myalgia, pain in extremity, arthalgia, bone pain)&nbsp;</p><p><strong>Reproduction Disorders</strong>: hemorrhagic corpus luteum/hemorrhagic ovarian cyst&nbsp;</p><p><strong>Blood and Lymphatic System Disorders</strong>: thrombotic microangiopathy&nbsp;</p><p><sup>1 </sup>Including some fatalities</p><p><u><strong>Reporting of suspected adverse reactions&nbsp;</strong></u></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side affects; you can help provide more information on the safety of this medicine.</p><p><strong><em>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></strong><strong>Saudi&nbsp; Arabia<em>:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:510px"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p><strong><em>&nbsp;o Other GCC States: </em></strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Experience with doses greater than 800 mg is limited. Isolated cases of imatinib mesylate overdose have been reported. In the event of overdosage, observe the patient and give appropriate supportive treatment.&nbsp;</p><p><strong>Adult Overdose&nbsp; </strong></p><p><strong>1,200 to 1,600 mg (duration varying between 1 to 10 days)</strong>: Nausea, vomiting, diarrhea, rash erythema, edema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite.&nbsp;</p><p><strong>1,800 to 3,200 mg (as high as 3,200 mg daily for 6 days)</strong>: Weakness, myalgia, increased CPK, increased bilirubin, gastrointestinal pain.&nbsp;</p><p><strong>6,400 mg (single dose)</strong>: One case in the literature reported one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, neutrophil count decreased, increase transaminases.&nbsp;</p><p><strong>8 to 10 g (single dose): </strong>Vomiting and gastrointestinal pain have been reported.&nbsp;</p><p>A patient with myeloid blast crisis experienced Grade 1 elevations of serum creatinine, Grade 2 ascites and elevated liver transaminase levels, and Grade 3 elevations of bilirubin after inadvertently taking 1,200 mg of imatinib mesylate tablets daily for 6 days. Therapy was temporarily interrupted and complete reversal of all abnormalities occurred within 1 week. Treatment was resumed at a dose of 400 mg daily without recurrence of adverse reactions. Another patient developed severe muscle cramps after taking 1,600 mg of imatinib mesylate tablets daily for 6 days. Complete resolution of muscle cramps occurred following interruption of therapy and treatment was subsequently resumed. Another patient that was prescribed 400 mg daily, took 800 mg of imatinib mesylate tablets on Day 1 and 1,200 mg on Day 2. Therapy was interrupted, no adverse reactions occurred and the patient resumed therapy.&nbsp;</p><p><strong>Pediatric Overdose </strong>&nbsp;</p><p>One 3-year-old male exposed to a single dose of 400 mg experienced vomiting, diarrhea and anorexia and another 3-yearold male exposed to a single dose of 980 mg experienced decreased white blood cell count and diarrhea.<strong><sup> </sup></strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group:</strong> Protein-tyrosine kinase inhibitor<strong>, ATC code: </strong>L01XE01<strong> </strong></p><p>&nbsp;</p><p><strong>Mechanism of action:&nbsp; </strong></p><p>Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutive abnormal tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Imatinib inhibits proliferation and induces apoptosis in BCR-ABL positive cell lines as well as fresh leukemic cells from Philadelphia chromosome positive chronic myeloid leukemia. Imatinib inhibits colony formation in assays using <em>ex vivo </em>peripheral blood and bone marrow samples from CML patients.&nbsp;</p><p><em>In vivo</em>, imatinib inhibits tumor growth of BCR-ABL transfected murine myeloid cells as well as BCR-ABL positive leukemia lines derived from CML patients in blast crisis.&nbsp;</p><p>Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, and inhibits PDGF-and SCF-mediated cellular events.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of imatinib mesylate tablets have been evaluated in studies in healthy subjects and in population pharmacokinetic studies in over 900 patients.&nbsp;</p><p><strong><em>Absorption and Distribution </em></strong>&nbsp;</p><p>Imatinib is well absorbed after oral administration with C<sub>max</sub> achieved within 2 to 4 hours postdose. Mean absolute bioavailability is 98%. Mean imatinib AUC increases proportionally with increasing doses ranging from 25 mg to 1,000 mg. There is no significant change in the pharmacokinetics of imatinib on repeated dosing, and accumulation is 1.5-to 2.5-fold at steady state when imatinib mesylate is dosed once-daily. At clinically relevant concentrations of imatinib, binding to plasma proteins in <em>in vitro </em>experiments is approximately 95%, mostly to albumin and &alpha;1-acid glycoprotein. <strong><em>Elimination </em></strong>&nbsp;</p><p><strong>Metabolism </strong>&nbsp;</p><p>CYP3A4 is the major enzyme responsible for metabolism of imatinib. Other cytochrome P450 enzymes, such as CYP1A2, CYP2D6, CYP2C9, and CYP2C19, play a minor role in its metabolism. The main circulating active metabolite in humans is the N-demethylated piperazine derivative, formed predominantly by CYP3A4. It shows <em>in vitro </em>potency similar to the parent imatinib. The plasma AUC for this metabolite is about 15% of the AUC for imatinib. The plasma protein binding of N-demethylated metabolite CGP74588 is similar to that of the parent compound. Human liver microsome studies demonstrated that imatinib mesylate is a potent competitive inhibitor of CYP2C9, CYP2D6, and CYP3A4/5 with Ki values of 27, 7.5, and 8 &mu;M, respectively.&nbsp; <strong>Excretion </strong>&nbsp;</p><p>Imatinib elimination is predominately in the feces, mostly as metabolites. Based on the recovery of compound(s) after an oral <sup>14</sup>C-labeled dose of imatinib, approximately 81% of the dose was eliminated within 7 days, in feces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% feces), the remainder being metabolites.&nbsp;</p><p>Following oral administration in healthy volunteers, the elimination half-lives of imatinib and its major active metabolite, the N-demethyl derivative (CGP74588), are approximately 18 and 40 hours, respectively.&nbsp;</p><p>Typically, clearance of imatinib in a 50-year-old patient weighing 50 kg is expected to be 8 L/h, while for a 50-year-old patient weighing 100 kg the clearance will increase to 14 L/h. The interpatient variability of 40% in clearance does not warrant initial dose adjustment based on body weight and/or age but indicates the need for close monitoring for treatment-related toxicity.&nbsp;</p><p><strong><em>Specific Populations </em></strong>&nbsp;</p><p><strong>Hepatic Impairment </strong>&nbsp;</p><p>The effect of hepatic impairment on the pharmacokinetics of both imatinib and its major metabolite, CGP74588, was assessed in 84 patients with cancer and varying degrees of hepatic impairment <em>&nbsp;</em>at imatinib doses ranging from 100 mg to 800 mg. Exposure to both imatinib and CGP74588 was comparable between each of the mildly and moderately hepatically-impaired groups and the normal group. Patients with severe hepatic impairment tend to have higher exposure to both imatinib and its metabolite than patients with normal hepatic function. At steady state, the mean C<sub>max</sub>/dose and AUC/dose for imatinib increased by about 63% and 45%, respectively, in patients with severe hepatic impairment compared to patients with normal hepatic function. The mean C<sub>max</sub>/dose and AUC/dose for CGP74588 increased by about 56% and 55%, respectively, in patients with severe hepatic impairment compared to patients with normal hepatic function. Dose reductions are necessary for patients with severe hepatic impairment.<em> </em>&nbsp;</p><p><strong>Renal Impairment </strong>&nbsp;</p><p>The effect of renal impairment on the pharmacokinetics of imatinib was assessed in 59 cancer patients with varying degrees of renal impairment at single and steady state imatinib doses ranging from 100 to 800 mg/day. The mean exposure to imatinib (dose normalized AUC) in patients with mild and moderate renal impairment increased 1.5-to 2-fold compared to patients with normal renal function. The AUCs did not increase for doses greater than 600 mg in patients with mild renal impairment. The AUCs did not increase for doses greater than 400 mg in patients with moderate renal impairment. Two patients with severe renal impairment were dosed with 100 mg/day and their exposures were similar to those seen in patients with normal renal function receiving 400 mg/day. Dose reductions are necessary for patients with moderate and severe renal impairment.&nbsp;</p><p><strong>Pediatric Use </strong>&nbsp;</p><p>As in adult patients, imatinib was rapidly absorbed after oral administration in pediatric patients,</p><p>&nbsp;with a C<sub>max</sub> of 2 to 4 hours. Apparent oral clearance was similar to adult values (11.0 L/hr/m<sup>2 </sup>in</p><p>&nbsp;children vs. 10.0 L/hr/m<sup>2 </sup>in adults), as was the half-life (14.8 hours in children vs. 17.1 hours in</p><p>&nbsp;adults). Dosing in children at both 260 mg/m<sup>2 </sup>and 340 mg/m<sup>2 </sup>achieved an AUC similar to the</p><p>&nbsp;</p><p>400 mg dose in adults. The comparison of AUC on Day 8 vs. Day 1 at 260 mg/m<sup>2 </sup>and 340</p><p>&nbsp;</p><p>mg/m<sup>2 </sup>dose levels revealed a 1.5-and 2.2-fold drug accumulation, respectively, after repeated once-daily dosing. Mean imatinib AUC did not increase proportionally with increasing dose.</p><p>Based on pooled population pharmacokinetic analysis in pediatric patients with hematological disorders (CML, or other hematological disorders treated with imatinib), clearance of imatinib increases with increasing body surface area (BSA). After correcting for the BSA effect, other demographics such as age, body weight and body mass index did not have clinically significant effects on the exposure of imatinib. The analysis confirmed that exposure of imatinib in pediatric</p><p>&nbsp; &nbsp;patients receiving 260 mg/m<sup>2 </sup>once-daily (not exceeding 400 mg once-daily) or 340 mg/m<sup>2 </sup>oncedaily (not exceeding 600 mg once-daily) were similar to those in adult patients who received imatinib 400 mg or 600 mg once-daily.&nbsp;</p><p><strong><em>Drug Interactions </em></strong>&nbsp;</p><p><strong>Agents Inducing CYP3A Metabolism </strong>&nbsp;</p><p>Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of imatinib mesylate, increased imatinib mesylate oral-dose clearance by 3.8-fold, which significantly (p less than 0.05) decreased mean C<sub>max</sub> and AUC.&nbsp;</p><p>Similar findings were observed in patients receiving 400 to 1200 mg/day imatinib mesylate tablets concomitantly with enzyme-inducing anti-epileptic drugs (EIAED) (e.g., carbamazepine, oxcarbamazepine, phenytoin, fosphenytoin, phenobarbital, and primidone). The mean dose normalized AUC for imatinib in the patients receiving EIAED&rsquo;s decreased by 73% compared to patients not receiving EIAED.&nbsp;</p><p>Concomitant administration of imatinib mesylate and St. John&rsquo;s Wort led to a 30% reduction in the AUC of imatinib.&nbsp;</p><p>Consider alternative therapeutic agents with less enzyme induction potential in patients when rifampin or other CYP3A4 inducers are indicated. Imatinib mesylate tablets doses up to 1200 mg/day (600 mg twice daily) have been given to patients receiving concomitant strong CYP3A4 inducers.&nbsp;</p><p><strong>Agents Inhibiting CYP3A Metabolism </strong>&nbsp;</p><p>There was a significant increase in exposure to imatinib (mean C<sub>max</sub> and AUC increased by 26% and 40%, respectively) in healthy subjects when imatinib mesylate was coadministered with a single dose of ketoconazole (a CYP3A4 inhibitor). Caution is recommended when administering imatinib mesylate with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice may also increase plasma concentrations of imatinib and should be avoided.&nbsp;</p><p><strong>Interactions with Drugs Metabolized by CYP3A4 </strong>&nbsp;</p><p>Imatinib mesylate increases the mean C<sub>max</sub> and AUC of simvastatin (CYP3A4 substrate) 2-and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by imatinib mesylate. Particular caution is recommended when administering imatinib mesylate with CYP3A4 substrates that have a narrow therapeutic window (e.g., alfentanil, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus or tacrolimus).&nbsp;</p><p>Imatinib mesylate will increase plasma concentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).&nbsp;</p><p>Because warfarin is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard heparin instead of warfarin.&nbsp;</p><p><strong>Interactions with Drugs Metabolized by CYP2D6 </strong>&nbsp;</p><p>Imatinib mesylate increased the mean C<sub>max</sub> and AUC of metoprolol by approximately 23% suggesting that imatinib mesylate has a weak inhibitory effect on CYP2D6-mediated metabolism. No dose adjustment is necessary, however, caution is recommended when administering imatinib mesylate with CYP2D6 substrates that have a narrow therapeutic window.</p><p><strong>Interactions with Acetaminophen&nbsp; </strong></p><p>&nbsp;</p><p><em>In vitro</em>, imatinib mesylate inhibits the acetaminophen O-glucuronidate pathway (K<sub>i</sub> 58.5 &mu;M). Coadministration of imatinib mesylate (400 mg/day for 8 days) with acetaminophen (1000 mg single dose on day 8) in patients with CML did not result in any changes in the pharmacokinetics of acetaminophen. Imatinib mesylate pharmacokinetics were not altered in the presence of single-dose acetaminophen. There is no pharmacokinetic or safety data on the concomitant use of imatinib mesylate at doses greater than 400 mg/day or the chronic use of concomitant acetaminophen and imatinib mesylate.</p><p><strong>USE IN SPECIFIC POPULATIONS </strong>&nbsp;</p><p><strong>Pregnancy </strong>&nbsp;</p><p>Risk Summary &nbsp;</p><p>Imatinib mesylate can cause fetal harm when administered to a pregnant woman based on human and animal data. There are no clinical studies regarding use of imatinib mesylate in pregnant women. There have been postmarket reports of spontaneous abortions and congenital anomalies from women who have been exposed to imatinib mesylate during pregnancy. Reproductive studies in rats have demonstrated that imatinib mesylate induced teratogenicity and increased incidence of congenital abnormalities following prenatal exposure to imatinib mesylate at doses equal to the highest recommended human dose of 800 mg/day based on body surface area. Advise women to avoid pregnancy when taking imatinib mesylate. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to the fetus.&nbsp;</p><p>The background risk of major birth defects and miscarriage for the indicated population is not known; however, in the U.S. general population, the estimated background risk of major birth defects of clinically recognized pregnancies is 2 to 4% and of miscarriage is 15% to 20%.&nbsp; <em>Data </em>&nbsp;</p><p>Animal Data&nbsp;</p><p>In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of imatinib mesylate up to 100 mg/kg/day and 60 mg/kg/day, respectively, during the period of organogenesis.&nbsp;</p><p>In rats, imatinib mesylate was teratogenic at 100 mg/kg/day (approximately equal to the maximum human dose of 800 mg/day based on body surface area), the number of fetuses with encephalocoele and exencephaly was higher than historical control values and these findings were associated with missing or underdeveloped cranial bones. Lower mean fetal body weights were associated with retarded skeletal ossifications.&nbsp;</p><p>&nbsp;</p><p>In rabbits, at doses 1.5 times higher than the maximum human dose of 800 mg/day based on body surface area, no effects on the reproductive parameters with respect to implantation sites, number of live fetuses, sex ratio or fetal weight were observed. The examinations of the fetuses did not reveal any drug related morphological changes.&nbsp;</p><p>In a pre-and postnatal development study in rats, pregnant rats received oral doses of imatinib mesylate during gestation (organogenesis) and lactation up to 45 mg/kg/day. Five animals developed a red vaginal discharge in the 45 mg/kg/day group on Days 14 or 15 of gestation, the significance of which is unknown since all females produced viable litters and none had increased post-implantation loss. Other maternal effects noted only at the dose of 45 mg/kg/day (approximately one-half the maximum human dose of 800 mg/day based on body surface area) included an increased numbers of stillborn pups and pups dying between postpartum Days 0 and 4. In the F<sup>1 </sup>offspring at this same dose level, mean body weights were reduced from birth until terminal sacrifice and the number of litters achieving criterion for preputial separation was slightly decreased. There were no other significant effects in developmental parameters or behavioral testing. F<sup>1 </sup>fertility was not affected but reproductive effects were noted at 45 mg/kg/day including an increased number of resorptions and a decreased number of viable fetuses. The NOEL for both maternal animals and the F<sup>1</sup> generation was 15 mg/kg/day.&nbsp;</p><p><strong>Lactation </strong>&nbsp;</p><p>Risk Summary &nbsp;</p><p>Imatinib and its active metabolite are excreted into human milk. Because of the potential for serious adverse reactions in breastfed infants from imatinib mesylate, advise a lactating woman not to breastfeed during treatment and for 1 month after the last dose.&nbsp; <em>Human Data </em>&nbsp;</p><p>Based on data from 3 breastfeeding women taking imatinib mesylate, the milk:plasma ratio is about 0.5 for imatinib and about 0.9 for the active metabolite. Considering the combined concentration of imatinib and active metabolite, a breastfed infant could receive up to 10% of the maternal therapeutic dose based on body weight.&nbsp;</p><p><strong>Females and Males of Reproductive Potential </strong>&nbsp;</p><p>Pregnancy Testing &nbsp;</p><p>Human postmarketing reports and animal studies have shown imatinib mesylate to be harmful to the developing fetus. Test pregnancy status in females with reproductive potential prior to the initiation of treatment with imatinib mesylate.&nbsp;</p><p><em>Contraception </em>&nbsp;</p><p>Females&nbsp;</p><p>Advise female patients of reproductive potential to use effective contraception (methods that result in less than 1 % pregnancy rates) when using imatinib mesylate during treatment and for fourteen days after stopping treatment with imatinib mesylate.</p><p>Infertility &nbsp;</p><p>The risk of infertility in females or males of reproductive potential has not been studied in humans. In a rat study, the fertility in males and females was not affected.</p><p><strong>Pediatric Use </strong>&nbsp;</p><p>The safety and effectiveness of imatinib mesylate tablets have been demonstrated in pediatric patients with newly diagnosed Ph+ chronic phase CML<em>. </em>There are no data in children under 1 year of age.&nbsp;</p><p><strong>Geriatric Use </strong>&nbsp;</p><p>In the CML clinical studies, approximately 20% of patients were older than 65 years. In the study of patients with newly diagnosed CML, 6% of patients were older than 65 years. The frequency of edema was higher in patients older than 65 years as compared to younger patients; no other difference in the safety profile was observed. The efficacy of imatinib mesylate was similar in older and younger patients.&nbsp;</p><p><strong>Hepatic Impairment </strong>&nbsp;</p><p>The effect of hepatic impairment on the pharmacokinetics of both imatinib and its major metabolite, CGP74588, was assessed in 84 patients with cancer with varying degrees of hepatic impairment at imatinib doses ranging from 100 mg to 800 mg.</p><p>Mild and moderate hepatic impairment do not influence exposure to imatinib and CGP74588. In patients with severe hepatic impairment, the imatinib C<sub>max </sub>and area under curve (AUC) increased by 63% and 45% and the CGP74588 C<sub>max</sub> and AUC increased by 56% and 55%, relative to patients with normal hepatic function. Reduce the dose by 25% for patients with severe hepatic impairment.&nbsp;</p><p><strong>Table 12: Liver Function Classification </strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p><strong>Liver Function </strong></p><p><strong>Test </strong></p></td><td style="vertical-align:top"><p><strong>Normal </strong></p><p><strong>(n=14) </strong></p></td><td style="vertical-align:top"><p><strong>Mild (n=30) </strong></p></td><td style="vertical-align:top"><p><strong>Moderate </strong></p><p><strong>(n=20) </strong></p></td><td style="vertical-align:top"><p><strong>Severe </strong></p><p><strong>(n=20) </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Total Bilirubin</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>less than or equal to</p><p>ULN</p></td><td style="vertical-align:top"><p>greater than 1.0 to</p><p>1.5 times the ULN</p></td><td style="vertical-align:top"><p>greater than 1.5 to 3 times the ULN</p></td><td style="vertical-align:top"><p>greater than 3 to 10 times the ULN</p></td></tr><tr><td style="vertical-align:top"><p><strong>SGOT</strong></p><p>&nbsp;</p></td><td><p>less than or equal to</p><p>ULN</p></td><td style="vertical-align:top"><p>greater than ULN</p><p>(can be normal if Total Bilirubin is greater than ULN)</p></td><td><p>Any</p></td><td><p>Any</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>ULN=upper limit of normal for the institution&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>Renal Impairment&nbsp; </strong></p><p>&nbsp;</p><p>The effect of renal impairment on the pharmacokinetics of imatinib was assessed in 59 patients with cancer and varying degrees of renal impairment at single and steady state imatinib doses ranging from 100 to 800 mg/day. The mean exposure to imatinib (dose normalized AUC) in patients with mild and moderate renal impairment increased 1.5-to 2-fold compared to patients with normal renal function. There are not sufficient data in patients with severe renal impairment. Dose reductions are necessary for patients with moderate and severe renal impairment.</p><p><strong>Table 13: Renal Function Classification </strong></p><p><strong>Renal Dysfunction </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal Function Tests </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p><strong>Mild</strong></p></td><td style="vertical-align:top"><p>CrCL = 40 to 59 mL/min</p></td></tr><tr><td style="vertical-align:top"><p><strong>Moderate </strong></p></td><td style="vertical-align:top"><p>CrCL = 20 to 39 mL/min</p></td></tr><tr><td style="vertical-align:top"><p><strong>Severe </strong></p></td><td style="vertical-align:top"><p>CrCL = less than 20 mL/min</p></td></tr><tr><td style="vertical-align:bottom"><p>CrCL = Creatinine Clearance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Carcinogenesis, Mutagenesis, Impairment of Fertility </strong>&nbsp;</p><p>In the 2-year rat carcinogenicity study administration of imatinib at 15, 30, and 60 mg/kg/day resulted in a statistically significant reduction in the longevity of males at 60 mg/kg/day and females at greater than or equal to 30 mg/kg/day. Target organs for neoplastic changes were the kidneys (renal tubule and renal pelvis), urinary bladder, urethra, preputial and clitoral gland, small intestine, parathyroid glands, adrenal glands and non-glandular stomach. Neoplastic lesions were not seen at: 30 mg/kg/day for the kidneys, urinary bladder, urethra, small intestine, parathyroid glands, adrenal glands and non-glandular stomach, and 15 mg/kg/day for the preputial and clitoral gland. The papilloma/carcinoma of the preputial/clitoral gland were noted at 30 and 60 mg/kg/day, representing approximately 0.5 to 4 or 0.3 to 2.4 times the human daily exposure (based on AUC) at 400 mg/day or 800 mg/day, respectively, and 0.4 to 3.0 times the daily exposure in children (based on AUC) at 340 mg/m<sup>2</sup>. The renal tubule adenoma/carcinoma, renal pelvis transitional cell neoplasms, the urinary bladder and urethra transitional cell papillomas, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumors of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day. The relevance of these findings in the rat carcinogenicity study for humans is not known. Positive genotoxic effects were obtained for imatinib in an <em>in vitro </em>mammalian cell assay (Chinese hamster ovary) for clastogenicity (chromosome aberrations) in the presence of metabolic activation. Two intermediates of the manufacturing process, which are also present in the final product, are positive for mutagenesis in the Ames assay. One of these intermediates was also positive in the mouse lymphoma assay. Imatinib was not genotoxic when tested in an <em>in vitro </em>bacterial cell assay (Ames test), an <em>in vitro </em>mammalian cell assay (mouse lymphoma) and an <em>in vivo </em>rat micronucleus assay.&nbsp;</p><p>In a study of fertility, male rats were dosed for 70 days prior to mating and female rats were dosed 14 days prior to mating and through to gestational Day 6. Testicular and epididymal weights and percent motile sperm were decreased at 60 mg/kg, approximately three-fourths the maximum clinical dose of 800 mg/day based on body surface area. This was not seen at doses less than or equal to 20 mg/kg (one-fourth the maximum human dose of 800 mg). The fertility of male and female rats was not affected.&nbsp;</p><p>Fertility was not affected in the preclinical fertility and early embryonic development study although lower testes and epididymal weights as well as a reduced number of motile sperm were observed in the high dose males rats. In the preclinical pre-and postnatal study in rats, fertility in the first generation offspring was also not affected by imatinib mesylate.&nbsp;</p><p><strong>Animal Toxicology and/or Pharmacology&nbsp; </strong></p><p><strong>Toxicities from Long-Term Use </strong>&nbsp;</p><p>It is important to consider potential toxicities suggested by animal studies, specifically, <em>liver, kidney, and cardiac toxicity and immunosuppression</em>. Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia. Renal toxicity was observed in monkeys treated for 2 weeks, with focal mineralization and dilation of the renal tubules and tubular nephrosis. Increased BUN and creatinine were observed in several of these animals. An increased rate of opportunistic infections was observed with chronic imatinib treatment in laboratory animal studies. In a 39 week monkey study, treatment with imatinib resulted in worsening of normally suppressed malarial infections in these animals. Lymphopenia was observed in animals (as in humans). Additional long-term toxicities were identified in a 2-year rat study. Histopathological examination of the treated rats that died on study revealed cardiomyopathy (both sexes), chronic progressive nephropathy (females) and preputial gland papilloma as principal causes of death or reasons for sacrifice. Non-neoplastic lesions seen in this 2-year study which were not identified in earlier preclinical studies were the cardiovascular system, pancreas, endocrine organs and teeth. The most important changes included cardiac hypertrophy and dilatation, leading to signs of cardiac insufficiency in some animals.&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>CLINICAL STUDIES </strong>&nbsp;</p><p><strong>Chronic Myeloid Leukemia&nbsp; </strong></p><p><strong>Chronic Phase, Newly Diagnosed: </strong>&nbsp;</p><p>An open-label, multicenter, international randomized Phase 3 study (imatinib mesylate versus IFN+Ara-C) has been conducted in patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. This study compared treatment with either single-agent imatinib mesylate or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C). Patients were allowed to cross over to the alternative treatment arm if they failed to show a complete hematologic response (CHR) at 6 months, a major cytogenetic response (MCyR) at 12 months, or if they lost a CHR or MCyR. Patients with increasing WBC or severe intolerance to treatment were also allowed to cross over to the alternative treatment arm with the permission of the study monitoring committee (SMC). In the imatinib mesylate arm, patients were treated initially with 400 mg daily. Dose escalations were allowed from 400 mg daily to 600 mg daily, then from 600 mg daily to 800 mg daily. In the IFN arm, patients were treated with a target dose of IFN of 5 MIU/m<sup>2</sup>/day subcutaneously in combination with subcutaneous Ara-C 20 mg/m<sup>2</sup>/day for 10 days/month.&nbsp;</p><p>A total of 1,106 patients were randomized from 177 centers in 16 countries, 553 to each arm. Baseline characteristics were well balanced between the two arms. Median age was 51 years (range 18 to 70 years), with 21.9% of patients greater than or equal to 60 years of age. There were 59% males and 41% females; 89.9% Caucasian and 4.7% black patients. At the cut-off for this analysis (7 years after last patient had been recruited), the median duration of first-line treatment was 82 and 8 months in the imatinib mesylate and IFN arm, respectively. The median duration of second-line treatment with imatinib mesylate was 64 months. Sixty percent of patients randomized to imatinib mesylate are still receiving first-line treatment. In these patients, the average dose of imatinib mesylate was 403 mg &plusmn; 57 mg. Overall, in patients receiving first line imatinib mesylate, the average daily dose delivered was 406 mg &plusmn; 76 mg. Due to discontinuations and cross-overs, only 2% of patients randomized to IFN were still on first-line treatment. In the IFN arm, withdrawal of consent (14%) was the most frequent reason for discontinuation of first-line therapy, and the most frequent reason for cross over to the imatinib mesylate arm was severe intolerance to treatment (26%) and progression (14%).&nbsp;</p><p>The primary efficacy endpoint of the study was progression-free survival (PFS). Progression was defined as any of the following events: progression to accelerated phase or blast crisis (AP/BC), death, loss of CHR or MCyR, or in patients not achieving a CHR an increasing WBC despite appropriate therapeutic management. The protocol specified that the progression analysis would compare the intent to treat (ITT) population: patients randomized to receive imatinib mesylate were compared with patients randomized to receive IFN. Patients that crossed over prior to progression were not censored at the time of cross-over, and events that occurred in these patients following cross-over were attributed to the original randomized treatment. The estimated rate of progression-free survival at 84 months in the ITT population was 81.2 % [95% CI: 78, 85] in the imatinib mesylate arm and 60.6 % [56, 65] in the IFN arm (p less than 0.0001, logrank test), (Figure 1). With 7 years follow up there were 93 (16.8%) progression events in the imatinib mesylate arm: 37(6.7%) progression to AP/BC, 31 (5.6%) loss of MCyR, 15 (2.7%) loss of CHR or increase in WBC and 10 (1.8%) CML unrelated deaths. In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm of which 130 occurred during first-line treatment with IFN-Ara-C. The estimated rate of patients free of progression to accelerated phase (AP) or blast crisis (BC) at 84 months was 92.5%[90, 95] in the imatinib mesylate arm compared to the 85.1%, [82, 89] (p less than or equal to 0.001) in the IFN arm, (Figure 2). The annual rates of any progression events have decreased with time on therapy. The probability of remaining progression free at 60 months was 95% for patients who were in complete cytogenetic response (CCyR) with molecular response (greater than or equal to 3 log reduction in BCR-ABL transcripts as measured by quantitative reverse transcriptase polymerase chain reaction) at 12 months, compared to 89% for patients in complete cytogenetic response but without a major molecular response and 70% in patients who were not in complete cytogenetic response at this time point (p less than 0.001).</p><p><strong>Figure 1: Progression Free Survival (ITT Principle) </strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_3487" o:spid="_x0000_i1030" type="#_x0000_t75"
 style='width:312pt;height:162.75pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="416" height="217" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Figure 2: Time to Progression to AP or BC (ITT Principle) </strong></p><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_3514" o:spid="_x0000_i1029" type="#_x0000_t75" style='width:306.75pt;
 height:200.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title=""/>
</v:shape><![endif]--><img width="409" height="267" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /><strong>&nbsp;</strong></p><p>A total of 71 (12.8%) and 85 (15.4%) patients died in the imatinib mesylate and IFN+Ara-C group, respectively. At 84 months the estimated overall survival is 86.4% (83, 90) vs. 83.3% (80, 87) in the randomized imatinib mesylate and the IFN+Ara-C group, respectively (p=0.073 logrank test). The hazard ratio is 0.750 with 95% CI 0.547 to 1.028. This time-to-event endpoint may be affected by the high crossover rate from IFN+Ara-C to imatinib mesylate. Major cytogenetic response, hematologic response, evaluation of minimal residual disease (molecular response), time to accelerated phase or blast crisis and survival were main secondary endpoints. Response data are shown in Table 14. Complete hematologic response, major cytogenetic response and complete cytogenetic response were also statistically significantly higher in the imatinib mesylate arm compared to the IFN + Ara-C arm (no cross-over data considered for evaluation of responses). Median time to CCyR in the 454 responders was 6 months (range 2 to</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>64 months, 25<sup>th </sup>to 75<sup>th </sup>percentiles=3 to 11 months) with 10% of responses seen only after 22 months of therapy</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Table 14: Response in Newly Diagnosed CML Study (84-Month Data)&nbsp; </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:574px"><tbody><tr><td style="vertical-align:top"><p><strong>(Best Response Rate) </strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Imatinib Mesylate </strong></p></td><td style="vertical-align:top"><p><strong>IFN+Ara&minus;C</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n=553</strong></p></td><td style="vertical-align:top"><p><strong>n=553</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hematologic Response<sup>1 </sup></strong>&nbsp;CHR Rate n (%)&nbsp;</p></td><td style="vertical-align:bottom"><p>534 (96.6%)*</p></td><td style="vertical-align:bottom"><p>313 (56.6%)*</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]&nbsp;</p></td><td style="vertical-align:top"><p>[94.7%, 97.9%]</p></td><td style="vertical-align:top"><p>[52.4%, 60.8%]</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cytogenetic Response<sup>2</sup> </strong>&nbsp;</p><p><strong>Major Cytogenetic Response n (%) </strong>&nbsp;</p></td><td style="vertical-align:bottom"><p>472 (85.4 %)*</p></td><td style="vertical-align:bottom"><p>93 (16.8%)*</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]&nbsp;</p></td><td style="vertical-align:top"><p>[82.1%, 88.2%]</p></td><td style="vertical-align:top"><p>[13.8%, 20.2</p></td></tr><tr><td style="vertical-align:top"><p>Unconfirmed<sup>3 </sup>&nbsp;</p></td><td style="vertical-align:top"><p>88.6%*</p></td><td style="vertical-align:top"><p>23.3%*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Complete Cytogenetic Response n (%) </strong>&nbsp;</p></td><td style="vertical-align:top"><p>413 (74.7%)*</p></td><td style="vertical-align:top"><p>36 (6.5%)*</p></td></tr><tr><td style="vertical-align:top"><p>[95% CI]&nbsp;</p></td><td style="vertical-align:top"><p>[70.8, 78.3]</p></td><td style="vertical-align:top"><p>[4.6, 8.9]</p></td></tr><tr><td style="vertical-align:top"><p>Unconfirmed<sup>3 </sup>&nbsp;</p></td><td style="vertical-align:top"><p>82.5%*</p></td><td style="vertical-align:top"><p>11.6%*</p></td></tr></tbody></table><p>*p less than 0.001, Fischer&rsquo;s exact test</p><p><strong><sup>1</sup></strong><strong>Hematologic response criteria </strong>(all responses to be confirmed after greater than or equal to 4 weeks): WBC less than 10 x 10<sup>9</sup>/L, platelet less than 450 x 10<sup>9</sup>/L, myelocyte + metamyelocyte less than 5% in blood, no blasts and promyelocytes in blood, no extramedullary involvement.</p><p><strong><sup>2</sup></strong><strong>Cytogenetic response criteria </strong>(confirmed after greater than or equal to 4 weeks): complete (0% Ph+ metaphases) or partial (1% to 35%). A major response (0% to 35%) combines both complete and partial responses.</p><p><strong><sup>3</sup></strong><strong>Unconfirmed cytogenetic response </strong>is based on a single bone marrow cytogenetic evaluation, therefore unconfirmed complete or partial cytogenetic responses might have had a lesser cytogenetic response on a subsequent bone marrow evaluation.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_80292" o:spid="_x0000_s1037" style='width:431.4pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="54787,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89321" o:spid="_x0000_s1038" style='position:absolute;
  width:54787;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5478780,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5478780,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5478780,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="575" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1028" type="#_x0000_t75" style='width:431.4pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>Molecular response was defined as follows: </strong>in the peripheral blood, after 12 months of therapy, reduction of greater than or equal to 3 logarithms in the amount of BCR-ABL transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardized baseline. Molecular response was only evaluated in a subset of patients who had a complete cytogenetic response by 12 months or later (N=333). The molecular response rate in patients who had a complete cytogenetic response in the imatinib mesylate arm was 59% at 12 months and 72% at 24 months.&nbsp;</p><p>Physical, functional, and treatment-specific biologic response modifier scales from the FACTBRM (Functional Assessment of Cancer Therapy - Biologic Response Modifier) instrument were used to assess patient-reported general effects of interferon toxicity in 1,067 patients with CML in chronic phase. After one month of therapy to 6 months of therapy, there was a 13% to 21% decrease in median index from baseline in patients treated with IFN, consistent with increased symptoms of IFN toxicity. There was no apparent change from baseline in median index for patients treated with imatinib mesylate.&nbsp;</p><p>An open-label, multicenter, randomized trial (imatinib mesylate versus nilotinib) was conducted to determine the efficacy of imatinib mesylate versus nilotinib in adult patients with cytogenetically confirmed, newly diagnosed Ph+ CML-CP. Patients were within 6 months of diagnosis and were previously untreated for CML-CP, except for hydroxyurea and/or anagrelide. Efficacy was based on a total of 846 patients: 283 patients in the imatinib mesylate tablets 400 mg once daily group, 282 patients in the nilotinib 300 mg twice daily group, 281 patients in the nilotinib 400 mg twice daily group.&nbsp;</p><p>Median age was 46 years in the imatinib mesylate group and 47 years in both nilotinib groups, with 12%, 13%, and 10% of patients greater than or equal to 65 years of age in imatinib mesylate tablets 400 mg once-daily, nilotinib 300 mg twice daily and nilotinib 400 mg twice daily treatment groups, respectively. There were slightly more male than female patients in all groups (56%, 56%, and 62% in imatinib mesylate tablets 400 mg once-daily, nilotinib 300 mg twicedaily and nilotinib 400 mg twice-daily treatment groups, respectively). More than 60% of all patients were Caucasian, and 25% were Asian.&nbsp;</p><p>The primary data analysis was performed when all 846 patients completed 12 months of treatment or discontinued earlier. Subsequent analyses were done when patients completed 24, 36, 48 and 60 months of treatment or discontinued earlier. The median time on treatment was approximately 61 months in all three treatment groups.&nbsp;</p><p>The primary efficacy endpoint was major molecular response (MMR) at 12 months after the start of study medication. MMR was defined as less than or equal to 0.1% BCR-ABL/ABL % by international scale measured by RQ-PCR, which corresponds to a greater than or equal to 3 log reduction of BCR-ABL transcript from standardized baseline. Efficacy endpoints are summarized in Table 15.</p><p>Twelve patients in the imatinib mesylate arm progressed to either accelerated phase or blast crises (7 patients within first 6 months, 2 patients within 6 to 12 months, 2 patients within 12 to 18 months and 1 patient within 18 to 24 months) while two patients on the nilotinib arm progressed to either accelerated phase or blast crisis (both within the first 6 months of treatment).&nbsp;</p><p><strong>Table 15: Efficacy (MMR and CCyR) of Imatinib Mesylate</strong><strong> Tablets</strong><strong> Compared to Nilotinib in Newly Diagnosed Ph+ CML-CP </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:616px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Imatinib mesylate Tablets</strong><strong> </strong></p><p><strong>400 mg once daily</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>nilotinib </strong></p><p><strong>300 mg twice daily</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>N=283&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>N=282&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>MMR at 12 months (95% CI)&nbsp;</p></td><td style="vertical-align:top"><p>22% (17.6, 27.6)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>44% (38.4, 50.3)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>P-Value<sup>a</sup>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CCyR<sup>b</sup> by 12 months (95% CI)&nbsp;</p></td><td style="vertical-align:top"><p>65% (59.2, 70.6)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>80% (75.0, 84.6)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>MMR at 24 months (95% CI)&nbsp;</p></td><td style="vertical-align:top"><p>38% (31.8, 43.4)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>62% (55.8, 67.4)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>CCyR<sup>b</sup> by 24 months (95% CI)&nbsp;</p></td><td style="vertical-align:top"><p>77% (71.7, 81.8)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>87% (82.4, 90.6)&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>CMH test stratified by Sokal risk group&nbsp; <sup>b</sup>CCyR: 0% Ph+ metaphases. Cytogenetic responses were based on the percentage of Ph-positive metaphases among greater than or equal to 20 metaphase cells in each bone marrow sample.&nbsp;</p><p>By the 60 months, MMR was achieved by 60% of patients on imatinib mesylate and 77% of patients on nilotinib.&nbsp;</p><p>Median overall survival was not reached in either arm. At the time of the 60-month final analysis, the estimated survival rate was 91.7% for patients on imatinib mesylate and 93.7% for patients on nilotinib.&nbsp;</p><p><strong>Late Chronic Phase CML and Advanced Stage CML</strong>: Three international, open-label, singlearm Phase 2 studies were conducted to determine the safety and efficacy of imatinib mesylate in patients with Ph+ CML: 1) in the chronic phase after failure of IFN therapy, 2) in accelerated phase disease, or 3) in myeloid blast crisis. About 45% of patients were women and 6% were black. In clinical studies, 38% to 40% of patients were greater than or equal to 60 years of age and 10% to 12% of patients were greater than or equal to 70 years of age.&nbsp;</p><p><strong>Chronic Phase, Prior Interferon-Alpha Treatment: </strong>532 patients were treated at a starting dose of 400 mg; dose escalation to 600 mg was allowed. The patients were distributed in three main categories according to their response to prior interferon: failure to achieve (within 6 months), or loss of a complete hematologic response (29%), failure to achieve (within 1 year) or loss of a major cytogenetic response (35%), or intolerance to interferon (36%). Patients had</p><p>&nbsp;received a median of 14 months of prior IFN therapy at doses greater than or equal to 25 x 10<sup>6</sup></p><p>IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months.</p><p>Effectiveness was evaluated on the basis of the rate of hematologic response and by bone marrow exams to assess the rate of major cytogenetic response (up to 35% Ph+ metaphases) or complete cytogenetic response (0% Ph+ metaphases). Median duration of treatment was 29 months with 81% of patients treated for greater than or equal to 24 months (maximum = 31.5 months). Efficacy results are reported in Table 16. Confirmed major cytogenetic response rates were higher in patients with IFN intolerance (66%) and cytogenetic failure (64%), then in patients with hematologic failure (47%). Hematologic response was achieved in 98% of patients with cytogenetic failure, 94% of patients with hematologic failure, and 92% of IFN-intolerant patients.&nbsp;</p><p><strong>Accelerated Phase: </strong>235 patients with accelerated phase disease were enrolled. These patients met one or more of the following criteria: greater than or equal to 15% - less than 30% blasts in PB or BM; greater than or equal to 30% blasts + promyelocytes in PB or BM; greater than or equal to 20% basophils in PB; and less than 100 x 10<sup>9</sup>/L platelets. The first 77 patients were started at 400 mg, with the remaining 158 patients starting at 600 mg.&nbsp;</p><p>Effectiveness was evaluated primarily on the basis of the rate of hematologic response, reported as either complete hematologic response, no evidence of leukemia (i.e., clearance of blasts from the marrow and the blood, but without a full peripheral blood recovery as for complete responses), or return to chronic phase CML. Cytogenetic responses were also evaluated. Median duration of treatment was 18 months with 45% of patients treated for greater than or equal to 24 months (maximum=35 months). Efficacy results are reported in Table 16. Response rates in accelerated phase CML were higher for the 600 mg dose group than for the 400 mg group: hematologic response (75% vs. 64%), confirmed and unconfirmed major cytogenetic response (31% vs. 19%).</p><p><strong>Myeloid Blast Crisis: </strong>260 patients with myeloid blast crisis were enrolled. These patients had greater than or equal to 30% blasts in PB or BM and/or extramedullary involvement other than spleen or liver; 95 (37%) had received prior chemotherapy for treatment of either accelerated phase or blast crisis (&ldquo;pretreated patients&rdquo;) whereas 165 (63%) had not (&ldquo;untreated patients&rdquo;).</p><p>The first 37 patients were started at 400 mg; the remaining 223 patients were started at 600 mg.&nbsp;</p><p>Effectiveness was evaluated primarily on the basis of rate of hematologic response, reported as either complete hematologic response, no evidence of leukemia, or return to chronic phase CML using the same criteria as for the study in accelerated phase. Cytogenetic responses were also assessed. Median duration of treatment was 4 months with 21% of patients treated for greater than or equal to 12 months and 10% for greater than or equal to 24 months (maximum=35 months). Efficacy results are reported in Table 20. The hematologic response rate was higher in untreated patients than in treated patients (36% vs. 22%, respectively) and in the group receiving an initial dose of 600 mg rather than 400 mg (33% vs. 16%). The confirmed and unconfirmed major cytogenetic response rate was also higher for the 600 mg dose group than for the 400 mg dose group (17% vs. 8%).&nbsp;</p><p><strong>Table 16: Response in CML Studies </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Chronic Phase IFN &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Failure &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Accelerated Phase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myeloid Blast Crisis </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:591px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>(n=532) </strong></p></td><td style="vertical-align:top"><p><strong>(n=235) </strong></p></td><td style="vertical-align:top"><p><strong>(n=260) </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>600 mg n=158 </strong></p></td><td style="vertical-align:top"><p><strong>600 mg n=223 </strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>400 mg </strong></p></td><td style="vertical-align:top"><p><strong>400 mg n=77 % of patients [CI<sub>95%</sub>] </strong></p></td><td style="vertical-align:top"><p><strong>400 mg n=37 </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Hematologic Response<sup>1</sup></strong></p></td><td style="vertical-align:top"><p>95% [92.3 to 96.3]<strong> </strong></p></td><td style="vertical-align:top"><p>71%[64.8 to 76.8]<strong> </strong></p></td><td style="vertical-align:top"><p>31% [25.2 to 36.8]<strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>Complete Hematologic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>Response (CHR)&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>95%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>38%</p></td><td style="vertical-align:bottom"><p>7%</p></td></tr><tr><td style="vertical-align:top"><p>No Evidence of Leukemia</p><p>(NEL)&nbsp;</p></td><td style="vertical-align:top"><p>Not applicable</p></td><td style="vertical-align:top"><p>13%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>Return to Chronic Phase</p><p>(RTC)&nbsp;</p></td><td style="vertical-align:top"><p>Not applicable</p></td><td style="vertical-align:top"><p>20%</p></td><td style="vertical-align:top"><p>18%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Major &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cytogenetic </strong></p><p><strong>&nbsp;</strong></p><p><strong>Response<sup>2</sup></strong></p></td><td style="vertical-align:top"><p>60% [55.3 to 63.8]</p></td><td style="vertical-align:top"><p>21% [16.2 to 27.1]</p></td><td style="vertical-align:top"><p>7% [4.5 to 11.2]</p></td></tr><tr><td style="vertical-align:top"><p>(Unconfirmed<sup>3</sup>)&nbsp;</p></td><td style="vertical-align:top"><p>(65%)</p></td><td style="vertical-align:top"><p>(27%)</p></td><td style="vertical-align:top"><p>(15%)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>Complete<sup>4 </sup>(Unconfirmed<sup>3</sup>)&nbsp;</p></td><td style="vertical-align:top"><p>39% (47%) 1</p></td><td style="vertical-align:top"><p>16% (20%)</p></td><td style="vertical-align:top"><p>2% (7%)</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_71167" o:spid="_x0000_s1035" style='width:442.8pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56235,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89323" o:spid="_x0000_s1036" style='position:absolute;
  width:56235;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5623560,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l5623560,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5623560,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="590" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1027" type="#_x0000_t75" style='width:442.8pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong><sup>1</sup></strong><strong>Hematologic response criteria </strong>(all responses to be confirmed after greater than or equal to 4 weeks): CHR:Chronic phase study [WBC less than 10 x 10<sup>9</sup>/L, platelet less than 450 x 10<sup>9</sup>/L, myelocytes + metamyelocytes less than 5% in blood, no blasts and promyelocytes in blood, basophils less than 20%, no extramedullary involvement] and in the accelerated and blast crisis studies [ANC greater than or equal to 1.5 x 10<sup>9</sup>/L, platelets greater than or equal to 100 x 10<sup>9</sup>/L, no blood blasts, BM blasts less than 5% and no extramedullary disease]&nbsp;</p><p>NEL: Same criteria as for CHR but ANC greater than or equal to 1 x 10<sup>9</sup>/L and platelets greater than or equal to 20 x 10<sup>9</sup>/L (accelerated and blast crisis studies)&nbsp;</p><p>RTC: less than 15% blasts BM and PB, less than 30% blasts + promyelocytes in BM and PB, less than 20% basophils in PB, no extramedullary disease other than spleen and liver (accelerated and blast crisis studies). BM=bone marrow, PB=peripheral blood&nbsp;</p><p><strong><sup>2</sup></strong><strong>Cytogenetic response criteria </strong>(confirmed after greater than or equal to 4 weeks): complete (0% Ph+ metaphases) or partial (1% to 35%). A major response (0% to 35%) combines both complete and partial responses.&nbsp;</p><p><strong><sup>3</sup></strong><strong>Unconfirmed cytogenetic response </strong>is based on a single bone marrow cytogenetic evaluation, therefore unconfirmed complete or partial cytogenetic responses might have had a lesser cytogenetic response on a subsequent bone marrow evaluation.</p><p><strong><sup>4</sup></strong><strong>Complete cytogenetic response </strong>confirmed by a second bone marrow cytogenetic evaluation performed at least 1 month after the initial bone marrow study.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_71168" o:spid="_x0000_s1033" style='width:443.5pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="56327,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89325" o:spid="_x0000_s1034" style='position:absolute;
  width:56327;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5632704,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5632704,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5632704,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="591" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image007.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:443.5pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>The median time to hematologic response was 1 month. In late chronic phase CML, with a median time from diagnosis of 32 months, an estimated 87.8% of patients who achieved MCyR maintained their response 2 years after achieving their initial response. After 2 years of treatment, an estimated 85.4% of patients were free of progression to AP or BC, and estimated overall survival was 90.8% [88.3, 93.2]. In accelerated phase, median duration of hematologic response was 28.8 months for patients with an initial dose of 600 mg (16.5 months for 400 mg). An estimated 63.8% of patients who achieved MCyR were still in response 2 years after achieving initial response. The median survival was 20.9 [13.1, 34.4] months for the 400 mg group and was not yet reached for the 600 mg group (p=0.0097). An estimated 46.2% [34.7, 57.7] vs. 65.8% [58.4, 73.3] of patients were still alive after 2 years of treatment in the 400 mg vs. 600 mg dose groups, respectively. In blast crisis, the estimated median duration of hematologic response is 10 months. An estimated 27.2% [16.8, 37.7] of hematologic responders maintained their response 2 years after achieving their initial response. Median survival was 6.9 [5.8, 8.6] months, and an estimated 18.3% [13.4, 23.3] of all patients with blast crisis were alive 2 years after start of study.&nbsp;</p><p>Efficacy results were similar in men and women and in patients younger and older than age 65. Responses were seen in black patients, but there were too few black patients to allow a quantitative comparison.&nbsp;</p><p><strong>Pediatric CML </strong>&nbsp;</p><p>A total of 51 pediatric patients with newly diagnosed and untreated CML in chronic phase were enrolled in an open-label, multicenter, single-arm Phase 2 trial. Patients were treated with imatinib mesylate tablets 340 mg/m<sup>2</sup>/day, with no interruptions in the absence of dose limiting toxicity. Complete hematologic response (CHR) was observed in 78% of patients after 8 weeks of therapy. The complete cytogenetic response rate (CCyR) was 65%, comparable to the results observed in adults. Additionally, partial cytogenetic response (PCyR) was observed in 16%. The majority of patients who achieved a CCyR developed the CCyR between months 3 and 10 with a median time to response based on the Kaplan-Meier estimate of 6.74 months. Patients were allowed to be removed from protocol therapy to undergo alternative therapy including hematopoietic stem cell transplantation. Thirty-one children received stem cell transplantation. Of the 31 children, 5 were transplanted after disease progression on study and 1 withdrew from study during first week treatment and received transplant approximately 4 months after withdrawal. Twenty-five children withdrew from protocol therapy to undergo stem cell transplant after receiving a median of 9 twenty-eight day courses (range 4 to 24). Of the 25 patients 13 (52%) had CCyR and 5 (20%) had PCyR at the end of protocol therapy.&nbsp;</p><p>One open-label, single-arm study enrolled 14 pediatric patients with Ph+ chronic phase CML recurrent after stem cell transplant or resistant to interferon-alpha therapy. These patients had not previously received imatinib mesylate and ranged in age from 3 to 20 years old; 3 were 3 to 11 years old, 9 were 12 to 18 years old, and 2 were greater than 18 years old. Patients were treated at doses of 260 mg/m<sup>2</sup>/day (n=3), 340 mg/m<sup>2</sup>/day (n=4), 440 mg/m<sup>2</sup>/day (n=5) and 570 mg/m<sup>2</sup>/day (n=2). In the 13 patients for whom cytogenetic data are available, 4 achieved a major cytogenetic response, 7 achieved a complete cytogenetic response, and 2 had a minimal cytogenetic response.&nbsp;</p><p>In a second study, 2 of 3 patients with Ph+ chronic phase CML resistant to interferon-alpha therapy achieved a complete cytogenetic response at doses of 242 and 257 mg/m<sup>2</sup>/day.&nbsp;</p><p><strong>Acute Lymphoblastic Leukemia&nbsp; </strong></p><p>&nbsp;</p><p>A total of 48 Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) patients with relapsed/refractory disease were studied, 43 of whom received the recommended imatinib mesylate tablets dose of 600 mg/day. In addition 2 patients with relapsed/refractory Ph+ ALL received imatinib mesylate tablets 600 mg/day in a Phase 1 study.&nbsp;</p><p>Confirmed and unconfirmed hematologic and cytogenetic response rates for the 43 relapsed/refractory Ph+ALL Phase 2 study patients and for the 2 Phase 1 patients are shown in Table 21. The median duration of hematologic response was 3.4 months and the median duration of MCyR was 2.3 months.</p><p><strong>Table 17: Effect of Imatinib Mesylate</strong> <strong>Tablets on Relapsed/Refractory Ph+ ALL&nbsp; </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Phase 2 Study</strong></p></td><td style="vertical-align:top"><p><strong>Phase 1 Study</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>(N=43)</strong></p></td><td style="vertical-align:top"><p><strong>(N=2)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>n(%)</strong></p></td><td style="vertical-align:top"><p><strong>n(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>CHR </strong>&nbsp;</p></td><td style="vertical-align:top"><p>8 (19)&nbsp;</p></td><td style="vertical-align:top"><p>2 (100)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>NEL </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 (12)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>RTC/PHR </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 11 (26)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>MCyR </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15 (35)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>CCyR </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9 (21)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>PCyR </strong>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6 (14)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Myelodysplastic/Myeloproliferative Diseases </strong>&nbsp;</p><p>An open-label, multicenter, Phase 2 clinical trial was conducted testing imatinib mesylate in diverse populations of patients suffering from life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 7 patients with MDS/MPD. These patients were treated with imatinib mesylate tablets 400 mg daily. The ages of the enrolled patients ranged from 20 to 86 years. A further 24 patients with MDS/MPD aged 2 to 79 years were reported in 12 published case reports and a clinical study. These patients also received imatinib mesylate tablets at a dose of 400 mg daily with the exception of three patients who received lower doses. Of the total population of 31 patients treated for MDS/MPD, 14 (45%) achieved a complete hematological response and 12 (39%) a major cytogenetic response (including 10 with a complete cytogenetic response). Sixteen patients had a translocation, involving chromosome 5q33 or 4q12, resulting in a PDGFR gene re-arrangement. All of these patients responded hematologically (13 completely). Cytogenetic response was evaluated in 12 out of 14 patients, all of whom responded (10 patients completely). Only 1 (7%) out of the 14 patients without a translocation associated with PDGFR gene re-arrangement achieved a complete hematological response and none achieved a major cytogenetic response. A further patient with a PDGFR gene re-arrangement in molecular relapse after bone marrow transplant responded molecularly. Median duration of therapy was 12.9 months (0.8 to 26.7) in the 7 patients treated within the Phase 2 study and ranged between 1 week and more than 18 months in responding patients in the published literature. Results are provided in Table 22. Response durations of Phase 2 study patients ranged from 141+ days to 457+ days.</p><p><strong>Table 22: Response in MDS/MPD&nbsp; </strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Number</strong> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Complete Hematologic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Major Cytogenetic</strong></p><p><strong>&nbsp;</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:591px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>of </strong></p></td><td style="vertical-align:top"><p><strong>Response&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>Response </strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>patients</strong></p><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong></p><p><strong>n (%)</strong></p></td><td style="vertical-align:bottom"><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall Population </strong>&nbsp;</p></td><td style="vertical-align:top"><p>31&nbsp;</p></td><td style="vertical-align:top"><p>14 (45)&nbsp;</p></td><td style="vertical-align:top"><p>12 (39)</p></td></tr><tr><td style="vertical-align:top"><p>Chromosome 5 Translocation&nbsp;</p></td><td style="vertical-align:top"><p>14&nbsp;</p></td><td style="vertical-align:top"><p>11 (79)&nbsp;</p></td><td style="vertical-align:top"><p>11 (79)</p></td></tr><tr><td style="vertical-align:top"><p>Chromosome 4 Translocation&nbsp;</p></td><td style="vertical-align:top"><p>2&nbsp;</p></td><td style="vertical-align:top"><p>2 (100)&nbsp;</p></td><td style="vertical-align:top"><p>1 (50)</p></td></tr><tr><td style="vertical-align:top"><p>Others / no Translocation&nbsp;</p></td><td style="vertical-align:top"><p>14&nbsp;</p></td><td style="vertical-align:top"><p>1 (7)&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p><u>Molecular Relapse&nbsp; </u></p><p><sup>1</sup> NE: Not Evaluable&nbsp;</p></td><td style="vertical-align:top"><p><u>1&nbsp; </u></p></td><td style="vertical-align:top"><p><u>NE</u>1 <u>&nbsp;</u></p></td><td style="vertical-align:top"><p><u>NE</u><sup>1</sup><u> </u></p></td></tr></tbody></table><p><strong>14.6&nbsp;&nbsp;&nbsp;&nbsp; Aggressive Systemic Mastocytosis </strong>&nbsp;</p><p>One open-label, multicenter, Phase 2 study was conducted testing imatinib mesylate in diverse populations of patients with life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 5 patients with ASM treated with 100 mg to 400 mg of imatinib mesylate daily. These 5 patients ranged from 49 to 74 years of age. In addition to these 5 patients, 10 published case reports and case series describe the use of imatinib mesylate in 23 additional patients with ASM aged 26 to 85 years who also received 100 mg to 400 mg of imatinib mesylate daily.&nbsp;</p><p>Cytogenetic abnormalities were evaluated in 20 of the 28 ASM patients treated with imatinib mesylate from the published reports and in the Phase 2 study. Seven of these 20 patients had the FIP1L1-PDGFR&alpha; fusion kinase (or CHIC2 deletion). Patients with this cytogenetic abnormality were predominantly males and had eosinophilia associated with their systemic mast cell disease. Two patients had a Kit mutation in the juxtamembrane region (one Phe522Cys and one K509I) and four patients had a D816V c-Kit mutation (not considered sensitive to imatinib mesylate), one with concomitant CML.&nbsp;</p><p>Of the 28 patients treated for ASM, 8 (29%) achieved a complete hematologic response and 9 (32%) a partial hematologic response (61% overall response rate). Median duration of imatinib mesylate therapy for the 5 ASM patients in the Phase 2 study was 13 months (range 1.4 to 22.3 months) and between 1 month and more than 30 months in the responding patients described in the published medical literature. A summary of the response rates to imatinib mesylate in ASM is provided in Table 18. Response durations of literature patients ranged from 1+ to 30+ months.</p><p>&nbsp;</p><p><strong>Table 18: Response in ASM </strong>&nbsp;</p><p><strong>Cytogenetic Abnormality </strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Number of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete Hematologic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Partial Hematologic</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:591px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Patients</strong></p></td><td style="vertical-align:top"><p><strong>Response</strong></p></td><td style="vertical-align:top"><p><strong>Response</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>N (%)</strong></p></td><td style="vertical-align:top"><p><strong>N (%)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</strong></p><p>FIP1L1-PDGFR&alpha; Fusion</p><p>Kinase (or CHIC2&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>7(100)</p></td><td style="vertical-align:bottom"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Deletion)&nbsp;</p><p><strong>&nbsp;</strong></p><p>Juxtamembrane Mutation&nbsp;</p></td><td style="vertical-align:bottom"><p>2&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p>0</p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p><p>2 (100)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown or No Cytogenetic Abnormality Detected&nbsp;</p></td><td><p>15&nbsp;</p></td><td><p>0</p></td><td><p>7 (44)</p></td></tr><tr><td style="vertical-align:top"><p>D816V Mutation&nbsp;</p></td><td style="vertical-align:top"><p>4&nbsp;</p></td><td style="vertical-align:top"><p>1* (25)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Total &nbsp;</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>8 (29)</p></td><td style="vertical-align:top"><p>9 (32 )</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*Patient had concomitant CML and ASM&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Imatinib mesylate has not been shown to be effective in patients with less aggressive forms of systemic mastocytosis (SM). Imatinib mesylate is therefore not recommended for use in patients with cutaneous mastocytosis, indolent systemic mastocytosis (smoldering SM or isolated bone marrow mastocytosis), SM with an associated clonal hematological non-mast cell lineage disease, mast cell leukemia, mast cell sarcoma or extracutaneous mastocytoma. Patients that harbor the D816V mutation of c-Kit are not sensitive to imatinib mesylate and should not receive imatinib mesylate.&nbsp;</p><p><strong>Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia&nbsp; </strong></p><p>&nbsp;</p><p>One open-label, multicenter, Phase 2 study was conducted testing imatinib mesylate in diverse populations of patients with life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 14 patients with Hypereosinophilic Syndrome/Chronic Eosinophilic Leukemia (HES/CEL). HES patients were treated with 100 mg to 1000 mg of imatinib mesylate daily. The ages of these patients ranged from 16 to 64 years. A further 162 patients with HES/CEL aged 11 to 78 years were reported in 35 published case reports and case series. These patients received imatinib mesylate at doses of 75 mg to 800 mg daily. Hematologic response rates are summarized in Table 19. Response durations for literature patients ranged from 6+ weeks to 44 months.&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong>Cytogenetic Abnormality </strong>&nbsp;</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Number of Patients</strong></p></td><td style="vertical-align:top"><p><strong>Complete </strong></p><p><strong>Hematological </strong></p><p><strong>Response </strong></p><p><strong>&nbsp;N (%)</strong></p></td><td style="vertical-align:top"><p><strong>Partial </strong></p><p><strong>Hematological </strong></p><p><strong>Response N (%)</strong></p></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Group_x0020_71580"
 o:spid="_x0000_s1031" style='position:absolute;left:0;text-align:left;
 margin-left:-5.4pt;margin-top:62.65pt;width:462.1pt;height:.5pt;z-index:251659264;
 mso-position-horizontal-relative:text;mso-position-vertical-relative:text'
 coordsize="58689,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89327" o:spid="_x0000_s1032" style='position:absolute;
  width:58689;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="5868924,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAV0hgawwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvC/6H8ARva6rCrlajqCB43a4evD2aZ1NsXkoT2/rvjSB4HGbmG2a16W0lWmp86VjBZJyAIM6d
LrlQcPo/fM9B+ICssXJMCh7kYbMefK0w1a7jP2qzUIgIYZ+iAhNCnUrpc0MW/djVxNG7usZiiLIp
pG6wi3BbyWmS/EiLJccFgzXtDeW37G4V7LpLaeydjll9u2zb7rxv++tDqdGw3y5BBOrDJ/xuH7WC
+WI2/YXXnXgF5PoJAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAFdIYGsMAAADeAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l5868924,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,5868924,9144"/>
 </v:shape><w:wrap type="square"/>
</v:group><![endif]--><img width="616" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><strong>Table 19: Response in HES/CEL </strong>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:555px"><tbody><tr><td style="vertical-align:top"><p>Positive FIP1L1-PDGFR&alpha; Fusion Kinase&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>61&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>61 (100)&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Negative FIP1L1-PDGFR&alpha; Fusion&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>56&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>12 (21)&nbsp;</p></td><td style="vertical-align:top"><p>9 (16)</p></td></tr><tr><td style="vertical-align:top"><p>Kinase&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Unknown Cytogenetic Abnormality&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>59&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>34 (58)&nbsp;</p></td><td style="vertical-align:top"><p>7 (12)</p></td></tr><tr><td style="vertical-align:top"><p>Total&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>176&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>107 (61)&nbsp;</p></td><td style="vertical-align:top"><p>23 (13)</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_71581" o:spid="_x0000_s1026" style='width:462.85pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="58780,60" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_89329" o:spid="_x0000_s1027" style='position:absolute;
  width:23065;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="2306574,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l2306574,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,2306574,9144"/>
 </v:shape><v:shape id="Shape_x0020_89330" o:spid="_x0000_s1028" style='position:absolute;
  left:22974;width:8664;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="866394,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l866394,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,866394,9144"/>
 </v:shape><v:shape id="Shape_x0020_89331" o:spid="_x0000_s1029" style='position:absolute;
  left:31546;width:12558;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1255776,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l1255776,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,1255776,9144"/>
 </v:shape><v:shape id="Shape_x0020_89332" o:spid="_x0000_s1030" style='position:absolute;
  left:44013;width:14767;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1476756,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB+xZ5ixQAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ra8Iw
FIXfhf2HcIW9aaoOcZ1RpmOj+Na6H3CXXNtic1OazGb/fhkMfDycc77D2e6j7cSNBt86VrCYZyCI
tTMt1wo+z++zDQgfkA12jknBD3nY7x4mW8yNG7mkWxVqkSDsc1TQhNDnUnrdkEU/dz1x8i5usBiS
HGppBhwT3HZymWVrabHltNBgT8eG9LX6tgroMOqvdXWxbTy9uY94LfRTWSj1OI2vLyACxXAP/7cL
o2DzvFot4e9OugJy9wsAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB+xZ5ixQAAAN4AAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m,l1476756,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:path arrowok="t" textboxrect="0,0,1476756,9144"/>
 </v:shape><w:wrap type="none" anchorx="page"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="617" height="1" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:462.85pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p><strong>&nbsp;</strong></p><p><strong>Dermatofibrosarcoma Protuberans&nbsp; </strong></p><p>&nbsp;</p><p>Dermatofibrosarcoma Protuberans (DFSP) is a cutaneous soft tissue sarcoma. It is characterized by a translocation of chromosomes 17 and 22 that results in the fusion of the collagen type 1 alpha 1 gene and the PDGF B gene.&nbsp;</p><p>An open-label, multicenter, Phase 2 study was conducted testing imatinib mesylate in a diverse population of patients with life-threatening diseases associated with Abl, Kit or PDGFR protein tyrosine kinases. This study included 12 patients with DFSP who were treated with imatinib mesylate tablets 800 mg daily (age range 23 to 75 years). DFSP was metastatic, locally recurrent following initial surgical resection and not considered amenable to further surgery at the time of study entry. A further 6 DFSP patients treated with imatinib mesylate are reported in 5 published case reports, their ages ranging from 18 months to 49 years. The total population treated for DFSP therefore comprises 18 patients, 8 of them with metastatic disease. The adult patients reported in the published literature were treated with either 400 mg (4 cases) or 800 mg (1 case) imatinib mesylate daily. A single pediatric patient received 400 mg/m<sup>2</sup>/daily, subsequently increased to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 520 mg/m<sup>2</sup>/daily. Ten patients had the PDGF B gene rearrangement, 5 had no available cytogenetics and 3 had complex cytogenetic abnormalities. Responses to treatment are described in Table 20.&nbsp;</p><p><strong>Table 20: Response in DFSP </strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Number of Patients (n=18) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; % </strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:617px"><tbody><tr><td style="vertical-align:top"><p>Complete Response&nbsp;</p></td><td style="vertical-align:top"><p>7&nbsp;</p></td><td style="vertical-align:top"><p>39&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Partial Response *&nbsp;</p></td><td style="vertical-align:top"><p>8&nbsp;</p></td><td style="vertical-align:top"><p>44&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Total Responders&nbsp;</p></td><td style="vertical-align:top"><p>15&nbsp;</p></td><td style="vertical-align:top"><p>83&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>*5 patients made disease free by surgery&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>Twelve of these 18 patients either achieved a complete response (7 patients) or were made disease free by surgery after a partial response (5 patients, including one child) for a total complete response rate of 67%. A further 3 patients achieved a partial response, for an overall response rate of 83%. Of the 8 patients with metastatic disease, five responded (62%), three of them completely (37%). For the 10 study patients with the PDGF B gene rearrangement, there were 4 complete and 6 partial responses. The median duration of response in the Phase 2 study was 6.2 months, with a maximum duration of 24.3 months, while in the published literature it ranged between 4 weeks and more than 20 months.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Imatinib Mesylate Tablets 100mg:</u> </strong></p><p>Hypromellose 2910 5cps (Methocel E5 LV Premium), Microcrystalline cellulose (Avicel PH 102), Crospovidone (Kollidon CL), Colloidal silicon dioxide (Aerosil 200), Magnesium stearate, Purified water.</p><p><strong>Coating Composition:</strong> HPMC 2910/ Hypromellose, Titanium Dioxide, Macrogol/PEG, Talc.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu-Alu blister</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Hetero Lab Co, Ltd. 
Aljameah Street, Malaz quarter, Riyadh 11441 
Saudi Arabia 
Tel: +966 11 477 2215 
Manufacture: 
Hetero Lab Unit V, Hyderabad, India  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>